{"title":"High-Purity Interleukins \u0026 Receptors for Research","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAt \u003c\/span\u003e\u003cspan\u003eBeta LifeScience\u003c\/span\u003e\u003cspan\u003e, we provide \u003c\/span\u003e\u003cspan\u003ehigh-purity interleukins\u003c\/span\u003e\u003cspan\u003e to support groundbreaking research in immunology, cancer therapy, and drug development. These \u003c\/span\u003e\u003cspan\u003ekey signaling proteins\u003c\/span\u003e\u003cspan\u003e play a vital role in immune response, inflammation, and disease treatment, making them essential for advanced scientific studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv style=\"text-align: left;\"\u003e\n\u003cspan\u003eOur collection includes IL-2, IL-6, IL-10, IL-12, IL-17, and more, ensuring you get the right interleukin for your experiments. Whether you're working on vaccine development, autoimmune research, or cancer immunotherapy, our proteins deliver the consistency and reliability your lab needs.\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003e\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cdiv style=\"text-align: left;\"\u003e\n\u003cspan\u003e\u003c\/span\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv style=\"text-align: left;\"\u003e\n\u003cspan\u003eExplore our selection and order with confidence, trusted quality, fast delivery, and expert support to power your research.\u003c\/span\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhat Are Interleukins?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eInterleukins\u003c\/span\u003e\u003cspan\u003e are a group of \u003c\/span\u003e\u003cspan\u003esignaling proteins\u003c\/span\u003e\u003cspan\u003e that help cells communicate within the immune system. They play a key role in \u003c\/span\u003e\u003cspan\u003eregulating inflammation, immune response, and cell growth\u003c\/span\u003e\u003cspan\u003e, making them essential for research in \u003c\/span\u003e\u003cspan\u003edisease treatment and immunotherapy\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEach interleukin (IL) has a specific function. For example, IL-2 stimulates the growth of T cells, crucial for immune defense, while IL-6 plays a dual role—triggering inflammation but also promoting tissue repair. Other interleukins, like IL-10, help reduce excessive immune responses, preventing autoimmune diseases.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBecause of their precise biological roles, interleukins are widely used in cancer immunotherapy, vaccine development, and autoimmune disease research. Understanding these proteins allows scientists to develop targeted treatments for conditions like rheumatoid arthritis, multiple sclerosis, and even COVID-19.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\n\u003cspan\u003eTypes of Interleukins \u0026amp; Their Functions\u003c\/span\u003e\u003cspan\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/pages\/interleukin-il-superfamily\" target=\"_blank\"\u003e\u003cspan\u003e\u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/Types_of_Interleukins.png?v=1742767621\"\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eInterleukin-6 (IL-6)\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIL-6 plays a dual role in the immune system. It helps fight infections by triggering inflammation but also supports tissue repair. This makes it a major focus in autoimmune disease research, chronic inflammation studies, and cancer treatments. Scientists are exploring ways to regulate IL-6 to develop better therapies for conditions like arthritis and cytokine storms.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eInterleukin-2 (IL-2)\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIL-2 is essential for immune defense, promoting the growth of T cells that fight infections and diseases. It’s widely used in cancer immunotherapy, especially for treating melanoma and kidney cancer. By boosting immune activity, IL-2 helps the body target and destroy harmful cells.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eInterleukin IL-1\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIL-1 acts as an alarm system for the body, kicking off fever and inflammation to fight infections. While it's crucial for defense, too much IL-1 can lead to chronic inflammatory diseases like rheumatoid arthritis. That’s why researchers focus on controlling IL-1 levels to prevent excessive immune reactions.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eIL-10, IL-12 \u0026amp; IL-17\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThese interleukins help fine-tune immune responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eIL-10 reduces inflammation, preventing the immune system from attacking healthy cells.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eIL-12 boosts natural killer (NK) cells and T cells, strengthening defenses against infections and cancer.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eIL-17 drives inflammation, playing a role in conditions like psoriasis and multiple sclerosis.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eOther Interleukins \u0026amp; Their Research Importance\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eInterleukins like IL-4, IL-5, IL-13, IL-14, IL-32, and IL-34 are linked to allergies, chronic diseases, and immune regulation. Understanding their roles helps scientists develop better treatments for asthma, cancer, and autoimmune disorders.\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"244\" data-start=\"194\"\u003eAdditional Interleukins \u0026amp; Receptor Proteins\u003c\/h3\u003e\n\u003cp data-end=\"342\" data-start=\"246\"\u003eFor advanced and targeted research, we also offer specialized interleukin and receptor proteins:\u003c\/p\u003e\n\u003cul data-end=\"1380\" data-start=\"344\"\u003e\n\u003cli data-end=\"516\" data-start=\"344\"\u003e\n\u003cp data-end=\"516\" data-start=\"346\"\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/collections\/interleukins-and-receptors\/il-18\" rel=\"noopener\" class=\"\" data-end=\"447\" data-start=\"346\"\u003eIL-18 Recombinant Protein\u003c\/a\u003e – Involved in immune response regulation and inflammatory signaling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"696\" data-start=\"517\"\u003e\n\u003cp data-end=\"696\" data-start=\"519\"\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/collections\/interleukins-and-receptors\/il-18bp\" rel=\"noopener\" class=\"\" data-end=\"624\" data-start=\"519\"\u003eIL-18BP Recombinant Protein\u003c\/a\u003e – Natural inhibitor of IL-18, useful for inflammation-related research.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"871\" data-start=\"697\"\u003e\n\u003cp data-end=\"871\" data-start=\"699\"\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/collections\/interleukins-and-receptors\/il-1racp\" rel=\"noopener\" class=\"\" data-end=\"806\" data-start=\"699\"\u003eIL-1RAcP Recombinant Protein\u003c\/a\u003e – Plays a role in IL-1 receptor signaling and immune regulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1044\" data-start=\"872\"\u003e\n\u003cp data-end=\"1044\" data-start=\"874\"\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/collections\/interleukins-and-receptors\/il-1rapl1\" rel=\"noopener\" class=\"\" data-end=\"983\" data-start=\"874\"\u003eIL-1RAPL1 Recombinant Protein\u003c\/a\u003e – Linked to neuronal development and inflammatory responses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1201\" data-start=\"1045\"\u003e\n\u003cp data-end=\"1201\" data-start=\"1047\"\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/collections\/interleukins-and-receptors\/il-36a\" rel=\"noopener\" class=\"\" data-end=\"1150\" data-start=\"1047\"\u003eIL-36A Recombinant Protein\u003c\/a\u003e – Associated with skin inflammation and psoriasis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1380\" data-start=\"1202\"\u003e\n\u003cp data-end=\"1380\" data-start=\"1204\"\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/collections\/interleukins-and-receptors\/il-36ra\" class=\"\" rel=\"noopener\" data-end=\"1309\" data-start=\"1204\"\u003eIL-36RA Recombinant Protein\u003c\/a\u003e – A natural antagonist of IL-36, important in regulating inflammation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhy Choose Beta LifeScience for Interleukin Proteins?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFinding high-quality \u003c\/span\u003e\u003cspan\u003einterleukin proteins\u003c\/span\u003e\u003cspan\u003e can be challenging, but at Beta LifeScience, we make it simple. Our interleukins are produced with precision to ensure high purity, consistency, and bioactivity. giving researchers the reliability they need for accurate results.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eWhat sets us apart?\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eExtensive Selection:\u003c\/span\u003e\u003cspan\u003e From \u003c\/span\u003e\u003cspan\u003eIL-2, IL-6, IL-10\u003c\/span\u003e\u003cspan\u003e to \u003c\/span\u003e\u003cspan\u003eIL-17 and more\u003c\/span\u003e\u003cspan\u003e, we provide a comprehensive range of interleukins tailored for various research applications.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eHigh Purity \u0026amp; Bioactivity:\u003c\/span\u003e\u003cspan\u003e Every batch undergoes rigorous quality checks to meet industry standards.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eFast \u0026amp; Reliable Shipping:\u003c\/span\u003e\u003cspan\u003e Get the proteins you need without delays, ensuring your research stays on track.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eTrusted by Researchers Worldwide:\u003c\/span\u003e\u003cspan\u003e Scientists in biotech, immunology, and pharmaceutical development rely on our products for breakthrough discoveries.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eWhether you're studying \u003c\/span\u003e\u003cspan\u003einflammation, immunity, or cell signaling\u003c\/span\u003e\u003cspan\u003e, our interleukin proteins deliver the precision and performance you need.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eOur interleukins and receptors are rigorously tested to achieve optimal performance, high purity, and activity, ensuring reliable and reproducible results for your experiments. Inquire online or call us today to learn more about our products and services.\u003c\/em\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFeatures:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eHigh purity\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eHigh biological activity\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eLow in endotoxin (\u0026lt;10EU\/mg)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan\u003eLow batch variation\u003c\/span\u003e\u003cspan\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eApplications of Interleukins in Research \u0026amp; Medicine\u003c\/h2\u003e\n\u003cp\u003eInterleukins are vital in immunology, disease treatment, and medical research, playing a key role in cell communication, inflammation control, and immune response regulation. Scientists and biotech companies rely on these proteins for various applications, including:\u003c\/p\u003e\n\u003ch3\u003eCancer Immunotherapy\u003c\/h3\u003e\n\u003cp\u003eInterleukins like \u003cstrong\u003eIL-2\u003c\/strong\u003e and \u003cstrong\u003eIL-12\u003c\/strong\u003e help activate T cells and natural killer (NK) cells, enhancing the body's ability to target and eliminate cancer cells. These proteins are widely used in experimental and approved immunotherapies for \u003cstrong\u003emelanoma, leukemia, and kidney cancer\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eAutoimmune Disease Treatment\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eIL-6\u003c\/strong\u003e and \u003cstrong\u003eIL-17\u003c\/strong\u003e are heavily involved in autoimmune disorders like \u003cstrong\u003erheumatoid arthritis\u003c\/strong\u003e and \u003cstrong\u003emultiple sclerosis\u003c\/strong\u003e. Targeting these interleukins helps develop treatments that reduce inflammation and prevent immune system overactivity.\u003c\/p\u003e\n\u003ch3\u003eVaccine Development\u003c\/h3\u003e\n\u003cp\u003eInterleukins play a crucial role in vaccine formulations. \u003cstrong\u003eIL-1, IL-6,\u003c\/strong\u003e and \u003cstrong\u003eIL-12\u003c\/strong\u003e enhance immune responses, making vaccines more effective against infectious diseases like \u003cstrong\u003eCOVID-19\u003c\/strong\u003e and \u003cstrong\u003einfluenza\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eInflammatory Disease Research\u003c\/h3\u003e\n\u003cp\u003eConditions like \u003cstrong\u003easthma, Crohn’s disease,\u003c\/strong\u003e and \u003cstrong\u003epsoriasis\u003c\/strong\u003e are linked to excessive interleukin activity. By studying how these proteins influence inflammation, researchers develop new ways to control immune system overreactions.\u003c\/p\u003e\n\u003ch3\u003eRegenerative Medicine\u003c\/h3\u003e\n\u003cp\u003eInterleukins such as \u003cstrong\u003eIL-10\u003c\/strong\u003e and \u003cstrong\u003eIL-4\u003c\/strong\u003e support \u003cstrong\u003etissue repair\u003c\/strong\u003e and \u003cstrong\u003ewound healing\u003c\/strong\u003e, making them valuable in regenerative medicine and post-surgical recovery treatments.\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003e\u003ca href=\"https:\/\/www.betalifesci.com\/pages\/interleukin-il-superfamily\" class=\"js-no-transition\"\u003e\u003cbutton class=\"btn btn--full\"\u003eLearn More About the Interleukin (IL) Superfamily\u003c\/button\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003c\/div\u003e","products":[{"product_id":"recombinant-mouse-st2-protein-fc-tag-bl-0231np","title":"Recombinant Mouse ST2 Protein (V192A, C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-1 receptor-like 1 is produced by our Mammalian expression system and the target gene encoding Ser27-Ala337 (Val192Ala) is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P14719-2\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P14719\/entry#P14719-2\"\u003eP14719-2\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor-like 1; Lymphocyte antigen 84; Protein ST2; Protein T1; Il1rl1; DER4; Fit-1; IL-1 R4; IL-1RL1; IL-33R; Ly84; ST2L; ST2V; suppression of tumorigenicity 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eST2, also called IL-1 R4, is an Interleukin-1 receptor family glycoprotein that plays a role in Th2 immune responses. ST2 is expressed on the surface of mast cells, activated Th2 cells, macrophages, and cardiac myocytes. This receptor is very similar to the IL-1 receptor type I and the IL-18 receptor α chain in that ST2 also has three extracellular Ig domains and an intracellular Toll domain. ST2 binds IL-33, enhances inflammatory cytokines by activating nuclear factor-κB (NF-κB) and mitogen activated protein (MAP) kinases. ST2 exists as either a membrane bound form (ST2L) or as a soluble form (sST2). ST2L acts as a transmembrane signalling receptor for IL-33 by mediating the effect of IL-33 on the inflammatory process, while sST2 can suppress IL-33 activity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e62.7 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e90-110 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915052155105,"sku":"BL-0231NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZeALfGdAACag3aA40Y728_2e7f9e6d-1d03-49d9-96fa-67a9e4b88e31.jpg?v=1685851653"},{"product_id":"recombinant-human-st2-protein-his-tag-bl-0930np","title":"Recombinant Human ST2 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-1 Receptor-like 1 is produced by our Mammalian expression system and the target gene encoding Lys19-Phe328 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q01638-2\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q01638\/entry#Q01638-2\"\u003eQ01638-2\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor-like 1;Protein ST2;DER4; ST2; T1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 1 receptor-like 1(IL1RL1) is a member of the interleukin-1 receptor family, Contains 3 Ig-like C2-type domains and 1 TIR domain. It is highly expressed in kidney, lung, placenta, stomach, skeletal muscle, colon and small intestine. IL1RL1 is a receptor for interleukin-33, its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3\/ERK1 and\/or MAPK1\/ERK2, MAPK14, and MAPK8. IL1RL1 may possibly be involved in helper T-cell function. Soluble IL1RL1 also acts as a negative regulator of Th2 cytokine production, it directly implicated in the progression of cardiac disease.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e36 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50-85 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915019157729,"sku":"BL-0930NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLYqAeSWqAAC0sn8KAhs522_876da656-d7dc-460c-a06e-02c1dfd3bcf4.jpg?v=1685850670"},{"product_id":"recombinant-mouse-st2-protein-his-tag-bl-1016np","title":"Recombinant Mouse ST2 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-1 Receptor-like 1 is produced by our Mammalian expression system and the target gene encoding Ser27-Ala337 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P14719-2\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P14719\/entry#P14719-2\"\u003eP14719-2\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor-like 1; Lymphocyte antigen 84; Protein ST2; Protein T1; Il1rl1; DER4; Fit-1; IL-1 R4; IL-1RL1; IL-33R; Ly84; ST2L; ST2V; suppression of tumorigenicity 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eST2, also called IL-1 R4, is an Interleukin-1 receptor family glycoprotein that plays a role in Th2 immune responses. ST2 is expressed on the surface of mast cells, activated Th2 cells, macrophages, and cardiac myocytes. This receptor is very similar to the IL-1 receptor type I and the IL-18 receptor α chain in that ST2 also has three extracellular Ig domains and an intracellular Toll domain. ST2 binds IL-33, enhances inflammatory cytokines by activating nuclear factor-κB (NF-κB) and mitogen activated protein (MAP) kinases. ST2 exists as either a membrane bound form (ST2L) or as a soluble form (sST2). ST2L acts as a transmembrane signalling receptor for IL-33 by mediating the effect of IL-33 on the inflammatory process, while sST2 can suppress IL-33 activity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e36.6 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e55-70 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915038916833,"sku":"BL-1016NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZaAG5QbAACnzIyozlM277_fb451470-edb0-4039-b833-903c542d09de.jpg?v=1685851189"},{"product_id":"recombinant-human-il4-r-protein-fc-tag-bl-0005np","title":"Recombinant Human IL-4 RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-4 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Met26-Gln231 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP24394\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-4 receptor subunit alpha; IL-4 receptor subunit alpha; IL-4R subunit alpha; IL-4R-alpha; IL-4RA; CD124; IL-4-binding protein; IL4-BP; IL4R; IL4RA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 4 Receptor alpha (IL4-Ra) is a widely expressed 140 kDa transmembrane glycoprotein in the class I cytokine receptor family. Mature human IL4-Ra consists of a 207 amino acid (aa) extracellular domain (ECD) that contains a cytokine binding region and one fibronectin type III domain, a 24 aa transmembrane segment, and a 569 aa cytoplasmic domain that contains one Box 1 motif and one ITIM motif. IL4-Ra plays an important role in Th2-biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. Soluble forms of IL4-Ra, generated by alternate splicing or proteolysis, retain ligand binding properties and inhibit IL-4 bioactivity. IL4-Ra is a component of two distinct receptor complexes and shows species selectivity between human and mouse. It can associate with the common gamma chain (γc) to form the IL-4 responsive type I receptor in which γc increases the affinity for IL-4 and enables signaling. It can alternatively associate with IL13-Ra1 to form the type II receptor which is responsive to both IL-4 and IL-13. The use of shared receptor components contributes to the overlapping biological effects of IL-4 and IL-13 as well as other cytokines that utilize γc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50.2 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-70 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for both interleukin 4 and interleukin 13. Couples to the JAK1\/2\/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4\/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1\/IRS2.; Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation and IL5 up-regulation by T-cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 4 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6015           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            147781           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3566           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000170630           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28706306            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Interleukin-4 receptor subunit alpha (IL-4Ralpha) haplotypes for Val75Ile, Ser503Pro, and Arg576Gln are associated with measles Immunoglobulin G production in Mozambican children but not Australian children. IL-4Ralpha 503Pro is more prevalent in Mozambique vaccine failure cases compared with controls.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28594599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We consider that although no association was found among diverse SNPs from human IL-10 and IL-4 promoter regions and gastric cancer event, the present research provides insight into two possible biomarkers of immunological nature (increased level of serum IL-4) and genetic nature (presence of the IL-10, -G1082A SNP) related to this neoplasm in our population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30526523            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL4RA and ADAM33 variants may be risk markers of asthma exacerbations in type-2 inflammatory endotype. Precise endotyping may facilitate the identification of genetic risk markers of asthma exacerbations.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28326636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that the IL-4Ralpha polymorphism is associated with susceptibility to chronic immune thrombocytopenia            \u003ca rel=\"nofollow\"\u003e             PMID:                        28511637            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here in this review, we discuss the structural details of IL-4 and IL-4Ralpha subunit and the structural similarities between IL-4 and IL-13. We also describe detailed chemistry of type-I and type-II receptor complexes and their signaling pathways. Furthermore, we elaborate the strength of type-II hetero dimer signals in response to IL-4 and IL-13.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27165851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Naive CD4+ Tconv cells from subjects with asthma bearing the IL4RR576 mutation show defective induction of iTreg cells and their skewing toward a TH17-like phenotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27479084            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Result showed that exposure of Peripheral Blood-Mesenchymal Stem Cells (PB-MSCs) to Noggin was associated with changes in pattern of CD29\/CD184 expression. The expression profile of CD29(+\/-)\/CD184(-) can be suggested as a robust signature for tracing differentiation of PB-MSCs into neuronal cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27478015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The promoter methylation levels of GATA3, IL-4, and TGF-beta were significantly higher in active VKH patients than in healthy individuals            \u003ca rel=\"nofollow\"\u003e             PMID:                        28278322            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A positive association exists between the IL-4R Q551R polymorphism and occurrence of chronic periodontitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28392616            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphism of IL-4Ralpha 175 V was linked to greater Atopic dermatitis risk at 2 to 3 years of age.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27274543            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4Ralpha gene (I50V) polymorphism may play a role in development of eczema among Saudi children            \u003ca rel=\"nofollow\"\u003e             PMID:                        27018548            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic polymorphism is associated with autoimmune hepatitis in Brazilian children            \u003ca rel=\"nofollow\"\u003e             PMID:                        26693492            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL4Rrs2107356 and IL8rs2227307 SNPs were associated with an increased risk of invasive aspergillosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26667837            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Essential role of endocytosis for interleukin-4-receptor-mediated JAK\/STAT signalling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26306492            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of IL-4 and IL-13 receptors in cancer biology and discussion of pre-clinical and clinical studies pertaining to recombinant immunotoxins designed to target these receptors [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26088753            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            review of IL-4 and IL-13 receptor structure, receptor regulation, signaling and experimental therapeutics [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26187331            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is no correlation between the Arg551Gln polymorphism in IL-4R gene and asthma predictive index results            \u003ca rel=\"nofollow\"\u003e             PMID:                        26695670            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studies indicate significant association between the interleukin-4receptor (IL-4R) Q576R polymorphism and the risk of asthma in the Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25867440            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results illustrated that Saudi vitiligo patients showed significantly higher frequency of the IL-4R (Q551R A\u0026gt;G) homozygous GG variant (recessive mode) as compared with their respective controls            \u003ca rel=\"nofollow\"\u003e             PMID:                        23774696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher frequency of polymorphisms in patients with familial hypercholesterolemia            \u003ca rel=\"nofollow\"\u003e             PMID:                        25110223            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4RA-1902 A\/A genotype has been associated with a reduced response to IL-4 and has been found in 90% oral mucous membrane pemphigoid patient            \u003ca rel=\"nofollow\"\u003e             PMID:                        23557074            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variants of NOS3, CD14, MMP3 and IL4R are implicated in the determination of VEGF expression and plasma levels.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26437765            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL4R mediates enhanced glucose and glutamine metabolism in breast cancer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25746764            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Receptor trafficking may play an important role for the regulation of IL-4R-mediated JAK\/STAT signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25468331            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Gene interactions were observed between IL4R and TNF-alpha genes in hand osteoarthritis patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25252624            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Selective augmentation of IL-4Ralpha signaling in Treg cells induced their reprogramming into Th2-like cells and disease susceptibility towards food allergy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25769611            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that high expression of interleukin-4 receptor IL-4Ralpha correlated with increased recurrence, while interleukin-13 receptor IL-13Ralpha1 had an inverse relationship to recurrence and survival in oral cavity squamous cell carcinoma patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25483786            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher TGF-beta with lower CD124 and TSLP, but no difference in PAR-2 expression in bronchial biopsy of bronchial asthma patients in comparison with COPD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24185116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Analysis of IL4R SNP haplotypes or complex alleles suggested no dominant protection in patients with Recurrent spontaneous abortion            \u003ca rel=\"nofollow\"\u003e             PMID:                        24803421            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that the physical interaction between the cytoplasmic domains of IL-13Ralpha2 and IL-4Ralpha regulates IL-4 signaling through the IL-4Ralpha-IL-13Ralpha1 receptor complex.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24056919            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            increased expression in B cells of patients with house dust mites allergic asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        24975796            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The binding of [AP1-V12]6 to cancer cells was remarkably reduced when IL-4 receptors were blocked by antibody against IL-4 receptor further confirmed its binding            \u003ca rel=\"nofollow\"\u003e             PMID:                        24339977            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased Th17 cell frequency and poor clinical outcome in rheumatoid arthritis are associated with a genetic variant in the IL4R gene, rs1805010.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24782180            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            beta-defensin-2 and interleukin-4 receptor are biomarkers that improve the prediction of poor-outcome over clinical variables in the acute phase of stroke            \u003ca rel=\"nofollow\"\u003e             PMID:                        24386991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL4RA I50V and Q551R polymorphisms may be risk factors for developing asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23922687            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This meta-analysis indicates that the I50V polymorphism of IL-4R gene may confer susceptibility to RA            \u003ca rel=\"nofollow\"\u003e             PMID:                        23972290            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the polymorphism of IL-4Ralpha rs1801275 confers individual's variable susceptibility to glioma, particularly among Asians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23979976            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Rs1805012 polymorphism of IL-4R gene is associated with asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24510574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variants in IL4R were identified, and their association with the progression rate of joint damage in rheumatoid arthritis was independently replicated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23983153            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphisms in IL4R gene is associated with the risk of adult glioma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23525950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The rs1801275 in IL-4R showed an increased risk of glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23663500            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            An meta-analysis suggests that the IL-4Ralpha rs1801275 polymorphism is not a genetic predictor for glioma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23395224            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            reduced IL-4R signalling has stage-specific effects on colorectal carcinogenesis (increased CRC initiation and risk but reduced tumour progression and no effect on CRC mortality).            \u003ca rel=\"nofollow\"\u003e             PMID:                        23784081            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings support a pathogenic role for IL-4Ralpha on Th cells following respiratory syncytial virus reinfection            \u003ca rel=\"nofollow\"\u003e             PMID:                        23543769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduced interleukin-4 receptor alpha expression on CD8+ T cells correlates with higher quality anti-viral immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23383283            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that single nucleotide polymorphism (SNP) rs1805015 in the IL4Ralpha gene was significantly associated with eczema in the additive and dominant models.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23480403            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Passive smoking causes significant rise in plasma TNFa and IL4 with a dose dependent effect            \u003ca rel=\"nofollow\"\u003e             PMID:                        23066418            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interacting determinants of atopy, total IgE, IgE against prevalent allergens, and IL4RA polymorphisms, contribute to the high prevalence of betalactams allergy in South of Spain.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22764749            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A protective association for Hodgkin lymphoma was observed on the IL4R gene with haplotype TCA            \u003ca rel=\"nofollow\"\u003e             PMID:                        22902050            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915018895585,"sku":"BL-0005NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLamAdhl6AACn1hjsELg470_8a3ca61b-2dda-486f-b1ff-703f39f54fc9.jpg?v=1685850663"},{"product_id":"recombinant-human-il17ra-protein-fc-tag-bl-0006np","title":"Recombinant Human IL-17RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-17 Receptor A is produced by our Mammalian expression system and the target gene encoding Leu33-Trp320 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ96F46\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17 receptor A; IL-17 receptor A; IL-17RA; CDw217; CD_antigen; CD217; IL17RA; IL17R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 17A (IL17A) is a proinflammatory cytokine secreted by activated T-lymphocytes. It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils. The transmembrane protein encoded by this gene (interleukin 17A receptor; IL17RA) is a ubiquitous type I membrane glycoprotein that binds with low affinity to interleukin 17A. Interleukin 17A and its receptor play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis. Like other cytokine receptors, this receptor likely has a multimeric structure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60.6 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e90-120  KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Involved in antimicrobial host defense primarily promoting neutrophil activation and recruitment at infection sites to destroy extracellular bacteria and fungi. In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells. Plays a role in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers. Involved in antiviral host defense through various mechanisms. Enhances immunity against West Nile virus by promoting T cell cytotoxicity. Contributes to Influenza virus clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense. Receptor for IL17C as part of a heterodimeric complex with IL17RE.; (Microbial infection) Receptor for SARS coronavirus-2\/SARS-CoV-2 virus protein ORF8, leading to IL17 pathway activation and an increased secretion of pro-inflammatory factors through activating NF-kappa-B signaling pathway.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            5985           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            605461           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:23765           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000320936           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27670766            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Combination of polymorphisms in the NOD2, IL17RA, EPHA2 and KALRN genes could play a significant role in the development of sarcoidosis by maintaining a chronic pro-inflammatory status in macrophages            \u003ca rel=\"nofollow\"\u003e             PMID:                        29554915            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data connect increased interleukin (IL)-17A\/IL-17RA signaling in autism spectrum disorder patients with enhanced oxidative inflammation in monocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28935156            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17RA is essential for mucocutaneous immunity to Candida and Staphylococcus, but otherwise largely redundant            \u003ca rel=\"nofollow\"\u003e             PMID:                        27930337            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here, we discuss the latest discoveries on the role of the IL-17A\/IL-17RA axis in driving host pulmonary defence and immunopathology.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27033174            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High IL-17RA expression is associated with prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26871944            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of these mediators was confirmed in end-stage COPD. Thus, accumulation of mast cells in COPD may contribute to vascular remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28298222            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            cyanidin specifically recognizes an IL-17A binding site in the IL-17A receptor subunit (IL-17RA) and inhibits the IL-17A\/IL-17RA interaction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28223414            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SNP rs4819554 in promoter is associated with functional severity of ankylosing spondylitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27415816            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown that IL-17 can be produced by enteroendocrine chromogranin A-positive cells as well as by goblet cells in the human colon.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27660002            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that IL-17-IL-17R interaction in GSCs induces an autocrine\/paracrine cytokine feedback loop, which may provide an important signaling component for maintenance\/self-renewal of GSCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26755664            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High IL-17RA expression is associated with Intrahepatic Cholangiocarcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26228109            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Identified the IL17RA rs4819554 SNP as a risk factor for psoriasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26347322            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17 receptor A and adenosine deaminase 2 deficiency due to deletion mutations was found in siblings with chronic mucocutaneous candidiasis and chronic systemic inflammation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26607704            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In vitro, CSE stimulation significantly increased IL-17F and IL-17R in 16HBE (2.5%) and A549 (5%) while IL-17A and IL-17F in PBMC (10%). IL-17A and CSE stimulation, rather than CSE or rhIL-17A alone, increased proliferation in 16HBE and apoptosis in A549            \u003ca rel=\"nofollow\"\u003e             PMID:                        26198032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data indicate that the genetic variants of rs2275913 in IL-17A, rs763780 in IL-17F, and rs4819554 in IL-17RA may not play a role in the pathogenesis of preeclampsia in Chinese Han women.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26451724            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL17F and IL17RA polymorphisms modulate susceptibility to cerebral malaria(CM) and provide evidence that IL-17F protects against CM.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26667835            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased expression of IL-17RA plays an important role in gastric cancer progression, migration and prognosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261590            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Both genetic variants of IL-17R (rs882643 and rs2241049) were associated with PGD. This confirms a genetic predisposition toward PGD and suggests a role of IL-17 in driving neutrophilia in PGD.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25935436            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The presence of IL7R polymorphisms seems to be related to severe liver disease in HIV\/hepatitis c virus coinfected patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26123260            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression of immunoreactivity for IL-17A, IL-17RA, IL-17E, and IL-17F was significantly elevated in prostatic tissue from benign prostatic hyperplasia and prostate cancer compared with that in controls            \u003ca rel=\"nofollow\"\u003e             PMID:                        26356122            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic polymorphism is associated with a reduced renal filtration rate, and with the risk of developing end stage renal disease in healthy elderly from Spain            \u003ca rel=\"nofollow\"\u003e             PMID:                        25636567            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL17RA polymorphisms, but not those of IL17, can influence both the development and the bilaterality of papillary thyroid carcinoma            \u003ca rel=\"nofollow\"\u003e             PMID:                        25484349            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17R was almost exclusively expressed by endothelial cells, not by myeloma cells in the masses of skeletal extramedullary disease patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24916639            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin-17 receptor A crystal structure shows that the downstream motif of IL-17RA SEFIR together with helix alpha C could provide a composite ligand-binding surface for recruiting Act1 during IL-17 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24816115            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL17-dependent retinal degeneration in a mouse model of focal retinal degeneration can be prevented by gene therapy with adeno-associated virus vector encoding soluble IL17 receptor            \u003ca rel=\"nofollow\"\u003e             PMID:                        24780906            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Whereas no association was found between the alternative splicing SNP, rs6897932, and multiple sclerosis, a significant link was found between the promoter single nucleotide polymorphism, rs11567685, and the disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24166352            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variation in interleukin-17 receptor A is functionally associated with chronic rejection after lung transplantation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24263024            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that the interleukin (IL)-17 receptor IL-17RA variant is generated by spliced out of exon 11 encoding the transmembrane region in a variety of tissues.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24084331            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The increased IL-25 levels in plasma and the expression of IL-17RA and IL-17RB on eosinophils in allergic asthma patients suggests that IL-25 may activate eosinophils during allergic inflammation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24247484            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crystal structures of homodimeric IL-17A and its complex with IL-17RA, are reported.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23695682            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Il-17R SNPs were not associated with psoriatic arthritis susceptibility in northern Italians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22955875            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            polymorphism of IL-17R plays no significant role in incidence of chronic periodontitis and Periimplantitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23852838            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results might be helpful for explaining the missing heritability of the psoriasis due to epistasis and provide a deep insight into the important role of the IL23\/Th17 pathway in the pathogenesis of psoriasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22909235            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that the interleukin 17 receptor A (IL17RA) minor alleles of the three single nucleotide polymorphisms (SNP) may decrease the risk of Aspirin Exacerbated Respiratory Disease (AERD) via attenuation of IL17RA gene expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23220496            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A\/IL-17RA interaction promoted the metastasis of OS in nude mice.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23192273            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data indicates that serum IL-17 levels are significantly increased in intractable Graves disease and affected thyrocytes show functional IL-17R expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23501056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Two polymorphisms within the IL17E and IL17RA genes are associated with ESRD independent of age and sex.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23147652            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that IL-17RA, IL-17RC, IL-22R1, ERK1\/2 MAPK and NF-kappaB pathways are involved in Th17 cytokine-induced proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22898922            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            protein levels of IL-17 and IL-17R positively correlated with the frequency of seizures in focal cortical dysplasias patients patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23334598            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IFN-alpha could be associated with the expansion of IL-7Ralpha(low) CD45RA(+) EM CD8(+) T cells in the CMV-uninfected elderly            \u003ca rel=\"nofollow\"\u003e             PMID:                        22484243            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blockage of IL-17RA with an anti-IL-17RA antibody inhibited the production of IL-6, IL-8, and MMP-3; demonstrate the functional significance of IL-17RA in psoriatic arthritis            \u003ca rel=\"nofollow\"\u003e             PMID:                        21894442            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            mRNA levels of IL-17, IL-17R and MMP-9 were also higher in the invasive group than in the non-invasive group in human pituitary adenomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21279695            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17\/IL-17RA signaling plays an important role in myocardial collagen metabolism in hypertension-induced diastolic dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21530504            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17 may have an important role in the occurrence of nasal polyps by specific combination with IL-17R and over-expression in nasal polyps.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16874957            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Human periodontal ligament fibroblasts are a target of Th17, and that IL-17 appears to up-regulate the expression of IL-23 p19 via a homeostatic mechanism involving Akt-, p38 MAPK-, and ERK 1\/2-dependent NF-kappaB signalling versus the JNK\/AP-1 pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21145111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            an extended SEFIR domain is required for il-17RA-mediated signal transduction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20729198            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis            \u003ca rel=\"nofollow\"\u003e             PMID:                        11966773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            cell membrane IL-17R is required for signaling by both IL-17A and IL-17F            \u003ca rel=\"nofollow\"\u003e             PMID:                        15972674            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In this JEG-3 cell model of human trophoblast, the IL-17 receptor may have a regulatory role in trophoblast invasion.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16533341            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915031216353,"sku":"BL-0006NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLYmAPKKDAACgQrRtB7o532_3a1c2e7b-79fc-4e43-8a21-d9bb89f8351d.jpg?v=1685850959"},{"product_id":"recombinant-human-il15ra-protein-fc-tag-bl-0008np","title":"Recombinant Human IL-15RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-15 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Ile31-Thr172 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q13261-3\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q13261\/entry#Q13261-3\"\u003eQ13261-3\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD215; IL15RA; CD215 antigen; IL-15 receptor subunit alpha; IL-15RA; IL-15R-alpha; interleukin 15 receptor; alpha; interleukin-15 receptor subunit alpha; MGC104179\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 15 Receptor alpha (IL-15Rα) is a transmembrane glycoprotein that plays a pleiotropic role in immune development and function, including the positive maintenance of lymphocyte homeostasis. IL-15Rα chain can bind soluble IL-15 and “transpresent” cytokine to the cells, allowing them to respond to IL-15. Soluble IL-15Rα can function as a specific high-affinity IL-15 antagonist. The soluble IL-15\/IL-15Rα complexes exhibit a strong agonistic activity which is mediated through membrane-bound IL-15 receptor β and γ heterodimers and enables signaling to cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e42.2 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-75 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915103797473,"sku":"BL-0008NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZOAOxFtAACa3CON6zA424_6f4678af-66d5-43e5-b7a4-7689fdc5195c.jpg?v=1685853391"},{"product_id":"recombinant-mouse-il15ra-protein-fc-tag-bl-0009np","title":"Recombinant Mouse IL-15RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-15 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Gly33-Lys205 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ60819\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-15 receptor subunit alpha; Il15ra; sIL-15 receptor subunit alpha\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMouse interleukin-15 receptor subunit alpha, also known as Il15ra, is a high-affinity receptor for interleukin-15. Il15ra associates as a heterotrimer with the IL-2 receptor beta and gamma subunits (Common gamma chain, or gamma c) to initiate signal transduction. It can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. Il15ra is expressed in special cells including a wide variety of Tand B cells and non-lymphoid cells. Human Il15ra shares 45% amino acid sequence homology with the mouse form of the receptor. Eight isoforms of IL-15 R alpha mRNA have been identified, resulting from alternative splicing events involving different exons.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45.5 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-90 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHigh-affinity receptor for interleukin-15. Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. In neutrophils, binds and activates kinase SYK in response to IL15 stimulation. In neutrophils, required for IL15-induced phagocytosis in a SYK-dependent manner.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein. Cell surface.; [Soluble interleukin-15 receptor subunit alpha]: Secreted, extracellular space.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:16169           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000077878           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28602725            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            These data provide additional evidence to implicate IL-15Ralpha as a regulator of skeletal muscle phenotypes through effects on the mitochondrion, and suggest these effects are driven by alterations to the mitochondrial proteome.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26458787            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Spontaneous cage activity was not different and IL-15 protein levels were lower in male and female mIl15ra(fl\/fl)\/Cre(+) mice.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25505029            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Despite being protected against diet induced obesity, IL-15R alpha knockout mice are hyperglycemic and insulin-resistant.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26269523            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Signaling through IL-15Ralpha regulates the development of gammadelta-17 cells early in ontogeny.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26195801            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            lower frequencies of IL-15Ralpha expression in PBMCs of Behcet's disease-like symptomatic mice            \u003ca rel=\"nofollow\"\u003e             PMID:                        23618691            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Epidermal IL-15Ralpha acts as an endogenous antagonist of psoriasiform inflammation in mouse and man.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24019554            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a greater mitochondrial density and mitochondrial DNA content was found in fast muscles from IL-15-Receptor-alpha KO mice that was not due to the presence of smaller muscle fibers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23116661            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15 is produced and secreted only as a heterodimer with IL-15Ralpha.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22496150            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Stage 3 thymic invariant natural killer NKT cells are specifically reduced in IL-15Ralpha-deficient mice, whereas the acquisition of natural killer (NK) receptors occurs at stage 3 IL15-dependent thymic cell development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21709149            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Different levels of IL-15 trans-presentation are required for different natural killer (NK) cell developmental events to reach full maturation status            \u003ca rel=\"nofollow\"\u003e             PMID:                        21715685            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15 receptor alpha has a role in endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles            \u003ca rel=\"nofollow\"\u003e             PMID:                        21765213            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The disrupted circadian rhythm of temperature and activity in the IL15Ralpha KO mice after LPS suggests that upregulated IL15 receptors may serve a beneficial role to counteract the consequences of neuroinflammation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20981579            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL15 is essential to maintain neurochemical homeostasis and thereby plays a role in preventing neuropsychiatric symptoms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20724079            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL15Ralpha is co-localized with co-receptor IL2Rgamma and IL-15 in neuroinflamed cerebral endothelia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21155807            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL15Ralpha is essential for normal anxiety-like behavior, but inhibition of gliosis in the fearless IL15Ralpha knockout mice or IL15 treatment of normal mice did not acutely modulate behavioral performance as tested            \u003ca rel=\"nofollow\"\u003e             PMID:                        20600810            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            T cells expressing low-avidity T cell receptors respond poorly to IL-15\/IL-15Ralpha complex, which correlates with a poor homeostatic proliferative response to lymphopenia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21041729            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            LFA-1 signal defect-induced CD8(+) T cell apoptosis is associated with reduced CD27 costimulation and IL-15R survival signal, elucidating the molecular mechanism associated with LFA-1 signaling in effector and memory CD8(+) T cell survival            \u003ca rel=\"nofollow\"\u003e             PMID:                        20569988            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Identified four novel IL15Ralpha splice variants in mouse cerebral microvessels composing the BBB, and showed their differential distribution and functions in endothelial signaling in response to IL15.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20374432            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that activation of hypothalamic neurons by IL-15 in mice contributes to thermoregulation and modifies the metabolic phenotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20012227            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15Ralpha(-\/-) renal cells exhibited a higher rate of cisplatin-induced apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        19958157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL15R signaling is essential to maintain hippocampal GABA concentrations, at least partially involving reduced GABA turnover, and results in facilitation of memory consolidation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20357123            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of soluble IL-15Ralpha (sIL-15Ralpha) mRNA declined 5-fold with age            \u003ca rel=\"nofollow\"\u003e             PMID:                        19854259            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Neuronal development in olfactory epithelium (OE) is inhibited by interleukin (IL)-15Ralpha deficiency because of decreased proliferative activity but not promoted apoptosis of OE cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        20021484            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that the short lifespan of T(H)17 cells was associated with small amounts of the antiapoptotic protein Bcl-2, the IL-15 receptor and the receptor CD27.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19935657            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15R alpha deficiency results in specific decreases in both the number and Bcl-2 content of CD8+ T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        11777964            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Treatment with soluble interleukin-15Ralpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response. (IL-15R alpha)            \u003ca rel=\"nofollow\"\u003e             PMID:                        12045244            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of the high-affinity receptor, IL-15R alpha, on T cells is dispensable for the generation or maintenance of memory CD8(+) T cells. By contrast, IL-15R alpha expression on cells other than T cells is absolutely critical for this function.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12671073            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings demonstrate that natural killer (NK) cell-independent interleukin-15 receptor alpha (IL-15Ralpha) expression is critical for maintaining peripheral NK cells, while IL-15Ralpha expression on NK cells is not required for this function.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12695489            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SOCS1 functions as an indispensable attenuator of IL-15 receptor signaling in developing CD8+ thymocytes            \u003ca rel=\"nofollow\"\u003e             PMID:                        12907450            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15 receptor alpha chain expression on developing natural killer (NK) cells is not critically important for the development of CD94\/NKG2+ lytic NK cells, but is required for further acquisition of Ly-49 receptors by NK cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14607906            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15 receptor alpha expression by murine dendritic cells is critical for natural killer (NK) cell activation and presentation of IL-15 in trans to NK cells during NK cell priming.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15356102            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15Ralpha defines homeostatic niches for NK and memory CD8+ T cells by controlling both the production and the presentation of IL-15 in trans to NK and CD8+ memory T cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        15452177            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15Ralpha can act in cis in addition to acting in trans to present IL-15 to responding cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18796634            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15 expression alone in TC-1 tumor cells partially inhibits tumor growth whereas IL-15 and IL-15Ralpha expression together completely inhibits tumor growth in a natural killer 1.1-positive cell- and CD8-positive T cell-dependent manner.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19050240            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The decidual leucocytes also up-regulated IL-15 and IL-15Ralpha in stromal fibroblasts which could produce a niche for uNK cells allowing proliferation within and recruitment into the uterus.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19088135            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Dendritic cell derived-exosomes promoted an IL-15Ralpha- and NKG2D-dependent NK cell proliferation and activation respectively, resulting in anti-metastatic effects            \u003ca rel=\"nofollow\"\u003e             PMID:                        19319200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that potential nuclear function of cleaved interleukin-2 receptor beta-chain and IL-15 receptor alpha-chain subunits is not plausible.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19329337            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            E4BP4 acted in a cell-intrinsic manner 'downstream' of the interleukin 15 receptor (IL-15R) and through the transcription factor Id2            \u003ca rel=\"nofollow\"\u003e             PMID:                        19749763            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-15R alpha expression on macrophages but not dendritic cells (DCs) supports the early transition of antigen specific effector CD8(+) T cells to memory cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        19913445            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915103600865,"sku":"BL-0009NP","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-mouse-il4ra-protein-fc-tag-bl-0029np","title":"Recombinant Mouse IL-4RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-4 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Ile26-Arg233 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P16382\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P16382\/entry\"\u003eP16382\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-4 receptor subunit alpha;IL-4R-alpha;CD124;IL4-BP;Soluble IL-4R-alpha\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-4 receptor subunit alpha(IL-4RA), alos known as Soluble IL-4 receptor subunit alpha, belongs to the type I cytokine receptor family and type 4 subfamily. It expressed in both Th1 and Th2 cells. It functions as receptor for both interleukin 4 and interleukin 13 and couples to the JAK1\/2\/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4\/IL13 responses are involved in regulating IgE production and chemokine and mucus production at sites of allergic inflammation. In certain cell types, IL-4RA can signal through activation of insulin receptor substrates, IRS1\/IRS2. The functional IL4 receptor is formed by initial binding of IL4 to IL4R. Subsequently it recruits to the complex of the common gamma chain. In immune cells, IL-4RA creates a type I receptor. In non-immune cells, it forms a type II receptor with of IL13RA1. IL4R can also interact with the IL13\/IL13RA1 complex to form a similar type II receptor and interacts with the SH2-containing phosphatases, PTPN6\/SHIP1, PTPN11\/SHIP2 and INPP5D\/SHIP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e51.5 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e65-80 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915028070625,"sku":"BL-0029NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWaARYylAACovCG_Mck532_566e72f9-2a9d-48c5-8d2d-c7fadff628f6.jpg?v=1685850873"},{"product_id":"recombinant-mouse-il13ra1-protein-fc-tag-bl-0032np","title":"Recombinant Mouse IL-13RA1 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-13 Receptor Subunit Alpha-1 is produced by our Mammalian expression system and the target gene encoding Ala25-Thr340 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"O09030\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/O09030\/entry\"\u003eO09030\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-13 receptor subunit alpha-1; IL-13RA1; Interleukin-13-binding protein; Novel cytokine receptor 4; NR4; CD213a1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-13 receptor subunit alpha-1(IL-13RA1), also known as NR4, belongs to the hemopoietin receptor family. Interleukin-13 receptor is a complex of IL4R, IL13RA1, and possibly other components. It interacts with TRAF3IP1 and binds with low affinity to interleukin-13(IL3). IL-13RA1, together with IL4RA, can form a functional receptor for IL13. It also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity. The WSXWS motif in domains appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e63 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e80-120 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915079352545,"sku":"BL-0032NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWeAFh0OAACx8WY-Km8989_3476d50b-81bd-4a25-9c3d-fd8e315758bd.jpg?v=1685852425"},{"product_id":"recombinant-human-il17b-protein-fc-tag-bl-0038np","title":"Recombinant Human IL-17B Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-17B is produced by our Mammalian expression system and the target gene encoding Gln21-Phe180 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ9UHF5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ecytokine Zcyto7;IL-17B; interleukin-17 beta; interleukin-17B;neuronal interleukin-17 related factor; Neuronal interleukin-17-related factor; NIRF; ZCYTO7interleukin-Cytokine Zcyto7; cytokine-like protein ZCYTO7; interleukin-17 beta;interleukin-17B; interleukin 17B; neuronal interleukin-17 related factor; Neuronal interleukin-17-related factor;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17B (IL-17B) is a member of IL-17 cytokines family that plays important roles in host defence responses and inflammatory diseases. In addition to IL-17B, members of the IL-17 family include IL-17A, IL-17C, IL-17D, IL-17E and IL-17F. The six IL-17 cytokines are highly conserved at C terminus, and contain five spatially conserved cysteine residues that mediate dimerization. Expression of IL-17B protein has been reported in neurons, testis, ovary, stomach, pancreas, small intestine and chondrocytes. IL-17B binds to Interleukine-17 receptor B (IL-17 RB) and induces the production of inflammatory cytokines and the infiltration of inflammatory immune cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45.1 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e48 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eStimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-17 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            5982           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            604627           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:27190           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000261796           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27146881            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Our data revealed a new mechanism that IL-17B enhanced the progression of gastric cancer by activating mesenchymal stem cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28145881            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Segregation analysis revealed that variants c.475T\u0026gt;G in SKP1, c.671G\u0026gt;A in PROB1, and c.527G\u0026gt;A in IL17B in the 5q31.1-q35.3 linkage region, and c.850G\u0026gt;A in HKDC1 in the 10q22 locus completely segregated with the phenotype in the studied Keratoconus family            \u003ca rel=\"nofollow\"\u003e             PMID:                        27703147            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This comprehensive review details the recognition of activity, signaling, and the roles of IL17B-IL17RB in breast cancer have caused to determination of new therapeutic mechanisms--{REVIEW}            \u003ca rel=\"nofollow\"\u003e             PMID:                        28160754            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studies indicate that interleukin 17 (IL-17B)\/interleukin 17 receptor B (IL-17RB) signaling is essential for pancreatic cancer malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26285835            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17B-IL-17RB signaling promotes pancreatic cancer malignancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25732306            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that amplified signaling of interleukin-17 receptor B (IL-17RB) and its ligand IL-17B promot tumorigenicity in breast cancer cells and impeded acinus formation in immortalized normal mammary epithelial cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23851503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17B can enhance the effects of TNF-alpha on the production of cytokines and chemokines that control immune cell trafficking and neutrophil homeostasis in the inflamed tissues.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24056520            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A, IL-17B, IL-17F and IL-23 in systemic lupus erythematosus patients were examined and the correlation between levels of the investigated cytokines and VEGF, PIGF, as well as number of endothelial cells, was investigated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23661335            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression and functional study of IL-17B            \u003ca rel=\"nofollow\"\u003e             PMID:                        22394632            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17 may play an important role in the occurrence of nasal polyps by overexpression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16805377            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915064541409,"sku":"BL-0038NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWqAX3MjAACiqLDWojI377_52864ceb-f09b-4ef5-8598-bd35f44799bd.jpg?v=1685851994"},{"product_id":"recombinant-human-il18bp-protein-fc-tag-bl-0042np","title":"Recombinant Human IL-18BP Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-18-binding Protein is produced by our Mammalian expression system and the target gene encoding Thr31-Gly194 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eO95998\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-18-binding protein; Tadekinig-alfa and IL18BP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-18-binding protein, also known as Tadekinig-alfa and IL18BP, contains 1 Ig-like C2-type domain. IL18BP is constitutively expressed and secreted in mononuclear cells. IL18BP functions as an IL18 inhibitor. IL18BP binds to IL18, prevents the binding of IL18 to its receptor, and thus inhibits IL18-induced IFN-gamma production. It has been shown that IL18BP may be a promising molecular approach to inhibit neointimal hyperplasia and arteriosclerosis progression following coronary and peripheral angioplasty.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e44.8 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-75 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIsoform A binds to IL-18 and inhibits its activity. Functions as an inhibitor of the early TH1 cytokine response.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            5987           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            604113           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:10068           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000260049           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27649785            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            epigenetic silencing by single CpG methylation determines differential IL18BP inducibility in monocytic versus epithelial cells. T            \u003ca rel=\"nofollow\"\u003e             PMID:                        29409936            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a large proportion blood basophils from patients with asthma express IL-18 and IL-18BP.  mast cells and basophils are implicated in the pathogenesis of asthma via an IL-18-related mechanism.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29505668            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The maintenance of normal production of IL-18BP may contribute, at least in part, to the ability ofLong Term Non-Progressors to delay AIDS progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27863336            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Platelets also contain the IL-18 antagonist, the IL-18-Binding Protein (IL-18BP); however, it is not synthesized in them de novo, is present in pre-made form and is released irrespective of platelet activation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27914933            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The serum levels of IL-37, which were correlated with antibody production and the serum levels of total IL-18 and IL-18BP, were elevated in the patients with primary Sjogren's syndrome.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28057714            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            an imbalance in the production of IL-18 and its antagonist (an increase in the production of IL-18 with a decrease, no increase or an insufficient increase in the production of IL-18BP) has been described in many chronic inflammatory diseases in humans.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26898120            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-18, IL-18R and IL-18BP expression in eosinophil are involved in the inflammatory reaction of asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28395725            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the inhibition of IL-18 signaling by IL-18BPa may be involved in the development of pulmonary vascular involvement leading to pulmonary hypertension and modulate the systemic inflammation in systemic sclerosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        26777734            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The natural IL-18 inhibitor IL-18BP further regulates IL-18 activity in the extracellular environment. Review.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25548255            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            imbalance of IL-18\/IL-18BP ratio in IgA nephropathy especially in patients with arteriolar lesions            \u003ca rel=\"nofollow\"\u003e             PMID:                        25807634            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-18, IL-18BP, and IL-18R may have roles in the pathogenesis of epithelial ovarian carcinoma            \u003ca rel=\"nofollow\"\u003e             PMID:                        24963217            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            HPV16 E7 oncoprotein increases production of the IL18BP in keratinocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24478434            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these data indicate that IL-18BP, which is produced in EOC in response to microenvironmental factors, may inhibit endogenous or exogenous IL-18 activity            \u003ca rel=\"nofollow\"\u003e             PMID:                        23873689            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that the imbalance of IL-18\/IL-18BP might play an important role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA) and it might go hand-in-hand with the severity of SJIA.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23419721            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Due to highly significant increases in circulating IL-18BP in schizophrenia compared to controls, the levels of free IL-18 are not significantly different between schizophrenic groups.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22913567            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Imbalance between IL-18 and IL-18BP may play an important role in pathogenesis of idiopathic thrombocytopenic purpura.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21867627            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High IL-18 BP levels indicate the severity of existing glomerular injury in systemic lupus erythematosus.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21656327            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The balance between interleukin-18 (IL-18) and its endogenous antagonist, IL-18 binding protein (IL-18BP), was evaluated in children with Henoch-Schonlein purpura.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22289535            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-18\/IL-18BP imbalance plays an important role in pathogenesis of primary immune thrombocytopenia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21418867            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In T2DM patients, 18 BP began to increase after IL-18 increased and reached a threshold, in which case kidney dysfunction would have developed.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21440322            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            increased levels of both IL-18 and its natural inhibitor IL-18BP, characterise SLE            \u003ca rel=\"nofollow\"\u003e             PMID:                        21126942            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In lines of intestinal epithelial cells from inflammatory bowel disease patients, interferon-gamma selectively up-regulated IL-18 binding protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21078084            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            lupus nephritis patients present lower IL-18BP mRNA expression and higher serum levels of IL-18 than those in normal controls            \u003ca rel=\"nofollow\"\u003e             PMID:                        20140691            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Altogether, data presented herein indicate that direct action of STAT1 on the IL-18BP promoter at the proximal GAS element is key to IL-18BP expression by IFN-gamma-stimulated DLD-1 colon carcinoma cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        19046253            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High circulating levels in patients with active Systemic Lupus Erythematosus            \u003ca rel=\"nofollow\"\u003e             PMID:                        19699611            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Endometrial interleukin-18 binding protein mRNA expression may possibly be responsible for the pathologic process of adenomyosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19394601            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that an early rise in IL-18 levels may play a role in reverse remodeling process following aortic valve replacement.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19961286            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Since IL-18 plays a major role in perpetuating hemophagocytosis, the failure of IFNgamma to induce IL-18BP may constitute a fundamental pathogenetic mechanism            \u003ca rel=\"nofollow\"\u003e             PMID:                        20072626            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            trancriptional activation and release of IL-18 binding protein in response to IFN-gamma            \u003ca rel=\"nofollow\"\u003e             PMID:                        11739524            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-18BP messenger transcript and protein are significantly increased in surgically resected specimens from active Crohn's disease compared with control patients, correlating with an up-regulation of IL-18.            \u003ca rel=\"nofollow\"\u003e             PMID:                        11907126            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            after binding to IL-18BP, IL-1F7b forms a complex with IL-18Rbeta, depriving the beta-chain of forming a functional receptor complex with IL-18Ralpha and thus inhibiting IL-18 activity            \u003ca rel=\"nofollow\"\u003e             PMID:                        12381835            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IRF-1-CEBPbeta complex activate the promoter of IL-18 binding protein.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12482935            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Administration of recombinant human IL-18BP not only reduces symptoms of murine contact hypersensitivity (CHS) during the elicitation phase but also significantly decreases inflammation in mice that had previously undergone CHS without treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12874202            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High endogenous levels of IL-18BP in trangenic mice effectively neutralize IL-18 and are protective in response to different inflammatory stimuli.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12960225            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            production of IL-18BP in response to IL-12 and IL-18 was regulated differently in blood and synovial cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15188356            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-18 levels, which are determined in part by variation in IL18\/IL18BP, play a role in coronary heart disease development and postsurgery outcome.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17951325            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Despite the elevated IL-18BP levels during active disease, free IL-18 remained higher than in the inactive disease stages, suggesting a potential benefit of administration of exogenous IL-18BP as a therapeutic approach for active Wegener's granulomatosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18594952            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915104551137,"sku":"BL-0042NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWuADdA6AACMNx95gjY452_f497eb1b-3c4e-4197-ae40-ce7b5e178ca1.jpg?v=1685853417"},{"product_id":"recombinant-human-il10rb-protein-fc-tag-bl-0047np","title":"Recombinant Human IL-10RB Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-10 Receptor Subunit Beta is produced by our Mammalian expression system and the target gene encoding Met20-Ser220 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q08334\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q08334\/entry\"\u003eQ08334\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-10 receptor subunit beta(IL10RB);Cytokine receptor class-II member 4;Cytokine receptor family 2 member 4;Interleukin-10 receptor subunit 2;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-10 receptor subunit beta(IL10RB), also known as Cytokine receptor class-II member 4,Cytokine receptor family 2 member 4,Interleukin-10 receptor subunit 2, belongs to the type II cytokine receptor family. IL10RB is a single- pass type I membrane protein and contains two fibronectin type-III domains. It is an accessory chain which is essential for the active interleukin 10 receptor complex. Coexpression of IL10RB and IL10RA proteins has been shown to be required for IL10-induced signal transduction. Defects in IL10RB are the cause of inflammatory bowel disease type 25 (IBD25) which is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50.6 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e75-95 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915105632481,"sku":"BL-0047NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLW2ABv0rAACYbkoheCU865_27e2b822-d8c5-41a4-83ae-1bedf2a392f9.jpg?v=1685853460"},{"product_id":"recombinant-human-il2r-protein-fc-tag-bl-0091np","title":"Recombinant Human IL-2RG Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cytokine Receptor Common Subunit Gamma is produced by our Mammalian expression system and the target gene encoding Leu23-Ala262 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP31785\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytokine receptor common subunit gamma; IL2RG; Interleukin-2 receptor subunit gamma; IL-2 receptor subunit gamma; IL-2R subunit gamma; gammaC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL2RG contains one fibronectin type-III domain. IL2RG is an important signaling component of many interleukin receptors, including those of interleukin -2, -4, -7 and -21, and is thus referred to as the common gamma chain. IL2RG interacts with SHB upon interleukin stimulation and HTLV-1 accessory protein p12I. Defects in IL2RG are the cause of X-linked combined immunodeficiency (XCID) and severe combined immunodeficiency X-linked T-cell-negative \/B-cell-positive \/ NK-cell-negative (XSCID).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e55.4 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e85-100 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCommon subunit for the receptors for a variety of interleukins. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein. Cell surface.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 5 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6010           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            300400           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3561           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000363318           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29388853            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            New insights of common gamma chain in hematological malignancies.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26748725            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that downregulation of miR-3940-5p promotes T-cell activity by targeting the cytokine receptor IL-2R gamma on human cutaneous T-cell lines            \u003ca rel=\"nofollow\"\u003e             PMID:                        27502164            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            systematic scoping review highlights the many potential uses of soluble interleukin-2 receptor measurement in the diagnosis and treatment of hemophagocytic syndromes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28497365            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype            \u003ca rel=\"nofollow\"\u003e             PMID:                        27566612            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            novel missense mutation in Japanese patient results in atypical X-linked severe combined immunodeficiency with the presence of T cells and NK cells and revertant somatic mosaicism            \u003ca rel=\"nofollow\"\u003e             PMID:                        26407811            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            reversion of mutation in common lymphoid progenitor results in mild phenotype of SCID            \u003ca rel=\"nofollow\"\u003e             PMID:                        26076747            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High IL2RG expression is associated with Sezary syndrome.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26551670            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Identification of a gammaC splice isoform revealed expression of soluble gammaC proteins (sgammaC). sgammaC directly interacted with surface IL-2Rbeta to suppress IL-2 signaling and to promote pro-inflammatory Th17 cell differentiation. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26468051            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study show the detection of IL2RG mutations in 2 families with X-SCID and identified 2 novel mutations, confirming the X-SCID pedigrees.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26125817            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin 2 receptor subunit gamma mutation is associated with X-linked severe combined immunodeficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26409833            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26183780            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results demonstrate that IL2Rgamma has an onogenic role in JAK3-mutation-positive leukemias.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25109334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that over-expression of the IL2RG gene may be implicated in altered immune response in schizophrenia and contribute to the pathomechanisms of this disorder            \u003ca rel=\"nofollow\"\u003e             PMID:                        24713359            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this is the first report on a de novo mutation in the IL2RG gene in a patient born after IVF            \u003ca rel=\"nofollow\"\u003e             PMID:                        23790094            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In a patient with a novel IL2RG mutation, gene-reverted CD8+ T cells accumulate over time.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23403317            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            in humans, signaling through the gammac pathway is not required for prethymic lymphoid commitment or for DNA rearrangement.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24771849            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we presented here a novel IL-2Rgammac mutation in a carrier and SCID patient presenting NK cells in the peripheral blood            \u003ca rel=\"nofollow\"\u003e             PMID:                        23940110            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Massively parallel sequencing reveals maternal somatic IL2RG mosaicism in an X-linked severe combined immunodeficiency family.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23683512            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Tax-specific cytotoxic T-lymphocyte cell treatment significantly decreases human soluble IL-2Rgamma serum concentrations and prolongation of survival time in a mouse model of adult T cell leukemia\/lymphoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23733874            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of multiorgan metastasis of human HER-2+ breast cancer in Rag2-\/-;Il2rg-\/- mice and treatment with PI3K inhibitor            \u003ca rel=\"nofollow\"\u003e             PMID:                        22737248            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data highlight the central role of IL-15 and gammac-receptor signaling in renal homeostasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22363690            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the amount of the gamma-chain transducing element is able to influence the transcription of genes involved in cell cycle progression, thus being directly involved in the regulatory control of cell proliferation of malignant hematopoietic cell            \u003ca rel=\"nofollow\"\u003e             PMID:                        22223761            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data imply that IL-21-mediated signaling is critical for long-lived humoral immunity and to restore antibody responses in IL2RG\/JAK3-deficient patients after hematopoietic cell transplantation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22039266            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We report a novel X-CID family with a unique mutation in the extracellular part of CD132 with almost normal T-cell counts but defective memory induction            \u003ca rel=\"nofollow\"\u003e             PMID:                        21831415            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21715655            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-2Rgamma(c) reconstituted T cells may persist more efficiently than natural killer (NK) cells due to compensation for suboptimal IL-2Rgamma(c) signaling by T cell receptors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20592278            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival and is regulated by theaflavins            \u003ca rel=\"nofollow\"\u003e             PMID:                        19812686            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma sIL-7Ralpha and sgamma(c) are present as heterocomplexes and sgamma(c) was found to be mainly associated with sIL-7Ralpha            \u003ca rel=\"nofollow\"\u003e             PMID:                        19494261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            presence of membrane-associated as well as soluble gamma c in cell lysates and cell free supernatants from peripheral blood lymphocyte cultures; panel of human serum samples was examined and compared with sIL-2R            \u003ca rel=\"nofollow\"\u003e             PMID:                        12036606            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In normal lung fibroblasts IL-4 \u0026amp; IL-13 induce gamma c chain \u0026amp; its association with JAK3. In myofibroblasts, constitutive gamma c chain together with JAK3 controls TYK2 phosphorylation \u0026amp; the balance between functional \u0026amp; decoy high-affinity receptors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12207328            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Human IL-21 and IL-4 bind to partially overlapping epitopes of common gamma-chain.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12504082            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The development of breast tumour is associated with an increased expression of IL-2 receptor gamma and this expression also seems to be associated with the malignancy of the tumour.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14680494            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A mutation in this locus resulting in severe combined immunodeficiency, initially diagnosed as HIV infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15702055            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The common cytokine receptor gamma-chain is a required signaling subunit of the growth hormone receptor (GHR) complex in B cell lines. Genetic alteration of the IL2RG gene results in growth failure in X-linked severe combined immunodeficiency (X-SCID).            \u003ca rel=\"nofollow\"\u003e             PMID:                        17082603            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results confirm that signal transduction via the IL-15R, and hence NK ontogeny, is preferentially retained relative to the IL-7R as gammac expression becomes limiting.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17363735            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Review describes current state of knowledge of how the gamma c cytokine network is affected during HIV infection, with a focus on how this impairs CD4+ and CD8+ T cell function while also benefiting the virus itself.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18417356            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report the selective expansion of genetically modified T cells using an antibody\/IL2RG receptor chimera.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18589435            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This suggests a role for gamma(C) cytokines in the pathogenesis of diseases in which CD127 expression is altered on CD8+ T cells such as in progressive viral infections and cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19011158            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Self-sufficient growth of B lymphoblastoid cells in X-linked combined immunodeficiency disease (SCID) cell lines is strongly dependent on common gamma-chain expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19234229            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the loss of NEDD4 association on IL-2Rgamma(c) is accompanied by a dramatic increase of the half-life of the receptor subunit.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19615332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Transgenic Jak3-dependent common gamma c cytokine signals are not required for naive primary CD4-positive T cell proliferation and cell cycle regulation in vitro.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19734221            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Meta-analysis and HuGE review of genotype prevalence, gene-disease association, genetic testing, and healthcare-related. (HuGE Navigator)            \u003ca rel=\"nofollow\"\u003e             PMID:                        14726805            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The immature form of the gamma(c) chain is a 54-58 kDa intracellular component localized in the endoplasmic reticulum of resting, unstimulated CD4 T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        11418669            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915101896929,"sku":"BL-0091NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLY-AEd_XAACYbIIOiq4030_a4b9efbe-e052-441f-8d34-834af0e3a2bd.jpg?v=1685853319"},{"product_id":"recombinant-human-il2ra-protein-fc-tag-bl-0100np","title":"Recombinant Human IL-2RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-2 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Glu22-Cys213 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP01589\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-2 receptor subunit alpha;CD25;p55;TAC antigen;IL2-RA;IL-2R subunit alpha;IL-2-RA;IL-2 receptor subunit alpha\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-2 receptor subunit alpha (IL2RA) is a single-pass type I membrane protein, contains 2 Sushi (CCP\/SCR) domains. The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e48.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-80 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6008           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            147730           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3559           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000369293           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29574662            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a significant association was found between IL2RA SNP and susceptibility to alopecia areata in Iranian cohort            \u003ca rel=\"nofollow\"\u003e             PMID:                        29979892            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The gene polymorphisms at the loci of IL2RA rs2104286 and rs12722489 are closely associated with susceptibility to MS in the Chinese.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30352019            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher frequency of IL2RA SNP could not be detected among multiple sclerosis patients. The difference of frequencies was statistically insignificant between groups, probably, due to low power of analysis and inadequate sample size.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29141792            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our meta-analysis suggests that the rs2104286 A allele is associated with increased MS risk in both Caucasians and Asians, whereas the rs12722489 C allele is associated with elevated MS risk in Caucasians but not in Asians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29648897            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            sIL-2R could be a promising new marker for determining inflammatory disease activity in CRPS.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28634419            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28511943            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28545581            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that interleukin-2 receptor alpha, tumor necrosis factor receptor 1, serum STimulation-2 (IL1RL1 gene product), and regenerating islet-derived 3-alpha were significantly associated with non-relapse mortality.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28126963            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High IL2RA expression is associated with CRLF2-rearranged acute lymphoblastic leukemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28866095            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inhibits CD25 translation through regulation of the LKB1-AMPK-mTOR pathway to suppress T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28230853            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Among patients with a low pretreatment sIL-2R level who exhibited a positive response to R-CHOP, the posttreatment sIL-2R level may help to identify those with a poor prognosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28413914            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The findings not only confirm the predictive power of CD25 expression for Philadelphia chromosome translocation (Ph)+ but also demonstrate that CD25 expression is associated with RD (a biomarker correlated with prognosis) in Ph- patients. The latter finding is likely associated with underlying molecular abnormalities, including Ph-like genotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28430957            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Through GWAS, we found that emotion dysregulation is associated at genome-wide level significance in a sex-specific manner, with a SNP in IL2RA in men.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27643478            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            it has been shown that CD25 serves as a negative growth regulator of Chronic myeloid leukemia leukemic stem cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28457753            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Decidual stromal cells affect IL-2 production and IL-2R expression and signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27651429            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The single nucleotide variant rs12722489 determines differential ERalpha binding and enhancer properties of an IL2RA intronic region.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28234966            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CDK6-mediated suppression of CD25 is required for initiation of T-ALL by activated Notch1            \u003ca rel=\"nofollow\"\u003e             PMID:                        26707936            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD4(+) CD25(+) GARP(+) Treg cells are defective in dilated cardiomyopathy patients and GARP seems to be a better molecular definition of the regulatory phenotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28207945            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studies indicate many potential uses of soluble interleukin-2 receptor measurement in the diagnosis and treatment of hemophagocytic syndromes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28497365            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that differential methylation of the IL2RA promoter in T cells could be an important pathogenic mechanism in multiple sclerosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28077880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sustained STAT5 transcription factor (STAT5) phosphorylation is necessary to induce long-term interleukin 2 receptor subunit alpha (CD25) expression in T lymphocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27936140            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Gastric adenocarcinoma patients present with increased PD-1(+) lymphocytes and CD4(+)CD25(+)FOXP3(+) regulatory T cells in the peripheral blood.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28031121            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The serum concentration of soluble IL2 receptor are increased in patients with Kawasaki disease. (Review)            \u003ca rel=\"nofollow\"\u003e             PMID:                        28081636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD25 is an independent prognostic factor in elderly AML patients. Alternative therapies for CD25-positive elderly AML patients are needed.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28097942            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The study demonstrated Increased level of CD25 in patients with active vitilligo.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27556155            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD45RA distinguishes CD4+CD25+CD127-\/low TSDR demethylated regulatory T cell subpopulations with differential stability and susceptibility to tacrolimus-mediated immunosuppression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28118317            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Combination with anti-programmed cell death protein-1 (PD-1) antibodies promoted complete tumor rejection, indicating the relevance of CD25 antigen as a therapeutic target and promising substrate for future combination approaches in immune-oncology.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28410988            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A compensatory mechanism of IL-7-mediated homeostatic proliferation can restore the inhibitory network of CD24+Foxp3+Treg cell after anti-CD25 induction therapy in islet allotransplantation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27306531            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            (99) Tc-methylene diphosphonate may improve the activity of RA through upregulating the frequency of peripheral gammadelta T cells and CD4(+) CD25(+) Foxp3(+) Tregs as well as affecting the serum cytokine environment by increasing TGF-beta and decreasing TNF-alpha and IL-6.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24467668            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-2Ra Interleukin-2 receptor antagonists (IL-2Ra) reduces the risk on new-onset diabetes after transplantation (NODAT) in liver transplant recipients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26588180            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The percentages of CD8(+)CD25(+)FoxP3(brigh) Tregs correlate with mean peak expiratory flow.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25921629            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Efficiently downregulated the percentages of CD4+CD25+Foxp3+ regulator T (Treg) cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27431260            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            introduce the combined use of CD25 and properly strati fi ed CD135 values as alternatives to testing for the FLT3-ITD mutation            \u003ca rel=\"nofollow\"\u003e             PMID:                        27087256            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that PTPN22 genetic polymorphisms play role in predisposition of type 1 diabetes mellitus in Egyptian children            \u003ca rel=\"nofollow\"\u003e             PMID:                        27288719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            dissected the first intron of the IL2RA gene and selected several single nucleotide polymorphisms (SNPs) that may influence the regulation of the IL2RA gene in cell types relevant to autoimmune pathology            \u003ca rel=\"nofollow\"\u003e             PMID:                        27876533            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Its levels correlate to disease stage, assess response to therapy and are predictive of recurrence or better survival. We suggest, therefore, using sIL-2R as a reliable prognostic marker in HNC patients as a single marker, or in a combined panel of biomarkers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27466555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD25 had an adverse prognostic impact on these patients, and this poor prognosis may not be overcome, even with transplant. Patients with AML with residual CD25-positive blasts at the time of transplant may require additional therapy before or after transplant to improve survival.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26422713            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL2RA and TAGAP are novel vitamin D target genes. The vitamin D response is observed in samples from both the multiple sclerosis (MS) patients and controls, and is not dependent on the genotype of MS-associated SNPs in the respective genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26765264            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Anti-CD25 recombinant immunotoxin LMB-2 had phase I activity limited by immunogenicity and rapid growth.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26350263            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Enhanced pretreatment CD25 expression on CD4+ T cells was associated with decreased survival rate of acute myeloid leukemia patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26721345            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function had been found in untreated ulcerative colitis patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26333292            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that an ultra-high level of serum serum soluble interleukin-2 receptor (sIL-2R) at diagnosis is a significant poor prognostic biomarker for angioimmunoblastic T-cell lymphoma (AITL).            \u003ca rel=\"nofollow\"\u003e             PMID:                        25563559            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The rs2104286 G allele in IL2RA is present at higher frequencies in neuromyelitis optica patients than in healthy controls within a Southern Han Chinese population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24257225            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that the CD34\/CD25\/CD123\/CD99(+) LAIP is strictly associated with FLT3-ITD-positive cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25957287            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin-2 Receptor alpha-Chain (CD25) Expression Predicts a Poor Prognosis in Acute Myeloid Leukemia            \u003ca rel=\"nofollow\"\u003e             PMID:                        26375984            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that interleukin 2 receptor subunit alpha (IL2RA)-single nucleotide polymorphism rs2104286 and serum sIL2Ralpha-level associated with rheumatoid arthritis (RA)-persistence.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26350950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD4+CD45RO+CD25-\/lowCD127+: CD4+CD45RO+CD25hiCD127-\/low ratio in peripheral blood indicates heart transplant recipients at risk for cardiac allograft vasculopathy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25539460            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of sIL-2R levels in sarcoidosis patients with renal insufficiency            \u003ca rel=\"nofollow\"\u003e             PMID:                        25745051            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            all five single nucleotide polymorphisms in the IL2RA gene are risk factors for type 1 diabetes risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26249556            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915016372449,"sku":"BL-0100NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZCAOCtWAACsHTi7W9Q036_55a6a400-aa7e-4e70-965b-eb9db09465e2.jpg?v=1685850598"},{"product_id":"recombinant-human-il2rb-protein-fc-tag-bl-0102np","title":"Recombinant Human IL-2RB Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-2 Receptor Subunit Beta is produced by our Mammalian expression system and the target gene encoding Ala27-Asp239 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P14784\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P14784\/entry\"\u003eP14784\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-2 receptor subunit beta;IL2RB;IL-2 receptor subunit beta;IL-2R subunit beta;High affinity IL-2 receptor subunit beta;CD122\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman IL-2RB, also known asinterleukin-2 receptor subunit beta,is the receptor for interleukin-2. IL2 receptor complex is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. IL2 receptor complex has three forms with respect to ability to bind IL2. IL-2RB is belonged to a type I  membrane protein,and has a 26 residue signal peptide, a 214 residue extracellular region, a 25 residue transmembrane region and a 286 residue cytoplasmic domain. IL-2RB is the subunit critical for receptor-mediated signaling via physically or functionally coupling to other signaling molecules, such as the Jak-STAT and Src-family protein tyrosine kinase although it lacks apparent catalytic motifs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e51.7 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-80 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915016667361,"sku":"BL-0102NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZCAVY7BAADf_H5BiY0246_0911d3e4-feb7-4316-9a6e-5a9a3a022cb4.jpg?v=1685850606"},{"product_id":"recombinant-mouse-il2ra-protein-fc-tag-bl-0109np","title":"Recombinant Mouse IL-2RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-2 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Glu22-Lys236 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P01590\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P01590\/entry\"\u003eP01590\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD25; IL-2 R alpha; IL2RA; CD25 antigen; IDDM10; IL-2 receptor subunit alpha; IL2R; IL-2R subunit alpha; IL-2-RA; IL2-RA; interleukin 2 receptor; alpha; interleukin-2 receptor subunit alpha; p55; TAC antigen; TCGFR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe interleukin 2 receptor alpha (IL2RA), also called CD25, is a type I transmembrane protein that presents on activated T cells, activated B cells, some thymocytes, myeloid precursors, and oligodendrocytes. IL2RA is a member of cytokine receptors family that utilizes the common gamma chain subunit (γc). IL2RA is expressed in most B-cell neoplasms, some acute nonlymphocytic leukemias, neuroblastomas, and tumor infiltrating lymphocytes. IL2RA associates with IL2RB (CD122) to form a heterodimer that can act as a high-affinity receptor for IL-2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e51.6 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-90 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915033247969,"sku":"BL-0109NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZOAD8RgAACvgYq3Q20182_08823b54-b9b0-4318-93da-fcb0a16f1450.jpg?v=1685851019"},{"product_id":"recombinant-human-il12rb1-protein-fc-tag-bl-0113np","title":"Recombinant Human IL-12RB1 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-12 Receptor Subunit Beta-1 is produced by our Mammalian expression system and the target gene encoding Cys24-Glu540 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP42701\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD212; IL12RB1; CD212; CD212 antigen; IL-12 receptor beta component; IL-12 receptor subunit beta-1; IL12R; IL-12R subunit beta-1; IL12RB; IL-12RB1; IL-12R-BETA1; IL-12R-beta-1; interleukin-12 receptor beta-1 chain; interleukin-12 receptor subunit beta-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin12 receptor subunit beta 1 (IL12RB1) is a type I transmembrane protein that belongs to the hemopoietin receptor superfamily. IL12RB1 can spontaneously form homodimers and -oligomers, which are able to bind IL12 with only low affinity. IL12 high affinity receptor complex is composed of two subunits designated IL12RB1 and IL12RB2. While IL12RB1 interacts with the IL-12p40 subunit, IL-12p35 is mainly connecting with IL12RB2. This receptor chain is also responsible for transmitting the IL12 signal into the cell. IL12RB1, to the contrary, is also part of the IL23R, where it interacts with the p40 subunit of IL23. IL12RB1 is expressed in activated T cells, NK cells and B cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e84.2 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e95-110 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 5% trehalose, 5% mannitol, 0.02% Tween80, pH8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFunctions as an interleukin receptor which binds interleukin-12 with low affinity and is involved in IL12 transduction. Associated with IL12RB2 it forms a functional, high affinity receptor for IL12. Associates also with IL23R to form the interleukin-23 receptor which functions in IL23 signal transduction probably through activation of the Jak-Stat signaling cascade.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 2 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            5971           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            601604           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3594           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000403103           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28450854            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            To our knowledge, this is the third patient with Mendelian susceptibility to mycobacterial disease due to IL-12Rbeta1 deficiency complicated with enteropathy and hypogammaglobulinemia and the first case of this disease to be described in Colombia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28865061            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Th17 cells expressed consistent high levels of the IL-12Rbeta1 subunit, which appeared a better predictor of responsiveness to IL-23 than the expression of the IL-23R subunit.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27645493            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Truncated IL12rbeta1\/Fc is a novel fusion protein for specific binding multiple forms of p40 subunit to exert potent anti-inflammatory effects.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26384304            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the introduction of RNA-DNA differences into an individual's IL12RB1 mRNA repertoire is a novel determinant of IL12\/23 sensitivity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26621740            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we describe cosegregation of a heterozygous germline defect in IL12RB1 and gastric cancer development in a family with IL-12Rbeta1 deficiency            \u003ca rel=\"nofollow\"\u003e             PMID:                        25467645            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            individual variability in IL12RB1 function is introduced at the epigenetic, genomic polymorphism, and mRNA splicing levels [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        25516297            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Early coupled up-regulation of IL12RB1 in CD8+ central memory and effector T cells result in better clinical outcomes in liver transplant recipients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25603847            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Strong association of rs438421 in the IL-12Rbeta1 gene with Allergic rhinitis in Chinese was demonstrated . The GG genotype of rs438421 was validated as stimulus factors to AR, while the AG genotype of rs438421 was confirmed as protective factors to AR.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24997981            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-23\/IL-23R\/IL-12Rbeta1 complex formation does not follow the classical \"site I-II-III\" architectural paradigm.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25371211            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-12Rbeta1 expression on the cell surface was negligible or absent.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23952477            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SNP rs2305743 in IL12RB1 was associated with systemic sclerosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25199642            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A review of the molecular genetics of all known IL12RB1 mutations and variants.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23864330            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL12Rbeta1 expression is lacking on CD8+ T and natural killer (NK) cell surface in a 33-year-old patient with Mycobacterium tilburgii infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24114017            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest a relationship between certain TNF-alpha and IL12B polymorphisms and the short-term response to anti-TNF-alpha drugs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23662788            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Although SNPs of the IL12RB1 gene do not seem to convey some genetic predisposition for hidradenitis suppurativa, they impact considerably on the clinical phenotype of the disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23557799            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL12RB1 is located on autosomal chromosome 19 at location 19p13.1 and comprises exons 1-9, 9b, and 10-17. IL12RB1 isoform 2 is distinct from isoform 1 and is derived from alternate 3' exon inclusion.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23024274            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL12RB1 polymorphisms may affect IL-12 and IL-23 binding and downstream effects, which are critical cytokines in the cell-mediated immune response to measles vaccine.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22504412            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that the effect of breast-feeding on food sensitization (FS) was modified by SNPs in the IL12RB1, TLR9, and TSLP genes both individually and jointly.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21689850            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            first cases in Mexico of patients with BCG disease traced to a mutation in the IL12RB1 gene, with a fatal outcome            \u003ca rel=\"nofollow\"\u003e             PMID:                        20171917            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            autosomal recessive IL12Rbeta1 deficiency who suffered from sepsis attributable to Klebsiella pneumoniae.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20855390            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Coupled regulation of interleukin-12 receptor beta-1 of CD8+ central memory and CCR7-negative            \u003ca rel=\"nofollow\"\u003e             PMID:                        20345976            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            rs438421 (IVS12+1266T\/C) SNP and the haplotype CCA (rs375947, rs438421, and rs1870063) significantly associated with atopic dermatitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        20060272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A splice acceptor mutation affecting exon 15 of the IL-12R beta 1 subunit gene results in complete loss of surface expression of this subunit, and impairment of memory CD4 T cells with Th1 effector function.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12496448            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12594833            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data suggest that the R214-T365-R378 allele, i.e., variation in IL12RB1, contribute to tuberculosis susceptibility in the Japanese population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12596048            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            impact of amino acid variations on the three-dimensional structure of the IL-12Rbeta1 protein            \u003ca rel=\"nofollow\"\u003e             PMID:                        12671732            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            surface expression of nonfunctional IL-12Rbeta1 is related to an IL12RB1 mutation            \u003ca rel=\"nofollow\"\u003e             PMID:                        15178580            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL12RB1 polymorphisms might influence the risk of development of pulmonary tuberculosis in adults            \u003ca rel=\"nofollow\"\u003e             PMID:                        15243935            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin-12 receptor beta 1 codon 378 gene polymorphism is not correlated with endometriosis development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16084898            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In individuals with the -111T\/T genotype, reduced IL-12Rbeta1 expression may lead to increased Th2 cytokine production in the skin and contribute to the development of Atopic dermatitis and other subsequent allergic diseases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16159888            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variants of IL12RB1, at least in part, confer genetic susceptibility to TB, and are associated with the progression of the disease, in Japanese.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17284226            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL12B promoter heterozygosity was associated with protection from tuberculosis in BCG-vaccinated individuals, supporting the role that IL-23, of which IL12B encodes a subunit, plays in generation of memory T cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        17392024            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A twofold increase in the percentage of CD4-resting T cells expressing IL-12Rbeta1 and IL-18Ralpha from HIV-1-infected patients; deregulation of the IL-12 and IL-18 pathways may play a role in the immunopathogenesis of HIV-1 infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17403771            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            data indicate that genetic variants of IL12RB1confer genetic susceptibility to SARS infection, but not necessary associated with the progression of the disease in Chinese population            \u003ca rel=\"nofollow\"\u003e             PMID:                        18478121            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-12Rbeta1 gene polymorphisms do not appear to be responsible for host susceptibility to nontuberculous mycobacterial lung disease in a Korean population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18493823            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-12Rbeta1- and STAT-3--dependent signals play a key role in the differentiation and\/or expansion of human IL-17-producing T cell populations in vivo.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18591412            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of a known (c.1623_1624delGCinsTT) and a novel mutation (c.65_68delCTGC of exon2) of the Interleukin-12 Receptor-beta1 gene in a patient with a fatal case of relapsing cervical lymphadenopathy due to Mycobacterium avium [case report]            \u003ca rel=\"nofollow\"\u003e             PMID:                        18940359            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A common haplotype spanning 1.45-3.51Mb was shared by all chromosomes carrying mutation 1623_1624delinsTT, an IL12RB1 mutation, which results in Mendelian Susceptibility to Mycobacterial Diseases; mutation was not detected on 100 control chromosomes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19460324            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            novel nonsense mutation in exon 4 results in protein deficiency and increased susceptibility to bacterial infections            \u003ca rel=\"nofollow\"\u003e             PMID:                        19839503            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915042193633,"sku":"BL-0113NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZSAKymRAACQPXAKf_8564_3e10b1b6-6582-4568-91e4-87407eb81915.jpg?v=1685851290"},{"product_id":"recombinant-mouse-il7ra-protein-fc-tag-bl-0119np","title":"Recombinant Mouse IL-7RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-7 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Glu21-Asp239 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP16872\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-7 receptor subunit alpha; Il7r; IL-7 receptor subunit alpha; IL-7R subunit alpha; IL-7R-alpha; IL-7RA; CD127\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 7 Receptor alpha (IL-7Rα), also known as CD127, is a 75 kDa hematopoietin receptor superfamily member that plays an important role in lymphocyte differentiation, proliferation, and survival. IL-7Rα is majorly expressed on T cells and their precursors, and early in B cell development as well, prior to the appearance of surface IgM. Dynamic regulation of IL-7Rα is important for the generation of appropriate immune responses.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e52.1 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e61-75 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 10% Sucrose, 3% Glycine, 100mM NaCl, 0.1mM EDTA, 0.05% Tween 80, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 4 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:16197           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000003981           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30451860            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            IL-7 receptor (IL-7R) is not strictly required for the development of any innate lymphoid cells subset.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28361874            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results indicate that endogenous IL-7R signals promote Th1 and Tc1 responses and IFN-gamma- and TNF-alpha production to sustain the persistence of SS-like sialadenitis in NOD mice. These findings suggest that IL-7 and Th1 cytokines could serve as promising therapeutic targets for this prevalent autoimmune disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29680668            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study demonstrates a key role for IL-7R in the generation of microenvironments required for thymic dendritic cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28890536            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            show that the differentiation of group 3 ILCs is controlled by the glutamylation of IL-7Ralpha and the induction of transcription factor Sall3            \u003ca rel=\"nofollow\"\u003e             PMID:                        28794449            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results demonstrated that forced expression of IL-7R not only improved the functionality of tolerized CD8 T cells, it also acted in synergy with PDL-1 deficiency to further promote CD8 T cell cytotoxicity to self antigens            \u003ca rel=\"nofollow\"\u003e             PMID:                        29272267            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that short-term blockade of IL-7Ralpha induces detectable changes in co-inhibitory receptor expression and Treg frequencies in peripheral blood of NOD mice            \u003ca rel=\"nofollow\"\u003e             PMID:                        28356069            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that the induction of IL-7Ralpha expression on dendritic cells (DCs) is critical for thymic stromal lymphopoietin responsiveness and that IL-4 can upregulate IL-7Ralpha on DCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28404633            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7RA role in hematopoiesis and development of the lympho-myeloid progenitors in the developing fetal liver            \u003ca rel=\"nofollow\"\u003e             PMID:                        26235516            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These studies provide in vivo evidence that IL-7Ralpha signals positively regulate normal human B-cell production and proliferation beyond the fetal period and suggest that TSLP can replace IL-7 in providing these signals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27325567            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Bcl6 promoted T follicular helper cell differentiation through antagonizing IL-7R \/ STAT5a axis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26876184            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that LNK suppresses IL-7R\/JAK\/STAT signaling to restrict pro-\/pre-B progenitor expansion and leukemia development, providing a pathogenic mechanism and a potential therapeutic approach for B-ALLs with LNK mutations.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26974155            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-7R plays an important role in the induction of HFD-induced adipogenesis and insulin resistance in mice.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26152662            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7R signaling in regulatory T cells maintains peripheral and allograft tolerance in mice.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26450881            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This work demonstrates that the CNS1 element controls IL-7Ralpha expression and maintenance of peripheral T cells, suggesting differential regulation of IL-7Ralpha expression between central and peripheral lymphoid organs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26336149            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inhibition of the IL-7 receptor inhibits tumor growth in murine models of melanoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24619454            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The combined loss of Gads and CD127 reveals a novel function of Gads prior to T cell receptor beta expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        25037454            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            data suggest that IL-7Ralpha Tyr(449) was essential for IL-7Ralpha signaling in bone marrow B cell development and survival.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25143441            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The development and survival but not function of follicular B cells is dependent on IL-7Ralpha Tyr449 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24551160            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            interleukin-7 receptor mutants induce early T cell precursor acute lymphoblastic leukemia by the block of thymocyte differentiation at the double negative 2 stage at which myeloid lineage and T lymphocyte developmental potential coexist.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24687960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The transcription factor GATA3 is critical for the development of all IL-7Ralpha-expressing innate lymphoid cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24631153            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of insertion mutation in combination with a Notch1 mutant led to the development of much more aggressive T-acute lymphoblastic leukemia than with wild-type IL7Ralpha.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24174626            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data indicate that IL7R+ B cells have a proinflammatory role in arthritis which can be inhibited by the sympathetic neurotransmitter norepinephrine via inhibition of IL-7R signalling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23505234            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7Ralpha transgenesis or T-cell-specific ablation of Gfi-1 restored IL-7Ralpha expression and largely ameliorated the development and homeostasis defects of TGF-beta-receptor-deficient T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23932572            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We have analyzed the discrete contributions of the antibody constant (Fc) and IL-7-binding (Fab) domains to the mechanism of binding to IL-7R.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23610371            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL7Ralpha has a role in potentiating IL-7 bioactivity and in promoting autoimmunity            \u003ca rel=\"nofollow\"\u003e             PMID:                        23610432            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pre-B cell receptor (BCR) cooperates with IL-7R in expanding the pre-B cell pool, but it also critically controls the differentiation program that shuts off the c-Myc gene in large pre-B cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23420891            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7Ralpha differentially controls development and maturation of thymocyte subpopulations in late developmental stages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23267098            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the in vivo regulatory role of Gfi1 was specific for CD8(+), and not CD4(+) T cells or immature thymocytes. These results identify Gfi1 as a specific transcriptional repressor of the Il7r gene in CD8 T lymphocytes in vivo.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22865857            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            show that interleukin-17A (IL-17A)-producing IL-7Ralpha(+) innate lymphoid cells (ILCs) were potent promoters of disease in Tbx21(-\/-)Rag2(-\/-) ulcerative colitis (TRUC) mice            \u003ca rel=\"nofollow\"\u003e             PMID:                        23063332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The durable efficacy and the multipronged tolerogenic mechanisms of IL-7Ralpha antibody therapy suggest a unique disease-modifying approach to T1D.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22733769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Blockade of IL-7\/IL-7Ralpha signaling in IL-7-dependent p53(null) cells reduced POT1 expression and caused telomere and chromosome abnormalities similar to those observed in DKO lymphomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22281704            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that this decrease in IL-7Ralpha is associated with defective hematopoietic development in Down Syndrome.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21504363            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased IL-7Ralpha (CD127) expression correlated, as previously reported with increased turnover of CD4 memory cells, however, this was not linked to protection or enhanced response to rechallenge            \u003ca rel=\"nofollow\"\u003e             PMID:                        22039531            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a novel function of Efnb1 and Efnb2 in stabilizing IL-7Ralpha expression at the post-translational level            \u003ca rel=\"nofollow\"\u003e             PMID:                        22069310            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7R-mediated signaling not only maintains the size but also impacts the diversity of the naive T-cell repertoire.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21339767            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7R-dependent survival and differentiation of early T-lineage progenitors is regulated by the BTB\/POZ domain transcription factor Miz-1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21258009            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of IL-7 receptor (IL-R)alpha on colitic CD4-positive memory T cells, but not on other cells, is essential for the development and persistence of chronic colitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21217010            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings highlight that IL-7Ralpha confers susceptibility by influencing autoimmune Th1\/Th17 responses in experimental autoimmune encephalomyelitis model of multiple sclerosis .            \u003ca rel=\"nofollow\"\u003e             PMID:                        20861865            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            T-cell homeostasis is maintained through a concerted regulation of Gfi-1-IL-7R-controlled cytokine responsiveness and ERK-mediated TCR signaling strength by the Cdc42-PAK1 signaling axis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20937872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            increased expression on activated FOXP3+CD4+ regulatory T cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        20690182            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            HIV Tat protein colocalizes with CD127 at the cell surface of resting CD8-positive T lymphocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20660706            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sin1-mTORC2 suppresses rag1,2 and il7r gene expression through Akt2 in B cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20705244            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study shows that IL-7Ralpha Y449 is important for lymphocyte transformation            \u003ca rel=\"nofollow\"\u003e             PMID:                        20440272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pre-pro-B cell growth-stimulating factor (PPBSF) upregulates IL-7Ralpha chain expression and enables pro-B cells to respond to monomeric IL-7.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12184921            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7R(alpha)(-\/-) mice lack detectable numbers of all downstream early B lineage precursors, including pre-pro-B cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        12208884            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-7R signals are able to stimulate T cell proliferation in lymphopenic hosts independently of lck-mediated T cell receptor (TCR) signaling, but they can also synergize with TCR signals to facilitate proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12244169            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-2 signaling can diminish IL-7Ralpha expression via a phosphatidylinositol 3-kinase\/Akt-dependent mechanism.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12354940            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The inability of B-cell progenitors in the thymus to mature is due to down-regulation of IL7Ralpha through a type 1 IFN receptor-independent mechanism            \u003ca rel=\"nofollow\"\u003e             PMID:                        12393710            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Bax deficiency partially corrects interleukin-7 receptor alpha deficiency            \u003ca rel=\"nofollow\"\u003e             PMID:                        12433363            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915069554913,"sku":"BL-0119NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZaAMNeBAACpYppQ7wM239_c398362d-a7bd-4bf5-90a1-f0044955f8d5.jpg?v=1685852147"},{"product_id":"recombinant-mouse-il12rb2-protein-fc-tag-bl-0124np","title":"Recombinant Mouse IL-12RB2 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-12 Receptor Subunit Beta-2 is produced by our Mammalian expression system and the target gene encoding Met1-Asn637 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P97378\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P97378\/entry\"\u003eP97378\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL12RB2; IL-12 receptor beta 2; IL-12 receptor subunit beta-2; IL-12R subunit beta-2; IL-12RB2; IL-12R-beta-2;  interleukin-12 receptor beta-2 chain; interleukin-12 receptor subunit beta-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe IL12 receptor complex, formed by IL12RB1 and IL12RB2, mediates the type I immune responses of various types of lymphocytes. Its ligand, IL12, is a heterodimeric cytokine composed of IL-12p35 and IL-12p40 subunits that are linked via disulfide bonds. Ligation of IL-12 to its receptor involves the binding of IL-12p35 to IL12RB1 and IL-12p40 to IL12RB2. This will result in the activation of tyrosine kinase 2 (TYK2), which is associated with the IL12RB1 chain and Janus kinase 2 (JAK2), which is associated with the IL12RB2 chain. Activated TYK2 and JAK2 direct the phosphorylation of STAT4. IL12RB1 is present on all lymphocytes, while the expression of IL12RB2 is tightly regulated. It has shown that the expression of IL12RB2 is limited to Th2 cells. IL12RB2 subunit plays an important role in Th1 cell differentiation, since its absence leads to an abortive Th1 differentiation that has dysfunctional production of Th1 effector molecules.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e98.4 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e125-160 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915089445089,"sku":"BL-0124NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZaAf1U0AACgEmhdi0s758_3d9f701d-881b-4373-84ef-09792251bbf3.jpg?v=1685852801"},{"product_id":"recombinant-mouse-il18bpd-protein-fc-tag-bl-0138np","title":"Recombinant Mouse IL-18BPd Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-18 Binding Protein Isoform d  is produced by our Mammalian expression system and the target gene encoding Thr29-Ala193 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ9Z0M9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 18 Binding Protein Isoform d; IL-18 BPd;Interleukin-18-binding protein;Interferon gamma-inducing factor-binding protein;Igifbp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 18 binding protein (IL-18BP) is a physiological inhibitor that acts through binding to the receptor-binding site of IL-18. IL-18 stimulates INF-γ, which then stimulates 18BP production via NF-κB. The interaction between IL-18 and IL-18BP has a significant role in the inflammation process. IL-18 BPs have four isoforms, a, b, c and d, which are spliced by different ways. The IL-18 BP isoforms a and c each contain one immunoglobulin (Ig)-like C2-type domain which is essential to the binding and neutralizing properties of the binding proteins. The IL-18 BP isoforms b and d lack a complete Ig domain. The expression of IL-18 and the IL-18BP are indentified in immune tissues such as the spleen, but also in nonimmune cells including keratinocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45.1 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-90 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBinds to IL-18 and inhibits its activity. Functions as an inhibitor of the early TH1 cytokine response.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:16068           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000091685           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        26340315            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Data show that IL-18bp acts as a sensor for IFN-gamma and can regulate both Th1 and Th17 responses in the CNS.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20644165            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Administratioan of murine IL-18BP at the time of the booster injection of bovine CII reduces the progressive severity of collagen-induced arthritis; both clinical disease activity and histological scores are decreased by 50%.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12574381            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            functional polarization of Ag-specific CD4(+) Th2 cells entering the CNS during the accelerating phase of experimental autoimmune encephalomyelitis is flexible and dependent on IL-18, which is overturned by IL-18 binding protein            \u003ca rel=\"nofollow\"\u003e             PMID:                        15778395            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-18 and IL-18BP may have roles in testicular development, and also in the regulation of testicular functions under physiological conditions            \u003ca rel=\"nofollow\"\u003e             PMID:                        18299271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A single intravenous dose of recombinant mouse IL18BP decreased neointimal hyperplasia and improved arterial L\/A ratios in an atherosclerotic balloon-injury animal model.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18455646            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915103568097,"sku":"BL-0138NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZqABRPUAACgGm-oecM387_00d3fcfc-74ab-40d8-a837-6a817d1f203b.jpg?v=1685853384"},{"product_id":"recombinant-human-il23r-protein-fc-tag-bl-0151np","title":"Recombinant Human IL-23R Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-23 Receptor is produced by our Mammalian expression system and the target gene encoding Gly24-Asp353 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ5VWK5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-23 receptor; IL23R; IL-23 receptor; IL-23R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 23 receptor (IL23R) is a type I cytokine receptor for IL23. IL23 receptor complex is comprised of two subunits, the IL12Rβ1 subunit, which is shared with several cytokines, and a subunit that is unique to IL-23. IL23, after binding to IL23R, activates memory T cells and mediates pro-inflammatory activities in part by the production of IL17 through activation of TH17 lymphocytes. IL23R is expressed on T cells, NK cells, dendritic cells, and macrophages. In fact, polymorphisms of the IL23R gene were reported to be associated with susceptibility to inflammatory diseases and autoimmune diseases such as psoriasis, multiple sclerosis, Graves's ophtalmopathy and inflammatory bowel diseases. The IL23R is known to be critically involved in the carcinogenesis of different malignant tumor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e65 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e90-120 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAssociates with IL12RB1 to form the interleukin-23 receptor. Binds IL23 and mediates T-cells, NK cells and possibly certain macrophage\/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. IL23 functions in innate and adaptive immunity and may participate in acute response to infection in peripheral tissues. IL23 may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 2 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            19100           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            607562           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:149233           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000321345           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29985710            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Study confirms an association between IL12B and IL23R genetic polymorphism and psoriasis vulgaris (with a protective effect of minor alleles).            \u003ca rel=\"nofollow\"\u003e             PMID:                        29454820            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL23R gene rs10889677 A allele confers increased risk of ankylosing spondylitis (AS) in Europeans, but its role in Asian populations needs further exploration.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29198991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that the variants +2199 A\/C IL-23R and -197 G\/A IL-17A could contribute to rheumatoid arthritis development in the studied population            \u003ca rel=\"nofollow\"\u003e             PMID:                        28547498            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that interleukin-23 receptor (IL-23R) single nucleotide polymorphism (SNP) rs11465817 contributes to the risk of recurrent oral ulceration (ROU) in Chinese.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29169427            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Findings indicate that IL17A -197 G\/A and IL23R H3Q are not associated with susceptibility to MM. However, IL-17 and IL-23R polymorphisms may affect severity, bone lesions, and extra-medullary disease in patients with MM.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28786198            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study provides evidence for three alcohol-induced ONFH susceptibility genes (NOS3, ABCB1 and IL23R) in Chinese males and polymorphisms of them may be associated with alcohol-induced ONFH risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28422712            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic association studies in population in southwest China: Data suggest that SNPs in STAT4 (rs7574865), IL23R (rs11209032), and STAT3 (rs744166) are associated with occurrence, severity, and immunosuppressive therapy outcomes of aplastic anemia in the population studied. (STAT = signal transducer and activator of transcription) [article includes Meta-Analysis]            \u003ca rel=\"nofollow\"\u003e             PMID:                        29330562            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study provides a comprehensive examination of the available evidence for the association between polymorphisms in the IL-23R gene and ulcerative colitis (UC). The meta-analysis suggests that IL-23R gene polymorphisms are associated with UC susceptibility, especially in Caucasians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27902482            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that the interleukin-23 receptor (IL-23R) SNPs rs11209026, p.Arg381Gln; rs41313262 p.Val362Ile were not associated with susceptibility to inflammatory bowel disease (IBD) in Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27765927            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin-23 receptor cytokine-binding homology region balances the ratio of Th17\/Th9\/Treg cells in collagen-induced arthritis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27177334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this meta-analysis suggests that each allele of IL-23R, including rs7519847, rs17375018 and rs11209032 was negatively associated with uveitis; however, homozygote models, including the rs17375018 GG genotype and rs11209032 AA genotype, were significantly associated with uveitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        28558665            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            an evaluation of what is currently known about the protective role of R381Q variant in IL-23R gene in immune-based diseases (Review).            \u003ca rel=\"nofollow\"\u003e             PMID:                        27043356            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Th17 cells expressed consistent high levels of the IL-12Rbeta1 subunit, which appeared a better predictor of responsiveness to IL-23 than the expression of the IL-23R subunit.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27645493            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We conclude that variants in IL-23A and IL-23R genes were associated with the risk of multiple sclerosis or other inflammatory demyelinating diseases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27893410            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-23 R (rs7517847) and LEP (rs7799039) polymorphisms were associated with an increased risk but not affecting the clinical presentation of HCC among Egyptian patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        28452232            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In a Turkish population, IL23R polymorphism is a risk factor for UC and is protective against CD.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27852544            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The current study emphasizes the lack of association of IL23R and IL17 polymorphisms with rheumatoid arthritis susceptibility in the Algerian population. However, the data showed the relationship between IL23R and IL17A polymorphisms and the production of the different RF isotypes in rheumatoid arthritis patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        27606475            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Haplotype of non-synonymous IL-23R variants increase susceptibility to severe malarial anemia in children of a holoendemic P. falciparum transmission area.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28427357            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            there is a positive association between the GWAS reported rs3762318 and leprosy, and SLC35D1 and IL23R might be the causal genes            \u003ca rel=\"nofollow\"\u003e             PMID:                        27712858            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study identified susceptibility single nucleotide polymorphisms in IL23R with Behcet's disease in Han Chinese            \u003ca rel=\"nofollow\"\u003e             PMID:                        27464962            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            HLA-B51 is a primary association marker in predisposition to Behcet disease, with IL-23R and IL12A being the additional strongest loci.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27548383            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study identified a possible silencer downstream of IL23R that includes the ankylosing spondylitis (AS)-associated SNP rs924080, which appears to modulate the functional effects of this regulatory element; confirmed the primary association of AS with rs11209032 in this region, but suggest that there could be a possible additional effect from rs924080 in a putative silencer on the same haplotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28381868            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study demonstrated susceptible or protective character of the investigated IL23R SNPs on the phenotype of ulcerative colitis, confirming the genetic association.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28210080            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In ankylosing spondylitis, conditional analysis identified rs11209032 as the probable causal single-nucleotide polymorphism within a 1.14 kb putative enhancer between IL23R and IL12RB2. The rs11209032 single-nucleotide polymorphism downstream of IL23R forms part of an enhancer, allelic variation of which may influence Th1-cell numbers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26916345            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results did not show any strong association between IL-23R polymorphisms and juvenile idiopathic arthritis or serum IL-17A levels in Iranian patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26016922            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results of this case-control study suggest that IL-12A, IL-12B, IL12RB1, IL12RB2 and IL23R make no genetic contribution to the susceptibility of Takayasu arteritis in Chinese populations            \u003ca rel=\"nofollow\"\u003e             PMID:                        26987707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows a lack of association of the IL-23 single nucleotide polymorphisms with the risk of acute lymphoblastic leukemia in Iran            \u003ca rel=\"nofollow\"\u003e             PMID:                        28341819            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The interleukin-23 receptor gene polymorphism may not contribute to the susceptibility of development of primary immune thrombocytopenia in Egyptian children.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26859125            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that there is no significant difference in mucosal IL-23R expression in Ulcerative Colitis patients with moderate-to-severe disease activity compared to those in remission            \u003ca rel=\"nofollow\"\u003e             PMID:                        27178149            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In this study, we were unable to establish a correlation between the IL-23R SNPs investigated and HLA-B27-associated acute anterior uveitis as well as idiopathic intermediate uveitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27009486            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that IL23R may contribute to the development of intracerebral hemorrhage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26846416            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The association of IL-23R and Ankylosing Spondylitis (AS) that is seen in Caucasian patients with AS is not present in Chinese patients with AS.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27650612            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Differential splicing generates antagonistic soluble IL-23R (sIL-23R) variants, which might limit IL-23-mediated immune responses. Here, ectodomain shedding of IL-23R was identified as an alternative pathway for the generation of sIL-23R.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26961870            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic polymorphism is associated with psoriasis in the South Indian Tamils            \u003ca rel=\"nofollow\"\u003e             PMID:                        26472011            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A significant association was found between all Crohn's disease and the rs7517847 polymorphism, especially in Caucasians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26678098            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL23R polymorphisms rs10889677, rs7517847, and the IL12B polymorphism rs3212227 are not associated with multiple sclerosis risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26000455            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest a convergent cause of IL23Ralpha variant protection against chronic inflammatory disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26887945            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            meta-analysis supports that two polymorphisms (rs11209026 and rs7517847) in the IL-23 gene may be considered to be protective factors against developing UC among Caucasian populations.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25497273            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results of the current study disclosers1343151 variant of IL23R as a susceptibility gene in CD.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25561320            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Lower LCN2 levels in Crohn's Disease patients carrying IBD risk-increasing IL23R variants may result from a restricted upregulation of LCN2 due to an impaired Th17 immune response            \u003ca rel=\"nofollow\"\u003e             PMID:                        26263469            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL23 receptor single nucleotide polymorphisms and gene copy number variation are associated with susceptibility to pulmonary tuberculosis in Chinese Uygurs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26626589            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results indicated an association between the rs11209026 G\u0026gt;A polymorphism of the IL-23 receptor gene and the risk of atherosclerosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261042            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low-Frequency IL23R Coding Variant is Associated with Crohn's Disease Susceptibility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26375822            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            R381Q polymorphism in IL-23 receptor may be a predisposing allele for asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26547706            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            GG genotype of the rs17375018 variant in the IL-23R gene enhances pro-inflammatory cytokine responses in Behcet's Disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26222305            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            it is concluded that the frequency of single nucleotide polymorphism in the IL-23 receptor (R381Q) in patients with recurrent spontaneous abortion (RSA) is less than that found in normal control women.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26269135            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            review and meta-analysis of association of polymorphisms rs6682925, rs10889677 and rs1884444 with cancer risk            \u003ca rel=\"nofollow\"\u003e             PMID:                        26717375            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Copy number variation of exon 11 in IL-23R is associated with pulmonary tuberculosis in the Chinese Uygur population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26829744            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A and IL-23R gene polymorphism were not associated with acute myeloid leukemia susceptibility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26191290            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915021910241,"sku":"BL-0151NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZ2AOURoAACyayD2_sE101_6216c34b-0838-4f35-b824-42cc997b39fe.jpg?v=1685850743"},{"product_id":"recombinant-human-il1r1-protein-fc-tag-bl-0159np","title":"Recombinant Human IL-1R1Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-1 Receptor Type 1\/IL-1R-1 is produced by our Mammalian expression system and the target gene encoding Leu18-Thr332 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P14778\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P14778\/entry\"\u003eP14778\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor type 1; IL-1R-1; IL-1RT-1; IL-1RT1; CD121 antigen-like family member A; Interleukin-1 receptor alpha; IL-1R-alpha; p80; CD121a\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 1 receptor, type I (IL-1R1) is an interleukin receptor that belongs to the interleukin-1 receptor family. IL-1R1 is an 80 kDa transmembrane protein that is expressed predominantly by T cells, fibroblasts, and endothelial cells. This gene along with IL1R2, IL1RL2, and IL1RL1 form a cytokine receptor gene cluster in a region mapped to chromosome 2q12. IL-1R1 is an important mediator involved in many cytokine induced immune and inflammatory responses. It binds to interleukin-1 associates with the corecptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. The signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor\/coreceptor subunits. It also binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex. An IL1 receptor accessory protein that can heterodimerize with the Type I receptor in the presence of IL1α or IL1β but not IL1ra, was identified. Recombinant IL1 soluble receptor Type I is a potent antagonist of IL1 action.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e62.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e80-105 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915082825953,"sku":"BL-0159NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZ6APi6PAACqE0pisss884_84081b0e-0336-4014-9801-c2cc0a7f9f00.jpg?v=1685852533"},{"product_id":"recombinant-human-il1r2-protein-fc-tag-bl-0160np","title":"Recombinant Human IL-1R2 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-1 Receptor Type 2\/IL-1R-2  is produced by our Mammalian expression system and the target gene encoding Phe14-Glu343 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P27930\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P27930\/entry\"\u003eP27930\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor type 2; IL-1R-2; IL-1RT-2; IL-1RT2; CD121 antigen-like family member B; CDw121b; IL-1 type II receptor; Interleukin-1 receptor beta; IL-1R-beta; Interleukin-1 receptor type II; CD121b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor type 2 (IL1R2) belongs to the interleukin-1 receptor family. Two distinct types of IL1 receptors which are able to bind IL1 specifically have been identified, designated as IL1RI (IL1RA) and IL1RII (IL1RB). IL1 receptor type II is a 68 kDa transmembrane protein found on B lymphocytes, neutrophils, monocytes, large granular leukocytes and endothelial cells. IL1R2 is non-signaling receptor forIL1A, IL1B and IL1RN, reduces IL1B activities. IL1R2 serves as a decoy receptor by competetive binding to IL1B and preventing its binding to IL1R1. IL1R2 modulates cellular response through non-signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly IL1A and IL1RN. The secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted\/soluble receptors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e64.5 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e80-95 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915105894625,"sku":"BL-0160NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZ6AbDjiAACXdc6efMU419_10655f8a-efdf-48a9-a389-6ef311874756.jpg?v=1685853471"},{"product_id":"recombinant-mouse-il1r1-protein-fc-tag-bl-0161np","title":"Recombinant Mouse IL-1R1 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-1 Receptor Type 1 is produced by our Mammalian expression system and the target gene encoding Leu20-Lys338 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P13504\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P13504\/entry\"\u003eP13504\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor type 1; IL-1R-1; IL-1RT-1; IL-1RT1; CD121 antigen-like family member A; Interleukin-1 receptor alpha; IL-1R-alpha; p80; CD121a; mIL-1R1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMouse Interleukin-1 receptor type 1\/IL-1 RI is a cytokine receptor that belongs to the interleukin-1 receptor family. This protein is a receptor for interleukin 1 alpha (IL1A), interleukin 1 beta (IL1B), and interleukin 1 receptor antagonist (IL1RA). It is an important mediator involved in many cytokine induced immune and inflammatory responses. An IL1 receptor accessory protein that can heterodimerize with the Type I receptor in the presence of IL1α or IL1βbut not IL1ra, was identified. This Type I receptor complex appears to mediate all the known IL1 biological responses. The receptor Type II has a short cytoplasmic domain and does not transduce IL1 signals. In addition to the membranebound form of IL1 RII, a naturallyoccurring soluble form of IL1 RII has been described. It has been suggested that the Type II receptor, either as the membranebound or as the soluble form, serves as a decoy for IL1 and inhibits IL1 action by blocking the binding of IL1 to the signaling Type I receptor complex.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e64 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e85-110 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915073978593,"sku":"BL-0161NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZ6ASCczAACsCsCoZrA919_edcd3521-c400-4a61-89b6-e001b243b278.jpg?v=1685852285"},{"product_id":"recombinant-mouse-il1r2-protein-fc-tag-bl-0162np","title":"Recombinant Mouse IL-1R2 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-1 Receptor Type 2 is produced by our Mammalian expression system and the target gene encoding Phe14-Glu355 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P27931\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P27931\/entry\"\u003eP27931\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor type 2; IL-1R-2; IL-1RT-2; IL-1RT2; CD121 antigen-like family member B; CD121b; IL-1 type II receptor; Interleukin-1 receptor beta; IL-1R-beta; Interleukin-1 receptor type II; CD121b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMouse Interleukin 1 receptor, type II (IL1R2) is a cytokine receptor that belongs to the interleukin-1 receptor family. This protein binds interleukin alpha (IL1A), interleukin beta (IL1B), and interleukin 1 receptor, type I (IL1R1\/IL1RA), and acts as a decoy receptor that inhibits the activity of its ligands. IL-1R2 structurally consisting of a ligand binding portion comprised of three Ig-like domains, a single transmembrane region, and a short cytoplasmic domain. It is expressed in a variety of cell types including B lymphocytes, neutrophils, monocytes, large granular leukocytes and endothelial cells. Mouse IL1RII shares 59% amino acid sequence homology with human IL1 RII in their extracellular domains. The pleiotropic cytokine IL1 is produced to regulate development and maintenance of the inflammatory responses, and binds to specific plasma membrane receptors on cells. Two distinct types of IL1 receptors which are able to bind IL1 specifically have been identified, designated as IL1RI (IL1RA) and IL1RII (IL1RB). IL1R1 contributes to IL-1 signaling, whereas the IL-1R2 has no signaling property and acts as a decoy for IL-1.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e64.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e85-110 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915105927393,"sku":"BL-0162NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZ6AJdVIAACf2Z_0F7k602_31106fa2-0c59-4d64-8e65-dfe83c1d0c9d.jpg?v=1685853472"},{"product_id":"recombinant-human-il5-r-il15ra-protein-fc-tag-bl-0180np","title":"Recombinant Human IL-5RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-5 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Asp21-Glu335 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q01344\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q01344\/entry\"\u003eQ01344\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-5 receptor subunit alpha; IL-5 receptor subunit alpha; IL-5R subunit alpha; IL-5R-alpha; IL-5RA; CDw125; CD125; IL5RA; IL5R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-5 Receptor alpha (IL-5Rα, CD125) is a 60 kDa hematopoietin receptor that plays a dominant role in eosinophil biology. Mature human IL-5 Rα consists of a 322 aa extracellular domain (ECD) with a WSxWS motif and a four cysteine motif, a 20 aa transmembrane segment, and a 58 aa cytoplasmic domain. Within the ECD, human IL-5Rα shares 71% aa sequence identity with mouse and rat IL-5 Rα. Alternate splicing of human IL-5 Rα generates soluble secreted forms which function as IL-5 antagonists. The high affinity receptor for IL-5 is a complex that consists of the ligand binding IL-5 Rα and the transmembrane common β chain (βc\/CD131) which is shared with the receptor complexes for IL-3 and GMCSF. IL-5 Rα binds IL-5 at low affinity and then associates with preformed βc oligomers to form the signaling competent receptor complex. IL-5 stimulation of CD34+ hematopoietic progenitor cells induces the up-regulation of transmembrane IL-5Rα followed by eosinophilic differentiation and activation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e62.5 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e70-85 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915070144737,"sku":"BL-0180NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLaqAPZOPAACZcLnHqHE151_4db601bf-6058-42a5-a0c9-aa0fe524ee6e.jpg?v=1685852170"},{"product_id":"recombinant-mouse-il2-r-il2rg-protein-fc-tag-bl-0189np","title":"Recombinant Mouse IL-2RG Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-2 Receptor Subunit Gamma is produced by our Mammalian expression system and the target gene encoding Ser25-Ala263 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q3UPA9\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q3UPA9\/entry\"\u003eQ3UPA9\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 2 receptor, gamma chain, isoform CRA_b; Il2rg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe Interleukin-2 receptor gamma chain (IL-2 Rγ, CD132) of the high affinity functional mouse IL-2 receptor complex is a member the hematopoietin receptor family. It is expressed on most lymphocyte (white blood cell) populations, and its gene is found on the X-chromosome of mammals. Common IL2 receptor-γ Chain is required for IL-2 receptor signaling. Besides IL-2, the Common IL2 receptor-γ chain has been shown to be a component of the functional receptor complexes for IL-4, IL-7, IL-9 and IL-15. It is a component of multiple cytokine receptors that are essential for lymphocyte development and function. Common IL2 receptor-γ Chain is also designated the common gamma chain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e55.1 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e80-100 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915106287841,"sku":"BL-0189NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLa2AdnwuAACzfC129D0702_702b77e1-5072-4d9f-bc13-1debc9fe1d57.jpg?v=1685853485"},{"product_id":"recombinant-human-il3ra-protein-fc-tag-bl-0198np","title":"Recombinant Human IL-3RA Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-3 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Thr19­Arg305  is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"P26951\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/P26951\/entry\"\u003eP26951\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-3 receptor subunit alpha; IL-3 receptor subunit alpha; IL-3R subunit alpha; IL-3R-alpha; IL-3RA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCD123, also known as Interleukin-3 receptor subunit alpha, belongs to the type I cytokine receptor family. In mouse, there are two classes of high-affinity IL3 receptors. One contains an IL3-specific beta subunit and the other contains the beta subunit also shared by high-affinity IL5 and GM-CSF receptors. CD123 stimulates the proliferation and differentiation of hemopoietic cells including the pluripotent hematopoietic stem cells as well as various lineage‑committed cells. CD123 is a heterodimer consisting of an alpha and a beta subunit. The alpha subunit alone binds IL‑3 with low affinity. The beta  subunit does not bind IL‑3 by itself but is required for the high‑affinity binding of IL‑3 to the heterodimeric receptor complex.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e80-100 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915032723681,"sku":"BL-0198NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLbCADj_-AACvbvBCrt4082_c617c5d5-24df-49c9-ab5d-0a6c1b6e4940.jpg?v=1685851002"},{"product_id":"recombinant-mouse-il11-protein-fc-tag-bl-0207np","title":"Recombinant Mouse IL-11 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-11 is produced by our Mammalian expression system and the target gene encoding Pro22-Leu199 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP47873\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-11; Il11; IL-11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-11(IL-11) is a secreted protein and belongs to the IL-6 superfamily. IL-11 has been demonstrated to improve platelet recovery after chemotherapy-induced thrombocytopenia, induceacute phase proteins, modulate antigen-antibody responses, participate in the regulation of bone cellproliferation and differentiation and could be use as a therapeutic for osteoporosis. IL-11 stimulates the growth of certain lymphocytes and, in the murine model, stimulates an increase in the cortical thickness and strength of long bones. In addition to having lymphopoietic\/hematopoietic and osteotrophic properties, it has functions in many other tissues, including the brain, gut, testis and bone.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e46.3 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50-60 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 10mM HAc-NaAc, 150mM NaCl, 0.004% Tween80, 5% Mannitol, pH 4.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. Also promotes the proliferation of hepatocytes in response to liver damage. Binding to its receptor formed by IL6ST and either IL11RA1 or IL11RA2 activates a signaling cascade that promotes cell proliferation, also in the context of various cancers. Signaling leads to the activation of intracellular protein kinases and the phosphorylation of STAT3. The interaction with the membrane-bound IL11RA and IL6ST stimulates 'classic signaling', whereas the binding of IL11 and soluble IL11RA to IL6ST stimulates 'trans-signaling'.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-6 superfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:16156           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000092492           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29217821            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            classic but not trans-signaling essential for fertility            \u003ca rel=\"nofollow\"\u003e             PMID:                        28864002            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            activates PDIA4 in placenta            \u003ca rel=\"nofollow\"\u003e             PMID:                        28487027            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that classic signalling rather than trans-signalling is the mode by which IL-11 promotes gastric tumourigenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28160627            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that iterleukin-11 (IL11) is causal of Preeclampsia (PE) features in a mouse model and likely in women, and suggest potential of IL11 inhibition to rescue PE symptoms in women.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26655736            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11-mediated STAT3 signaling not only reduces hepatocellular apoptosis, but also inhibits inflammatory responses.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25946003            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-1 signaling antagonizes IL-11\/STAT3 mediated pathology and the genetic deletion of IL-1RT1 results in increased tumor burden.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25528766            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PGF2alpha inhibits adipocyte differentiation by means of an IL-11 mediated autocrine negative feedback loop, that acts via gp130 to block adipogenesis through the essential actions of the STAT1 transcription factor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24519625            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that colonic inflammation was more severe in mice fed an iron-supplemented compared with a control diet one week post-DSS treatment, with enhanced colonic IL-6 and IL-11 release and Stat3 phosphorylation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24223168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 reduced the production of reactive oxygen species.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23852503            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 therefore drives a pathway that enhances HSPC radioresistance and radiation-induced B-cell malignancies, but is normally attenuated by the inhibitory adaptor Lnk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24297922            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 signaling may not play as significant a role in spinal cord injury as other glycoprotein gp130 cytokines.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22715999            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data support the view that IL-11 is a key regulator of gastric damage acting to initiate chronic atrophic gastritis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22180059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Bovine lactoferrin administration prevented the progression of hepatic failure in human myofibroblasts and mice, and enhanced IL-11 and BMP2 expression in the small intestine.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21688123            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling            \u003ca rel=\"nofollow\"\u003e             PMID:                        22523320            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 provides a functional link between oxidative stress and compensatory proliferation            \u003ca rel=\"nofollow\"\u003e             PMID:                        22253262            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings imply a pathogenic role for IL-11 during the early phase of Mycobacterium tuberculosis-triggered disease in a genetically susceptible host.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21789190            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Mechanical stress activates Smad pathway through PKCdelta to enhance interleukin-11 gene transcription in osteoblasts.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20927330            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Addition of exogenous IL-11 protected against the lethal colitis in TLR2-deficient mice via STAT3 activation in intestinal epithelial cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20600022            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 attenuated cardiac fibrosis after MI through STAT3. Activation of the IL-11\/glycoprotein 130\/STAT3 axis may be a novel therapeutic strategy against cardiovascular diseases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20100971            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These observations are consistent with the notion that mechanical stress stimulates IL-11 gene transcription via an enhanced DeltaFosB\/JunD binding to the IL-11 gene promoter.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19665600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 stimulates osteoclastic resorption in mouse calvariae that is independent of cell growth; partially dependent on prostaglandin biosynthesis; sensitive to inhibition by IL-4, IL-13 and OPG; and associated with enhanced expression of RANKL and OPG.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12110441            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Tumor-derived IL-11 may play a role in the depressed IL-12 production by macrophages, leading to the impaired immune functions observed during mammary tumorigenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12527946            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The induction of hsp25 by IL-11 confers epithelial-specific cytoprotection that is independent of phosphorylation-dependent co-localization of hsp25 to F-actin, contributing to the protective effects of IL-11 in models of intestinal epithelial injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12730876            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            interleukin-11 regulates adipocyte metabolism and gene expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        12791389            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of interleukin 11 is associated with breast cancer metastasis to bone            \u003ca rel=\"nofollow\"\u003e             PMID:                        12842083            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            two tandem activating protein-1 (AP-1) sites that reside immediately upstream of TATA box play critical roles in IL-11 gene transcription            \u003ca rel=\"nofollow\"\u003e             PMID:                        12929935            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 signaling is required for decidual-specific maturation of natural killer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15499555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            heparin enhances IL-11-induced STAT3 activation and thus osteoclast formation, by a mechanism that is independent of STAT3 Ser-727 phosphorylation but that involves up-regulation of the MAPK pathway            \u003ca rel=\"nofollow\"\u003e             PMID:                        16720575            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 signals through the Jak2\/Stat3 pathway in decidual cells to stimulate the expression of alpha(2)-MG, a protease inhibitor essential for normal placentation in pregnancy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16959875            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetically define distinct roles of IL-6 and IL-11 in driving pathologic hematopoietic and lymphoid responses mediated by STAT3 hyperactivation            \u003ca rel=\"nofollow\"\u003e             PMID:                        17082315            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Gnai2 knockout mice show significantly reduced intestinal IL-11 production. Suggest MAP kinases, PGE2 and cAMP mediated signaling involved.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17332478            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results provide, at least in part, an explanation for the defective small decidua of mice lacking the Il11ra gene, and reveal for the first time that cyclin D3, CDKN1A (p21), and BIRC5 (Survivin) are targets of IL11 in the decidua.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17881769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            An increase in caspase-3 was seen in hyperoxia-exposed lungs of wild-type pups compared to IL-11 (+) pups            \u003ca rel=\"nofollow\"\u003e             PMID:                        18214944            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data identify IL-11 as a crucial cytokine promoting chronic gastric inflammation and associated tumorigenesis in gp130 receptor-eficient mice mediated by excessive activation of STAT3 and STAT1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18431520            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Th2 and IL-13 responses can be regulated by interventions that manipulate IL-11 signaling in the murine lung.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18617680            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased gastric IL-11 alters expression of proliferative and cytoprotective genes and promotes pretumorigenic cellular changes            \u003ca rel=\"nofollow\"\u003e             PMID:                        19121317            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-11 regulates inflammatory demyelination via a unique combination of immunoregulation and neuroprotection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19734214            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915100848353,"sku":"BL-0207NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLY-AKByJAACr_fZ72UU508_07eae65f-1d80-4007-ac54-8617ba930f22.jpg?v=1685853274"},{"product_id":"recombinant-human-il1rapl1-protein-fc-tag-bl-0213np","title":"Recombinant Human IL-1RAPL1 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-1 Receptor Accessory Protein-like 1 is produced by our Mammalian expression system and the target gene encoding Leu19-Thr357 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q9NZN1\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q9NZN1\/entry\"\u003eQ9NZN1\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 Receptor Accessory Protein-Like 1; IL-1-RAPL-1; IL-1RAPL-1; IL1RAPL-1; Oligophrenin-4; Three Immunoglobulin Domain-Containing IL-1 Receptor-Related 2; TIGIRR-2; X-Linked Interleukin-1 Receptor Accessory Protein-Like 1; IL1RAPL1; OPHN4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 receptor accessory protein-like 1, also known as IL1RAPL1, can be detected at low levels in heart, skeletal muscle, ovary, skin, amygdala, caudate nucleus, corpus callosum, hippocampus, substantia nigra and thalamus. IL1RAPL1 functions as a homodimer, it interacts with NCS1, PTPRD. This interaction is PTPRD-splicing-dependent and induces pre- and post-synaptic differentiation of neurons and is required for IL1RAPL1-mediated synapse formation. During dendritic spine formation, it can bidirectionally induce pre- and post-synaptic differentiation of neurons by trans-synaptically binding to PTPRD.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e68 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e80-100 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915085316321,"sku":"BL-0213NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLV2ASg1aAACzAX_OqeU415_a6964fee-49b2-458e-8fd0-e11f421cdadf.jpg?v=1685852638"},{"product_id":"recombinant-human-il20rb-protein-fc-tag-bl-0239np","title":"Recombinant Human IL-20RB Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-20 Receptor Subunit Beta\/IL-20RB is produced by our Mammalian expression system and the target gene encoding Asp30-Ala230 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ6UXL0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-20 receptor subunit beta; IL-20 receptor subunit beta; IL-20R-beta; IL-20RB; IL-20R2; DIRS1; hCG_2022374; FNDC6; MGC34923;  fibronectin type III domain containing 6; interleukin-20 receptor II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-20 receptor subunit beta（IL20RB） is a single-pass type I membrane protein and belongs to the type II cytokine receptor family. It contains 2 fibronectin type-III domains. There are two kinds of type II cytokine receptors : cytokine receptors that bind type I and type II interferons; cytokine receptors that bind members of the interleukin-10 family (interleukin-10, interleukin-20 and interleukin-22). Type II cytokine receptors are similar to type I cytokine receptors except they do not possess the signature sequence WSXWS that is characteristic of type I receptors. They are expressed on the surface of certain cells, which bind and respond to a select group of cytokines. These receptors are related predominantly by sequence similarities in their extracellular portions that are composed of tandem Ig-like domains. The intracellular domain of type II cytokine receptors is typically associated with a tyrosine kinase belonging to the Janus kinase (JAK) family.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e49.6 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-85 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSupplied as a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eStore at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped on dry ice\/polar packs.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe IL20RA\/IL20RB dimer is a receptor for IL19, IL20 and IL24. The IL22RA1\/IL20RB dimer is a receptor for IL20 and IL24.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType II cytokine receptor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6004           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            605621           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:53833           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000328133           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        24455976            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            The crystal structure of the IL-20\/IL-20R1\/IL-20R2 complex reveals how type I and II complexes discriminate cognate from noncognate ligands            \u003ca rel=\"nofollow\"\u003e             PMID:                        22802649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The hypotheses that genetic variations of the IL-20-RI influence susceptibility to psoriasis and single nucleotide polymorphisms (SNPs) in the IL20RA and IL20RB genes in psoriasis patients were investigated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18480827            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915106451681,"sku":"BL-0239NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/rB9Eh2Q6rtuAVSzYAAB5stN-m-w392_8c0c6269-7b35-458c-b21d-6f24122d86d0.jpg?v=1685853490"},{"product_id":"recombinant-human-il15ra-il15-protein-fc-tag-bl-0245np","title":"Recombinant Human IL-15RA\u0026IL-15 Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-15 Receptor Alpha \u0026amp; Interleukin-15 Fusion Protein is produced by our Mammalian expression system and the target gene encoding Ile31-Asp96\u0026amp;Asn49-Ser162(Asn120Asp) is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ13261\u0026amp;P40933\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL15RA\u0026amp;IL15; Interleukin-15; IL-15; IL15; IL-15 receptor subunit alpha; IL-15RA; IL-15R-alpha;  interleukin-15 receptor subunit alpha\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL15RA is a high-affinity receptor for interleukin-15. Il15ra associates as a heterotrimer with the IL-2 receptor beta and gamma subunits to initiate signal transduction. It can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. Il15ra is expressed in special cells including a wide variety of Tand B cells and non-lymphoid cells.IL-15 is a cytokine that regulates T cell and natural killer cell activation and proliferation. IL-15 binds to the alpha subunit of the IL-15RA with high affinity. IL-15 also binds to the beta and gamma chains of the IL-2 receptor, but not the alpha subunit of the IL2 receptor. IL-15 is structurally and functionally related to IL-2. Both cytokines share some subunits of receptors, allowing them to compete for and negatively regulate each other's activity. The number of CD8+ memory T cells is controlled by a balance between IL-15 and IL-2. Despite their many overlapping functional properties, IL-2 and IL-15 are, in fact, quite distinct players in the immune system. IL-15 is constitutively expressed by a wide variety of cell types and tissues, including monocytes, macrophages and DCs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e46.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50-60 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 8% Trehalose, 4% Mannitol, 0.02% Tween80 (w\/v), pH 7.5.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915098980577,"sku":"BL-0245NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZaAcAU9AACw-sPmtNM990_749798e2-0bec-41b6-a0b8-ac8f12f2256c.jpg?v=1685853196"},{"product_id":"recombinant-human-il3-protein-his-tag-bl-0275np","title":"Recombinant Human IL-3 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-3 is produced by our Mammalian expression system and the target gene encoding Ala20-Phe152 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP08700\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-3; IL-3; Hematopoietic Growth Factor; Mast Cell Growth Factor; MCGF; Multipotential Colony-Stimulating Factor; P-Cell-Stimulating Factor; IL3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-3 (IL-3) is a potent growth promoting cytokine. IL-3 can stimulate the proliferation and differentiation of pluripotent hematopoietic stem cells as well as various lineage committed progenitors. IL-3 exerts its biological function through binding to specific cell surface receptors. The amino acid sequences of this protein among different species share relatively low identity and its activity is highly species-specific. IL-3 has also been shown to possess neurotrophic activity, and is thought to be associated with neurologic disorders.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e16.1 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e17-30 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.001 ng\/µg (0.01 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGranulocyte\/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages.; This CSF induces granulocytes, macrophages, mast cells, stem cells, erythroid cells, eosinophils and megakaryocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-3 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6011           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            147740           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3562           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000296870           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29554544            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            The present study demonstrates for the first time that IL-3 has an important role in enhancing the migration of human MSCs through regulation of the CXCR4\/SDF-1alpha axis. These findings suggest a potential role of IL-3 in improving the efficacy of MSCs in regenerative cell therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28705238            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results indicate that IL-3 regulates endothelial cells-extracellular vesicles release, cargo and IL-3 angiogenic paracrine action via STAT5.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27157262            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            T-GM-CSF and -IL-3 significantly, and reciprocally, blunted receptor binding and myeloid progenitor cell proliferation activity of both FL-GM-CSF and -IL-3 in vitro and in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        28344320            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that IL-3 induces several signaling pathways associated with increased cell survival under oxidative stress. This activity correlates with previous fi ndings indicating glucose uptake stimulation by IL-3, which together contribute to an emerging picture of a broader mechanism promoting cell survival.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27862234            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-3\/ GM-CSF effected on the myofibroblastic differentiation of human adipose derive stromal cells (hASCs) as well as it did on human dermal fibroblasts (HDFs).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28377320            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models            \u003ca rel=\"nofollow\"\u003e             PMID:                        28456746            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-3 hardly down-regulates the alpha-chain of its receptor without depleting the common beta-chain, which enables extraordinarily sustained signaling events, predominantly the activation of Stat5.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27443880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic polymorphisms in the immune genes IL-3 rs181781 and CTLA4 rs4553808 may influence the TAC dose-adjusted concentrations            \u003ca rel=\"nofollow\"\u003e             PMID:                        28112181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results indicated that the IL-3 and IL-13 polymorphisms were not associated with rheumatoid arthritis (RA).  stratification analyses suggested that the IL-13 rs1800925 CT and CT\/CC genotypes increased the risk of RA in patients with erythrocyte sedimentation rate (ESR) \u0026lt;25.00.  these findings suggest that the IL-13 rs1800925 C\/T polymorphism may be associated with increased risk of RA in ESR            \u003ca rel=\"nofollow\"\u003e             PMID:                        27323078            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that IL-3 and IL-12p40 could be considered as molecular predictors for recurrent wheezing due to RSV infection            \u003ca rel=\"nofollow\"\u003e             PMID:                        26299549            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that IL3 is an important genetic regulator for human brain volume variation and implied that IL3 might have experienced weak or modest positive selection in the evolutionary history of humans            \u003ca rel=\"nofollow\"\u003e             PMID:                        26875095            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent            \u003ca rel=\"nofollow\"\u003e             PMID:                        25962901            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            were not able to confirm the association of IL-3 SNPs with schizophrenia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26277822            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings showed that high plasma IL-3 levels are associated with high mortality in sepsis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25766237            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variation in interleukin-3 gene is associated with breast cancer risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24670917            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that HuR recognizes the ARE-rich region in the IL-3 3'-UTR and plays a role in the IL-3 3'-UTR-mediated post-transcriptional control in T-cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        24658545            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A single nucleotide polymorphism (SNP; rs20541) in the IL-13 gene has been recognized as a risk factor for asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23978640            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study is the first to link beta-catenin activation to IL-3 and suggests that targeting IL-3 signaling may be an effective approach for the inhibition of beta-catenin activity in some patients with AML.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24598054            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL3 SNP rs40401 is significantly associated with the risk of asthma in young adult Japanese women.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24684517            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This is the first study to show a significant positive association between IL3 SNP rs40401 variant and the risk of rhinoconjunctivitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23953855            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL3 rs2073506 G\u0026gt;A polymorphism is associated with an increased risk for esophageal cancer of nodal and metastatic stages.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23726808            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variation in the IL3 promoter affects human brain volume by regulating proliferation and survival of neural progenitors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23226269            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Transgenic mice are used to study the developmental regulation of the closely linked IL-3 and granulocyte-macrophage colony stimulting factor (GM-CSF) locus and to identify DNA enhancer elements required for its correct activity in vivo.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23024272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            data indicate that within microenvironments rich in betac-family cytokines and TNF, eosinophils are a source of proMMP-9 and highlight a previously unrecognized role for synergistic interaction between TNF and betac-family cytokinea, for proMMP-9 synthesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        22321809            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study demonistrated that Carriers of the minor allele for a single nucleotide polymorphism in IL13 (rs1295686) were more likely to report breast pain prior to surgery (P = .019).            \u003ca rel=\"nofollow\"\u003e             PMID:                        22515947            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            an IL-3 autocrine loop can drive a tumor endothelial switch and that targeting IL-3 might confer a significant therapeutic advantage to hamper tumor angiogenesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        21643009            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-3 provides cellular protection against amyloid-beta neurotoxicity in primary cortical neuronal cells and may play a neuroprotective role in Alzheimer's disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20964623            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL3 genotypes rs40401 and rs40401 were found to exert a protective effect against malaria attacks.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21224257            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate a role for PLCgamma2 and Ca(2+) signaling through the modulation of MEK\/ERK in IL3\/GM-csf stimulated human hematopoietic stem\/progenitor cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21506110            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The interaction of 6-locus from the 5 interleukin genes might confer higher risk for graves'disease and Graves'ophthalmopathy than single risk allele.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20332709            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-3 genotypes of 60 acute rejection (AR) subjects and the 270 patients without AR demonstrated a significant relationship between genotype frequencies and the SNPs            \u003ca rel=\"nofollow\"\u003e             PMID:                        21168724            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Human IL-3\/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21262803            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            propose that RhoH functions as a negative regulator for IL3-induced signals through modulation of the JAK-STAT pathway            \u003ca rel=\"nofollow\"\u003e             PMID:                        20738848            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the domain 1 D-E loop disulfide of hbetac and beta(IL-3) in maintaining the precise positions of ligand-binding residues necessary for normal high affinity binding and signaling            \u003ca rel=\"nofollow\"\u003e             PMID:                        20516062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Two different modes of beta c binding are utilized in the presence of the hIL-3R alpha isoforms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20472554            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a novel role for VPA in enhancing the potential of IL-3 to stimulate megakaryopoiesis as well as erythropoiesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        20381581            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-3\/GM-CSF locus undergoes progressive stages of activation, with stepwise increases in active modifications and the proportion of cytokine-expressing cells, throughout the course of T cell differentiation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20147630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-3 and oncogenic Abl regulate the myeloblast transcriptome by altering mRNA stability            \u003ca rel=\"nofollow\"\u003e             PMID:                        19829692            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            binding kinetics of native IL-3 and several variants to IL-3 receptor            \u003ca rel=\"nofollow\"\u003e             PMID:                        11700046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-3 induces MHC class II and B7.2 expression on eosinophils and renders them capable of supporting T cell proliferation to superantigen and antigen-derived peptides.            \u003ca rel=\"nofollow\"\u003e             PMID:                        11714768            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            inhibition of signaling by antisense oligodeoxynucleotides targeting the common beta chain of receptors            \u003ca rel=\"nofollow\"\u003e             PMID:                        11763346            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ectopically expressed in myeloid leukemic cells with t(5;12)(q31;p13), suggesting that expression of IL3 was deregulated by the translocation, indicating a variant leukemogenic mechanism for translocations involving the 5' end of ETV6            \u003ca rel=\"nofollow\"\u003e             PMID:                        11861295            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Antiapoptotic cytokine IL-3 + SCF + FLT3L influence on proliferation of gamma-irradiated AC133+\/CD34+ progenitor cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12002675            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Monocytes cultured in the presence of IL-3 (plus IL-4) differentiate into dendritic cells that produce less IL-12 and shift T helper (Th) cell responses toward a Th2 cytokine pattern.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12055233            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that increased activity of mutated interleukin 3 is due to a change from a rare ligand to a common one, allowing the increase in IL-3-dependent signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12093816            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            role in potentiating hematopoietic cell migration            \u003ca rel=\"nofollow\"\u003e             PMID:                        12135758            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-3 gene is regulated by two enhancers that have distinct but overlapping tissue specificities.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12165512            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            WEHI-3B-derived IL-3 stimulation of mcl-1 gene transcription through the SIE motif involves phosphorylation of PU.1 at serine 142 by a p38(MAPK)-dependent pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12612065            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Incubation of eosinophils with IL-3 leads to reduced expression of IL-5R alpha which is sustained for up to 5 days; in contrast, expression of IL-3R alpha is increased by IL-3, whereas GM-CSF receptor alpha expression in eosinophils is unaffected by IL-3.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12759409            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915098259681,"sku":"BL-0275NP","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-il5-protein-his-tag-bl-0276np","title":"Recombinant Human IL-5 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-5 is produced by our Mammalian expression system and the target gene encoding Ile20-Ser134 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP05113\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-5 is expressed in eosinophils, NK cells, TC2 CD8+ T cells, mast cells, CD45+ CD4+ T cells, gamma delta T cells and IL-1 beta activated endothelial cells. IL-5 acts as a growth and differentiation factor for both B cells and eosinophils. Relative to B cells, IL-5 appears to induce the differentiation of activated conventional B-2 cells into Ig-secreting cells. In addition, it induces the growth of B-1 progenitors as well as IgM production by B-1 cells.IL-5 appears to perform a number of functions on eosinophils. These include the down modulation of Mac-1,the upregulation of receptors for IgA and IgG,the stimulation of lipid mediator (leukotriene C4 and PAF) secretion and the induction of granule release.IL-5 also promotes the growth and differentiation of eosinophils.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e14.2 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e20 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by SEC-HPLC. (Regularly tested)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFactor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-5 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6016           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            147850           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3567           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000231454           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29602685            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            eosinophilia in FE is secondary to dysregulation of IL-5 production in PBMC (and their component subsets).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28226398            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that interleukin-5 (IL-5) was that only serum cytokines show statistical significance between severe chronic obstructive pulmonary disease (COPD) and controls.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28398462            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum IL-5 and IL-13 are reliable biomarkers for the blood eosinophilia asthma phenotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27060452            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Longitudinal co-variations between inflammatory cytokines, lung function and patient reported outcomes in patients with asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        28915273            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Obesity alters the lung neutrophil infiltration to enhance breast cancer metastasis through IL5 and GM-CSF.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28737771            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            simvastatin was demonstrated to inhibit IL-5-induced CCR3 expression and chemotaxis of eosinophils mediated via the mevalonate pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27275740            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin-5\/-targeted treatments offer promises to patients with eosinophilic respiratory disorders; review            \u003ca rel=\"nofollow\"\u003e             PMID:                        26859368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that interleukin 5 (IL-5)-associated single nucleotide polymorphisms (SNPs) were not associated with carotid intima-media thickness.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26821299            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Post-liver transplant patients with food allergy showed a unique cytokine profile in response to various stimuli, with extremely elevated IL-5, low IL-10 secretion.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26282695            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Production of IL-5 in response to both extract and the Bet v1-derived peptide mix strongly suggested that T cells were a major source of IL-5.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25817862            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It has been shown in this study that the level of IL-5, one of the markers of eosinophilic inflammation, is higher in EBC of children with atopic asthma than in those with nonatopic asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25937050            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-5 may be part of protective mechanisms operating in early atherosclerosis, at least in women            \u003ca rel=\"nofollow\"\u003e             PMID:                        25587992            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results showed that PAX2 expression is significantly overexpressed in esophageal squamous cell carcinoma tissues and IL-5 is identified as PAX2's effector for metastasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25613757            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Subsequent IL-5-stimulated signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25121926            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            increased levels in recurrent versus nonrecurrent rhinosinusitis with nasal polyps at the moment of the first surgery            \u003ca rel=\"nofollow\"\u003e             PMID:                        24980230            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            HDM-specific IL-5 responses at age 3 years or later are the best measure of T cell function for predicting asthma at age 8 years.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24875149            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fibrocytes studied were generated in vitro from PBMCs by culturing in the presence of platelet derived growth factors and stimulated by IL-33. Fibrocytes constitutively expressed IL-13 and IL-5, which was augmented by stimulation with IL-33.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24822215            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24530098            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Patients with the 'IL-5, IL-17A, IL-25-high' airway inflammatory pattern are often uncontrolled asthmatics, despite daily treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23957336            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These unexpected results provide a theoretical basis for the therapeutic targeting of IL-5 in bladder cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        23770289            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In activated eosinophils ligation of Siglec-8 leads to ROS-dependent enhancement of IL-5-induced ERK phosphorylation, which results in a novel mode of biochemically regulated eosinophil cell death.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23684072            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            When patients were classified according to sputum IgE levels, it appeared that IL-5, IL-6, IL-17 and TNF-alpha sputum supernatant levels were raised in the \"IgE high\" asthmatics when compared to \"IgE low\" asthmatics            \u003ca rel=\"nofollow\"\u003e             PMID:                        23555579            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            alpha(M)beta(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23306834            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Type I interferon (IFN)-dependent inhibition of T cell-derived IL-5 is mediated by IFN-alpha acting directly on activated T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23382558            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Strong IL-5 production was detected in response to peptides from several of the previously undescribed proteins of grass pollen.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23401558            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Topical steroid treatment may suppress IL-5 gene expression, and steroids may inhibit eosinophil functions in nasal polyps.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15835818            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated expression of inflammatory cytokines (IL-5, IL-20, and IL-28A) is associated with bladder cancer development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22962576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            binding of IL-5 to IL-5Ralpha plays a critical role in MMP-9 expression, which may be involved in the migration of bladder cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22710862            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The study reports the crystal structure of dimeric IL-5 in complex with the IL5RA extracellular domains.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22528658            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated levels of IL-5, which uses the neural plasticity-related RAS GTPase-ERK pathway to mediate its actions in the central nervous system, could be one of the factors underlying the depression-related changes in CNS plasticity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22230487            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            elevated levels in induced sputum from patients with asthma and allergic rhinitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        22186238            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            REVIEW: Interleukin-5 and IL-5 receptor in health and disease            \u003ca rel=\"nofollow\"\u003e             PMID:                        21986312            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The structure demonstrates that for steric reasons, homodimeric IL-5 can bind only one receptor molecule, even though two equivalent receptor-binding sites exist.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22153509            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is no correlation between the eosinophilic infiltration and the expression of IL-5 in lung cancer tissues.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21609545            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Transplantation of human mesenchymal stem cells suppresses middle cerebral artery occlusion (MCAO) focal ischemia-induced inflammation, possibly through expression of fractalkine and interleukin (IL)-5.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21168500            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results demonstrate that IL-5(+) and IL-5(-) Th2 cells, respectively, represent more and less highly differentiated Th2 cell subpopulations            \u003ca rel=\"nofollow\"\u003e             PMID:                        21849680            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-5 may play a role in the early phase of acute pneumonia caused by the 2009 H1N1 virus in Japanese children.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21323726            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Activation of GATA-3 might be one of the mechanisms for induction of IL-5 expression in chronic rhinosinusitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17628972            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            AP-1 may participate in the signal transduction of PKC-triggered expression of IL-5 in allergic rhinitis T lymphocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17438848            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PPD-induced preferential secretion by PBMCs of Warao indigenous patients in Venezuela            \u003ca rel=\"nofollow\"\u003e             PMID:                        20650294            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Functional polymorphisms in the genes encoding the Th2 cytokines Il-5, IL-6, and IL-13, are associated differently with the development and prognosis of autoimmune thyroid disease from each other.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21235536            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-5 and IL-8 are the key cytokines in the formation of nasal polyps.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16929824            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that IL-5 responses in cord blood samples were strongly related to the season of birth.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20825427            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            promotes increased immunoglobulin M at the site of disease in leprosy            \u003ca rel=\"nofollow\"\u003e             PMID:                        20561085            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our study identifies CXCL10 and IL-5 as proteins differentiating complicated and uncomplicated plaques from human carotid arteries            \u003ca rel=\"nofollow\"\u003e             PMID:                        20943047            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sputum IL-5 was associated with a sputum eosinophilia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19478474            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            data indicate that ability to produce the type 2 cytokines IL-13 and IL-5 defines CD161(+) NK cells at intermediate stages of differentiation, and is lost upon terminal functional differentiation, concomitant with acquired ability to produce IFN-gamma            \u003ca rel=\"nofollow\"\u003e             PMID:                        11830476            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD4(+) T cells are the major source of IL-5 among CD3(+) lymphocytes in atopic asthmatic subjects, whereas in nonatopic asthmatic subjects CD8 (+) T cells as well as CD4(+) T cells contribute to the increased production of IL-5            \u003ca rel=\"nofollow\"\u003e             PMID:                        11842300            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            By itself, IL5 increases nerve growth factor level in eosinophils, but in combination with immune complexes, significantly reduces eosinophil NGF levels.            \u003ca rel=\"nofollow\"\u003e             PMID:                        11877300            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915098685665,"sku":"BL-0276NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLYmAUkQPAACpmkd4RzM867_8d8ced9a-7d0c-4122-932e-a29fd989657f.jpg?v=1685853188"},{"product_id":"recombinant-mouse-il4-protein-his-tag-bl-0279np","title":"Recombinant Mouse IL-4 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-4 is produced by our Mammalian expression system and the target gene encoding His21-Ser140 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP07750\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-4; IL-4; IL4; B-cell IgG differentiation factor; B-cell growth factor 1; B-cell stimulatory factor 1; BSF-1; IGG1 induction factor; Lymphocyte stimulatory factor 1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-4 (IL-4) is a pleiotropic cytokine that regulates diverse T and B cell responses including cell proliferation, survival and gene expression. IL-4 is produced by mast cells, T cells, and bone marrow stromal cells. IL-4 regulates the differentiation of naive CD4+ T cells into helper Th2 cells, characterized by their cytokine-secretion profile that includes secretion of IL-4, IL-5, IL-6, IL-10, and IL-13, which favor a humoral immune response. Another dominant function of IL-4 is the regulation of immunoglobulin class switching to the IgG1 and IgE isotypes. Excessive IL-4 production by Th2 cells has been associated with elevated IgE production and allergic response.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e14.6 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15-19 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eParticipates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes. Positively regulates IL31RA expression in macrophages. Stimulates autophagy in dendritic cells by interfering with mTORC1 signaling and through the induction of RUFY4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-4\/IL-13 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:16189           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000000889           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30451856            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Ndfip1 preserves Treg lineage stability and immune homeostasis by preventing the expansion of highly proliferative and metabolically active Treg cells and by preventing pathological secretion of IL-4 from Treg cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28580955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4\/ STAT6 signaling needs to be well adjusted to ensure proper development and function of homing Th2 cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29738764            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            By establishing that IL-4 is posttranslationally regulated by TRX-promoted reduction of a disulfide bond, our findings highlight a novel regulatory mechanism of the type 2 immune response that is specific to IL-4 over IL-13.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30104382            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The VEGFR1-mediated signaling suppressed IL-4-induced Arg-1 expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29110610            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results obtained in the present study suggest that a signaling pathway mediated by FcRg or the FcRg-Syk axis is commonly required for innate basophil IL-4 responses under conditions mimicking encounters with allergen sources.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26703455            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4Delta2 did not compete with IL-4 for IL-4Ralpha binding and did not interfere with the downstream STAT-6 phosphorylation in T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28917204            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that IL4 and IL21 cooperate to induce the high Bcl6 protein level required for germinal center formation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28875978            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The complex role of IL-4 in autoimmunity and cholangitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27721424            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results demonstrate that IL-4 can restore insulin sensitivity in adipocytes via mechanisms not associated with induced adipogenesis or de novo formation of lipid depots.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29738684            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin 4 (IL-4) signaling prevents Chlamydia trachomatis Infection from Inducing upper genital tract (UGT) pathology.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28765368            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the lung, surfactant protein A (SP-A) enhanced interleukin-4 (IL-4)-dependent macrophage proliferation and activation, accelerating parasite clearance and reducing pulmonary injury after infection with a lung-migrating helminth. In the peritoneal cavity and liver, C1q enhancement of type 2 macrophage activation was required for liver repair after bacterial infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28495878            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data, including data from studies using transgenic mice, suggest that over-expression of IL4 (interleukin 4) in thyroid tissue\/cells up-regulates expression of Duox1 (dual oxidase 1), Duoxa1 (dual oxidase maturation factor 1), and Slc26a4 (pendrin) in thyroid tissue\/cells; expression of Slc5a5 (sodium-iodide symporter) is down-regulated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27599561            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we defined a molecular mechanism for IL-4 downregulation of involucrin in keratinocytes, which may play an important role in the pathogenesis of AD.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26918372            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In this study, the effect of continuous IL-4 delivery or bioactive implant coating that constitutively releases a protein inhibitor of CCL2 signaling (7ND) on particle induced osteolysis were studied in the murine continuous femoral intramedullary particle infusion model            \u003ca rel=\"nofollow\"\u003e             PMID:                        27114284            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            T follicular helper (Tfh) cells arise in tumor-draining lymph nodes where they produce an abundance of IL4. Deletion of IL4-expressing Tfh cells improves antitumor immunity, delays tumor growth, and reduces the generation of immunosuppressive myeloid cells in the lymph nodes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27920023            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Findings suggest that interleukin 4 (IL-4) affects anti-tumor immunity and constitutes an attractive therapeutic target to reduce immune suppression in the tumor microenvironment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28733709            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that environmental IL-4 plays a role in conditioning early thymic progenitors lineage choice, which would impact T cell development            \u003ca rel=\"nofollow\"\u003e             PMID:                        28893952            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that eosinophils subvert host resistance to an intracellular pathogen by instigating non-protective IL-4 in CCR2(-\/-) mice            \u003ca rel=\"nofollow\"\u003e             PMID:                        27049063            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings show that during intestinal helminth infection, IL-4 derived from T follicular helper cells is required for IgE class switching and plasmablast formation            \u003ca rel=\"nofollow\"\u003e             PMID:                        28533444            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that Il4 (usually released from helper T-cells) induces Cox1 in macrophages at post-transcriptional level; activation of Ampk (catalytic subunit Prkaa1) by metformin blocks Il4-dependent induction of Cox1 and blocks macrophage polarization\/activation. (Il4 = interleukin-4; Cox1 = cyclooxygenase 1; Ampk = AMP-activated protein kinase)            \u003ca rel=\"nofollow\"\u003e             PMID:                        28684424            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4 is required for the development of ex-Foxp3 T helper 2 cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28507062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            conclude that a state of haploinsufficiency for the Il4 gene locus is specifically relevant for IL-4-dependent IgE responses to allergens with the amount of IL-4 produced in the hemizygous condition falling close to the threshold required for switching to IgE production            \u003ca rel=\"nofollow\"\u003e             PMID:                        28115531            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            priming of T helper cells by IL-6-deficient antigen-presenting dendritic cells preferentially leads to accumulation of a subset of Follicular helper T cells characterized by high expression of GATA3 and IL-4.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27474166            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            eosinophils drive progression of myocarditis to Inflammatory dilated cardiomyopathy (DCMi), cause severe DCMi when present in large numbers, and mediate this process through IL-4.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28302646            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data suggest that although IL-4-stimulated alternatively activated macrophages upregulate fatty acid oxidation, fatty acid oxidation is dispensable for macrophage polarization and high-fat diet-induced metabolic dysfunction. Macrophage fatty acid oxidation likely plays a correlative, rather than causative, role in systemic metabolic dysfunction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28223293            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Excessive IL-4 levels in the mesenteric lymph nodes (MLNs) directly inhibited the induction of aiTregs and caused enteropathy. The aiTregs generated in the attenuation of T cell-dependent food allergic enteropathy may function differently than aiTregs induced in a tolerance model.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28234975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that wild-type mice develop an eosinophilic Th2 airway disease in response to Alternaria alternata exposure, whereas IL-4-deficient mice exhibit a primarily neutrophilic response            \u003ca rel=\"nofollow\"\u003e             PMID:                        27815425            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study showed that the intraperitoneal administration of the exogenous cytokines IFN-gamma (to promote M1 microglia ) and IL-4 (to promote M2 microglia) can correctly modulate the timing of the M1 to M2 ratio to affect epileptogenesis and to improve cognitive function in pilocarpine-induced status epilepticus.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27956120            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings indicate that IL-4, a canonical Th2 cell cytokine, can sometimes promote rather than impair Th1 cell-type immune responses            \u003ca rel=\"nofollow\"\u003e             PMID:                        27298446            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Keratinocyte gene expression is critically shaped by IL-4, altering cell fate decisions, which are likely important for the clinical manifestations and pathology of allergic skin disease            \u003ca rel=\"nofollow\"\u003e             PMID:                        27554818            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that lactic acid in tumor microenvironments inhibited interferon-gamma (IFNgamma) and intert=leukin-4 (IL4) productions from NKT cells by inhibiting mammalian target of rapamycin (mTOR) signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27995420            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that IL-4-mediated control of the precursor population affects the development of virus-specific CD8+ T-cell memory            \u003ca rel=\"nofollow\"\u003e             PMID:                        27457412            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4 secretion by group 2 innate lymphoid cells contributes to the allergic response in food allergy by reducing allergen-specific Treg cell and activating mast cell counts            \u003ca rel=\"nofollow\"\u003e             PMID:                        27177780            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These studies clearly show a crucial role for IL-4 in the induction of airway hyperresponsiveness following Strongyloides venezuelensis infection and for IL-33\/ST2 in maintaining airway hyperresponsiveness and lung Th2 responses.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27102638            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we used recombinant herpes simplex virus vector S4IL4 that encode mouse il4 gene to evaluate the therapeutic potential of IL-4 in naloxone-precipitation morphine withdrawal (MW). One week after microinjection of the vector S4IL4 into the PAG LacZ or mouse IL-4 immunoreactivity in the vlPAG was visualized. ELISA assay showed that vector S4IL4 into the PAG induced the expression of IL-4            \u003ca rel=\"nofollow\"\u003e             PMID:                        28206989            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that IL-4 is increased in the brain of T cell receptor transgenic mice, which exhibit impaired memory and adult hippocampal neurogenesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27432189            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that il-4 plays an important role in ESAT-6-induced MCP-1 production by macrophages, and suggest a pathway with significance in tuberculosis pathogenesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27154637            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            indicate that Siglec-9 affects several different signaling pathways in IL-4-stimulated macrophages, which resulted in enhanced induction of Arg1 in Siglec-9-expressing RAW264 cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        26540411            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Oct-1 and Oct-2 bound within the Il4 promoter region and the Th2 LCR            \u003ca rel=\"nofollow\"\u003e             PMID:                        26840450            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Loss of IL-4 promoted expression of M1 microglia\/macrophage markers and impaired expression of M2 markers after transient or permanent middle cerebral artery occlusion.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26732561            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results indicate a positive role of Batf in promoting the generation of pro-allergic IL-4-producing T-follicular helper cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26278622            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4 induces miR-142-5p and downregulates miR-130a-3p in macrophages, regulating macrophage profibrogenic gene expression in chronic inflammation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26436920            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings underscore the important collaboration between IL-4 and IL-21 in shaping T-dependent B cells antibody responses.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26491200            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4 KO mice display state, but not trait, anxiety suggesting that reductions in endogenous anti-inflammatory bioactives can engender subtypes of anxiety            \u003ca rel=\"nofollow\"\u003e             PMID:                        25772794            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            physiologic doses of interleukin-4 (IL-4) and interleukin-13 (IL-13) have profound anti-lymphangiogenic effects and potently impair LEC survival, proliferation, migration            \u003ca rel=\"nofollow\"\u003e             PMID:                        26039103            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Concerted activity of IgG1 antibodies and IL-4\/IL-25-dependent effector cells trap helminth larvae in the tissues following vaccination with defined secreted antigens, providing sterile immunity to challenge infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25816012            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            may be an important factor in providing 1,25D3-induced protection from experimental autoimmune encephalomyelitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        25574039            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4-producing DCs are induced under some Th2-provoking situations, and they should play important roles in initiation of Th2 response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26363056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            RUN and FYVE domain-containing protein 4 enhances autophagy and lysosome tethering in response to Interleukin-4.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26416964            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915097374945,"sku":"BL-0279NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLZWAUAgwAACYpYh7qYs165_d3b671c2-e300-47c1-8bfe-cba68ec02e52.jpg?v=1685853135"},{"product_id":"recombinant-human-il4-r-il4ra-protein-his-tag-bl-0304np","title":"Recombinant Human IL-4 RA Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-4 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Met26-His232  is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP24394\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-4 receptor subunit alpha; IL-4 receptor subunit alpha; IL-4R subunit alpha; IL-4R-alpha; IL-4RA; CD124; IL-4-binding protein; IL4-BP; IL4R; IL4RA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 4 Receptor alpha (IL4-Ra) is a widely expressed 140 kDa transmembrane glycoprotein in the class I cytokine receptor family. Mature human IL4-Ra consists of a 207 amino acid (aa) extracellular domain (ECD) that contains a cytokine binding region and one fibronectin type III domain, a 24 aa transmembrane segment, and a 569 aa cytoplasmic domain that contains one Box 1 motif and one ITIM motif. IL4-Ra plays an important role in Th2-biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. Soluble forms of IL4-Ra, generated by alternate splicing or proteolysis, retain ligand binding properties and inhibit IL-4 bioactivity. IL4-Ra is a component of two distinct receptor complexes and shows species selectivity between human and mouse. It can associate with the common gamma chain (γc) to form the IL-4 responsive type I receptor in which γc increases the affinity for IL-4 and enables signaling. It can alternatively associate with IL13-Ra1 to form the type II receptor which is responsive to both IL-4 and IL-13. The use of shared receptor components contributes to the overlapping biological effects of IL-4 and IL-13 as well as other cytokines that utilize γc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e24.4 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e35-60 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for both interleukin 4 and interleukin 13. Couples to the JAK1\/2\/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4\/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1\/IRS2.; Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation and IL5 up-regulation by T-cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 4 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6015           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            147781           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3566           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000170630           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28706306            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Interleukin-4 receptor subunit alpha (IL-4Ralpha) haplotypes for Val75Ile, Ser503Pro, and Arg576Gln are associated with measles Immunoglobulin G production in Mozambican children but not Australian children. IL-4Ralpha 503Pro is more prevalent in Mozambique vaccine failure cases compared with controls.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28594599            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We consider that although no association was found among diverse SNPs from human IL-10 and IL-4 promoter regions and gastric cancer event, the present research provides insight into two possible biomarkers of immunological nature (increased level of serum IL-4) and genetic nature (presence of the IL-10, -G1082A SNP) related to this neoplasm in our population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30526523            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL4RA and ADAM33 variants may be risk markers of asthma exacerbations in type-2 inflammatory endotype. Precise endotyping may facilitate the identification of genetic risk markers of asthma exacerbations.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28326636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that the IL-4Ralpha polymorphism is associated with susceptibility to chronic immune thrombocytopenia            \u003ca rel=\"nofollow\"\u003e             PMID:                        28511637            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here in this review, we discuss the structural details of IL-4 and IL-4Ralpha subunit and the structural similarities between IL-4 and IL-13. We also describe detailed chemistry of type-I and type-II receptor complexes and their signaling pathways. Furthermore, we elaborate the strength of type-II hetero dimer signals in response to IL-4 and IL-13.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27165851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Naive CD4+ Tconv cells from subjects with asthma bearing the IL4RR576 mutation show defective induction of iTreg cells and their skewing toward a TH17-like phenotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27479084            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Result showed that exposure of Peripheral Blood-Mesenchymal Stem Cells (PB-MSCs) to Noggin was associated with changes in pattern of CD29\/CD184 expression. The expression profile of CD29(+\/-)\/CD184(-) can be suggested as a robust signature for tracing differentiation of PB-MSCs into neuronal cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27478015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The promoter methylation levels of GATA3, IL-4, and TGF-beta were significantly higher in active VKH patients than in healthy individuals            \u003ca rel=\"nofollow\"\u003e             PMID:                        28278322            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A positive association exists between the IL-4R Q551R polymorphism and occurrence of chronic periodontitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28392616            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphism of IL-4Ralpha 175 V was linked to greater Atopic dermatitis risk at 2 to 3 years of age.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27274543            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4Ralpha gene (I50V) polymorphism may play a role in development of eczema among Saudi children            \u003ca rel=\"nofollow\"\u003e             PMID:                        27018548            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic polymorphism is associated with autoimmune hepatitis in Brazilian children            \u003ca rel=\"nofollow\"\u003e             PMID:                        26693492            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL4Rrs2107356 and IL8rs2227307 SNPs were associated with an increased risk of invasive aspergillosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26667837            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Essential role of endocytosis for interleukin-4-receptor-mediated JAK\/STAT signalling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26306492            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of IL-4 and IL-13 receptors in cancer biology and discussion of pre-clinical and clinical studies pertaining to recombinant immunotoxins designed to target these receptors [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26088753            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            review of IL-4 and IL-13 receptor structure, receptor regulation, signaling and experimental therapeutics [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26187331            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is no correlation between the Arg551Gln polymorphism in IL-4R gene and asthma predictive index results            \u003ca rel=\"nofollow\"\u003e             PMID:                        26695670            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studies indicate significant association between the interleukin-4receptor (IL-4R) Q576R polymorphism and the risk of asthma in the Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25867440            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results illustrated that Saudi vitiligo patients showed significantly higher frequency of the IL-4R (Q551R A\u0026gt;G) homozygous GG variant (recessive mode) as compared with their respective controls            \u003ca rel=\"nofollow\"\u003e             PMID:                        23774696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher frequency of polymorphisms in patients with familial hypercholesterolemia            \u003ca rel=\"nofollow\"\u003e             PMID:                        25110223            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-4RA-1902 A\/A genotype has been associated with a reduced response to IL-4 and has been found in 90% oral mucous membrane pemphigoid patient            \u003ca rel=\"nofollow\"\u003e             PMID:                        23557074            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variants of NOS3, CD14, MMP3 and IL4R are implicated in the determination of VEGF expression and plasma levels.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26437765            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL4R mediates enhanced glucose and glutamine metabolism in breast cancer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25746764            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Receptor trafficking may play an important role for the regulation of IL-4R-mediated JAK\/STAT signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25468331            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Gene interactions were observed between IL4R and TNF-alpha genes in hand osteoarthritis patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25252624            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Selective augmentation of IL-4Ralpha signaling in Treg cells induced their reprogramming into Th2-like cells and disease susceptibility towards food allergy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25769611            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that high expression of interleukin-4 receptor IL-4Ralpha correlated with increased recurrence, while interleukin-13 receptor IL-13Ralpha1 had an inverse relationship to recurrence and survival in oral cavity squamous cell carcinoma patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25483786            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher TGF-beta with lower CD124 and TSLP, but no difference in PAR-2 expression in bronchial biopsy of bronchial asthma patients in comparison with COPD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24185116            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Analysis of IL4R SNP haplotypes or complex alleles suggested no dominant protection in patients with Recurrent spontaneous abortion            \u003ca rel=\"nofollow\"\u003e             PMID:                        24803421            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that the physical interaction between the cytoplasmic domains of IL-13Ralpha2 and IL-4Ralpha regulates IL-4 signaling through the IL-4Ralpha-IL-13Ralpha1 receptor complex.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24056919            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            increased expression in B cells of patients with house dust mites allergic asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        24975796            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The binding of [AP1-V12]6 to cancer cells was remarkably reduced when IL-4 receptors were blocked by antibody against IL-4 receptor further confirmed its binding            \u003ca rel=\"nofollow\"\u003e             PMID:                        24339977            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Increased Th17 cell frequency and poor clinical outcome in rheumatoid arthritis are associated with a genetic variant in the IL4R gene, rs1805010.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24782180            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            beta-defensin-2 and interleukin-4 receptor are biomarkers that improve the prediction of poor-outcome over clinical variables in the acute phase of stroke            \u003ca rel=\"nofollow\"\u003e             PMID:                        24386991            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL4RA I50V and Q551R polymorphisms may be risk factors for developing asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23922687            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This meta-analysis indicates that the I50V polymorphism of IL-4R gene may confer susceptibility to RA            \u003ca rel=\"nofollow\"\u003e             PMID:                        23972290            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the polymorphism of IL-4Ralpha rs1801275 confers individual's variable susceptibility to glioma, particularly among Asians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23979976            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Rs1805012 polymorphism of IL-4R gene is associated with asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24510574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genetic variants in IL4R were identified, and their association with the progression rate of joint damage in rheumatoid arthritis was independently replicated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23983153            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphisms in IL4R gene is associated with the risk of adult glioma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23525950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The rs1801275 in IL-4R showed an increased risk of glioblastoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23663500            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            An meta-analysis suggests that the IL-4Ralpha rs1801275 polymorphism is not a genetic predictor for glioma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23395224            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            reduced IL-4R signalling has stage-specific effects on colorectal carcinogenesis (increased CRC initiation and risk but reduced tumour progression and no effect on CRC mortality).            \u003ca rel=\"nofollow\"\u003e             PMID:                        23784081            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings support a pathogenic role for IL-4Ralpha on Th cells following respiratory syncytial virus reinfection            \u003ca rel=\"nofollow\"\u003e             PMID:                        23543769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduced interleukin-4 receptor alpha expression on CD8+ T cells correlates with higher quality anti-viral immunity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23383283            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that single nucleotide polymorphism (SNP) rs1805015 in the IL4Ralpha gene was significantly associated with eczema in the additive and dominant models.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23480403            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Passive smoking causes significant rise in plasma TNFa and IL4 with a dose dependent effect            \u003ca rel=\"nofollow\"\u003e             PMID:                        23066418            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interacting determinants of atopy, total IgE, IgE against prevalent allergens, and IL4RA polymorphisms, contribute to the high prevalence of betalactams allergy in South of Spain.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22764749            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A protective association for Hodgkin lymphoma was observed on the IL4R gene with haplotype TCA            \u003ca rel=\"nofollow\"\u003e             PMID:                        22902050            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915016241377,"sku":"BL-0304NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLamAYKh0AACksqL8wMo339_abb56c1e-d03c-4e97-8027-6ebc1c9b414d.jpg?v=1685850593"},{"product_id":"recombinant-human-il13ra1-protein-his-tag-bl-0305np","title":"Recombinant Human IL-13RA1 Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-13 Receptor Subunit Alpha-1 is produced by our Mammalian expression system and the target gene encoding Gly22-Thr343 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP78552\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-13 receptor subunit alpha-1; IL-13 receptor subunit alpha-1; IL-13R subunit alpha-1; IL-13R-alpha-1; IL-13RA1; Cancer\/testis antigen 19; CT19; CD213a1; IL13RA1; IL13R; IL13RA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-13 receptor subunit alpha-1(IL13RA1) is a subunit of the interleukin 13 receptor. This subunit forms a receptor complex with IL4 receptor alpha, a subunit shared by IL13 and IL4 receptors. The human IL13-Rα1 was originally cloned based on sequence homology to the mouse IL13-Rα1, it share 76% aa sequence identity. Human The IL13-Rα1 cDNA encodes a 427 amino acid (aa) residue precursor protein with a putative 21 aa residue signal peptide, a 324 aa residue extracellular domain, a 23 aa residue transmembrane region and a 59 aa residue cytoplasmic tail. The extracellular domain of IL13-Rα1 is also closely related to that of IL13-Rα2. It binds with low affinity to interleukin-13(IL13). IL13RA1 serves as a primary IL13- binding subunit of the IL13 receptor, and may also be a component of IL4 receptors. This protein has been shown to bind tyrosine kinase TYK2, and thus may mediate the signaling processes that lead to the activation of JAK1, STAT3 and STAT6 induced by IL13 and IL4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e37.7 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e55-65 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBinds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 5 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            5974           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            300119           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3597           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000360730           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28634667            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            in humans and mice indicate, for the first time, a role of interleukin-13 receptor alpha1 in myocardial homeostasis and heart failure and suggests a new therapeutic target to treat heart disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28528324            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            sIL13ralpha1 as a circulating human protein with an unexpected role in glucose metabolism.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28874358            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-13Ralpha1 has a protective role in bleomycin-induced pulmonary injury and repair.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26153764            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            required for induction of the alternative macrophage activation pathway by IL-13 but not by IL-4            \u003ca rel=\"nofollow\"\u003e             PMID:                        25766112            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results identified FAM120A in the IL13\/IL13Ralpha2 signaling pathway as a key mediator of invasion and liver metastasis in colon cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25896327            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-143 regulation of IL-13-induced inflammatory cytokine and mucus production in nasal epithelial cells from allergic rhinitis patients probably partly depends on inhibition of IL13Ralpha1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25529447            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            MiR-143 may be associated with allergic reaction in human mast cells via downregulation of IL13RA1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23965966            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In humans, IL-13Ralpha1 lies within the PARK12 locus of susceptibility to Parkinson's disease and may have a role in the pathogenesis of this neurodegenerative disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23169588            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results indicate that an inherited polymorphism of the IL-4R controls the ability of the human immune system to regulate the magnitude of IL-17 production            \u003ca rel=\"nofollow\"\u003e             PMID:                        21294892            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-13R A(1) +1398 A\/G polymorphism does not contribute to asthma or allergic rhinitis susceptibility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21425907            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-13Ralpha1 is expressed on human CD4(+) T(H)17 cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        21236478            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Mutation and functional analysis in human malignant glioma cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        11939409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL4RA and STAT6 are candidate genes for atopic disorders. 26 single-nucleotide polymorphisms (SNPs)and simple repeats are being reported spanning a total of 147kb in IL4RA and STAT6 genes of the Indian population            \u003ca rel=\"nofollow\"\u003e             PMID:                        12522691            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Allele frequency of IL13RA1 polymorphism was not associated with rapid decline of lung function in smokers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12594065            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of IL-13Ralpha1 may play some role in pathogenesis of chronic stage of atopic dermatitis or psoriasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14527737            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Bronchial submucosal mast cell IL-13 receptor alpha 1 expression is higher in asthmatics than normal controls.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16918506            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-13Ralpha1 polymorphism was associated with higher total IgE in children with atopic asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        17006604            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the IL13RA1 subunit gene -281T\u0026gt;G and 1365A\u0026gt;G polymorphisms do not contribute to asthma susceptibility or severity, although the IL13RA1 subunit gene locus might be involved in the control of immunoglobulin E production            \u003ca rel=\"nofollow\"\u003e             PMID:                        17392323            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            concomitant expression of IL-13Ralpha1 and IL-13Ralpha2 may be associated with the pathogenesis of idiopathic interstitial pneumonia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19654941            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915052384481,"sku":"BL-0305NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLamAVpFJAACshjcwZXo504_15877b04-756d-4d3d-a876-dc5cf44beca4.jpg?v=1685851660"},{"product_id":"recombinant-human-il17f-protein-his-tag-bl-0308np","title":"Recombinant Human IL-17F Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-17F is produced by our Mammalian expression system and the target gene encoding Arg31-Gln163 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAAH70124.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17F; IL-17F; Cytokine ML-1; IL17F\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17F (IL-17F) exists in a disulfide-linked heterodimer that belongs to the IL-17 family. IL-17F is expressed in activated, but not resting, CD4+ T-cells and activated monocytes. IL-17F has been shown to stimulate the production of several other cytokines, including IL-6, IL-8, and granulocyte colony-stimulating factor. IL-17F can regulate cartilage matrix turnover and stimulates PBMC and T-cell proliferation. IL-17F is also found to inhibit the angiogenesis of endothelial cells and induce endothelial cells to produce IL2, TGFB1\/TGFB, and monocyte chemoattractant protein-1. Defects in IL-17F are the cause of familial candidiasis type 6 (CANDF6).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15.96 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEffector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. IL17A-IL17F signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. IL17A-IL17F is primarily involved in host defense against extracellular bacteria and fungi by inducing neutrophilic inflammation. As signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers. IL17F homodimer can signal via IL17RC homodimeric receptor complex, triggering downstream activation of TRAF6 and NF-kappa-B signaling pathway. Via IL17RC induces transcriptional activation of IL33, a potent cytokine that stimulates group 2 innate lymphoid cells and adaptive T-helper 2 cells involved in pulmonary allergic response to fungi. Likely via IL17RC, promotes sympathetic innervation of peripheral organs by coordinating the communication between gamma-delta T cells and parenchymal cells. Stimulates sympathetic innervation of thermogenic adipose tissue by driving TGFB1 expression. Regulates the composition of intestinal microbiota and immune tolerance by inducing antimicrobial proteins that specifically control the growth of commensal Firmicutes and Bacteroidetes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-17 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            16404           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            606496           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:112744           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000337432           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29985710            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            The expression of IL-6 gene and protein was significantly induced by IL-17F. IL-17F activated TAK1 and NF-kappaB in airway smooth muscle cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28474507            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17FA7488G polymorphism was not significantly associated with colorectal cancer risk            \u003ca rel=\"nofollow\"\u003e             PMID:                        29970680            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a dietary pattern reflecting inflammation was significantly associated with colorectal cancer risk and this association could be modified according to the IL-17F rs763780 genotype and anatomic site.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29874787            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Malignant T cells activate endothelial cells via IL-17 F.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28731459            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The AA genotype on 7489A\/G single nucleotide polymorphism of IL-17F and the A allele might be associated with a lower risk of acute rejection with better graft survival in kidney transplant recipients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29407292            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Findings suggest that IL-17F rs1889570 gene polymorphisms are significantly associated with the susceptibility to severe EV71 infection in Chinese Han children.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29549443            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            P-TEFb is involved in IL-17F-induced IL-8 expression and that steroids diminish it via the inhibition of CDK9 phosphorylation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29649811            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-17F (+7488A\/G) genotype revealed a significantly increased risk of accelerated silicosis. The IL-17F (+7488 G) allele was associated with an increased risk of accelerated silicosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28481151            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            developed ultrasensitive methods for measuring IL-17A and IL-17F in human serum samples and found that serum from psoriasis patients had higher and a broader range of concentrations of both IL-17 proteins compared to healthy volunteers            \u003ca rel=\"nofollow\"\u003e             PMID:                        28534291            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SNPs of rs3819024 in IL-17A and rs763780 in IL-17F were weakly related to a prognosis of tuberculosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27339100            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL17F (rs2397084) and IL10 (rs1800871) genes are associated with functional dyspepsia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28965252            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a mutation in IL-17F is associated with susceptibility to recurrent aphthous stomatitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        29458167            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the G allele at rs763780 (IL-17F) was significantly associated with Takayasu Arteritis in Asian Indian population            \u003ca rel=\"nofollow\"\u003e             PMID:                        28438554            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            levels of mRNA IL-17F and IL17F might be useful parameters for the diagnosis of atopic asthma patient            \u003ca rel=\"nofollow\"\u003e             PMID:                        28606156            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17F rs763780 polymorphisms may be associated with the development of primary immune thrombocytopenia in a Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26620416            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In this study, IL-17F was demonstrated to have functions comparable to IL-17A in human keratinocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27576147            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum IL-17F predicted increased knee bone marrow lesion scores in females only among patients with knee osteoarthritis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27836676            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A and IL-17F polymorphisms therefore have the potential to act as predictive biomarkers for cervical cancer risk            \u003ca rel=\"nofollow\"\u003e             PMID:                        28621613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results suggest the possible involvement of the polymorphisms of IL17A G197A (rs2275913) and IL17F T7488C (rs763780) in the susceptibility to chronic Chagas disease and in development and progression of cardiomyopathy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28470012            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            our study provides an inclusive meta-analysis of the function of IL-17A rs2275913 and IL-17F rs763780 genetic variations in inflammatory diseases risk. The results indicated that these two genetic variations of IL-17A and IL-17F were risk factors for inflammatory diseases, particularly RA.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28186427            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This meta-analysis with seven articles in 697 patients diagnosed with chronic periodontitis , 188 patients diagnosed with aggressive periodontitis and 655 control patients totaling 1540 participants showed a non-significant association between the rs2275913 polymorphism in the IL-17A gene and the rs763780 polymorphism in the IL-17F gene with the risk of chronic periodontitis, or with aggressive periodontitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        29027636            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            our study provides the evidence that functional IL-23R rs1884444 G\/T and IL-17F rs763780 A\/G polymorphisms may be a new genetic susceptibility factor to SLE, especially in the Polish population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27320770            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL23R rs10889677 and IL17A rs2275913 were not associated with the susceptibility to Necrotizing enterocolitis (NEC). In conclusion, data suggest that a variant of IL17F (rs763780) may contribute to the development of NEC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28224332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results confirmed IL17A and IL17F as potential candidate genes involved in RA. They play pivoting roles in the susceptibility and in clinical features of RA disease. Responses to RA treatments are differently conditioned by polymorphisms in IL17A and IL17F genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28143790            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL17A and IL17F gene polymorphism are not the important factors associated with susceptibility and some clinical parameters of rheumatoid arthritis in a Polish population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27169372            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we aimed to investigate the associations between the 7383A\/G and 7488A\/G polymorphisms of the interleukin (IL)-17F gene with disease activity and clinical outcomes in Turkish patients with ankylosing spondylitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27155445            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Using an in-vitro migration assay, B cells were shown to migrate towards both IL-17A and IL-17F. These observations indicate a direct chemotactic effect of IL-17 cytokines on primary peripheral blood B cells with higher effect being on asthmatic B cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25494178            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17-related cytokines expression was amplified in bronchial\/nasal mucosa of neutrophilic asthma prone to exacerbation, suggesting a pathogenic role of IL-17F in frequent exacerbators.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27931975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A (-197G\/A) and IL-17F (7488T\/C) SNPs were not associated with susceptibility to rheumatoid arthritis or secondary Sjogrens syndrome (sSS, p \u0026gt; 0.05 for both SNPs). In addition, they did not influence RA activity or clinical markers of SS.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26232893            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            It can be stated that the IL17A and IL17F polymorphisms are not markers of susceptibility to psoriasis. However, the IL17F polymorphism may affect the response to NB-UVB therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27591988            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Elevated aAbs against IL-17F correlate with disease activity in patients with early rheumatoid arthritis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26087054            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study provides evidence that polymorphisms of both IL-17A and IL-17F may increase lung cancer risk in Chinese population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26073462            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that Korean patients with psoriasis show a strong association for IL17F single nucleotide polymorphism            \u003ca rel=\"nofollow\"\u003e             PMID:                        27774581            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we analyzed the association of three polymorphism loci (rs2275913, 197 G\/A; rs3748067, 383 A\/G; and rs763780, 7488 T\/C) of IL-17A and IL-17F with laryngeal cancer. Allele and genotype frequencies of IL-17A rs2275913 were significantly different between patients and controls with rs2275913 (197 G\/A) AA and GA+AA genotypes compared to the GG genotype significantly higher in patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28362993            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings identify a novel biological function for IL-17A\/F as an indirect angiogenic agent.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27594509            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17F was correlated with increased autoantibody levels and disease activity in primary Sjogren's syndrome and is more clinically relevant than IL-17A.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28210632            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No relationship between IL17F rs763780 and rs9463772 polymorphisms and Henoch-Schonlein purpura susceptibility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27021337            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphisms in IL-17F A7488G but not IL-17A are associated with the development of chronic immune thrombocytopenia in China.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27312555            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study represents a comprehensive meta-analysis of the role of IL-17A rs2275913 and IL-17F rs763780 polymorphisms in cancer risk and demonstrated that these two polymorphisms significantly increase the risk of development of cancer, particularly gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26843459            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Levels of IL-17FF were significantly higher in rheumatoid arthritis sera and showed a trend of increase in relapsing remitting multiple sclerosis, as compared with normal healthy subjects.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27620302            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Polymorphism of IL-17 rs3748067 and rs763780 is closely associated with gastric cancer development. Polymorphism of L-17 rs2275913 and rs4711998 may be correlated with the risk for gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27097946            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ELISA analysis verified high levels of Th17-associated proinflammatory cytokines such as interleukin-17A\/F, interleukin-6 and interleukin-23 and low levels of inflammatory inhibitory factors including interleukin-10 and transforming growth factor-beta in primary immune thrombocytopenia patients compared with normal controls.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26484642            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The GGAGAA combined genotype and the GGA haplotype of IL-17A rs2275913, IL-17F rs763780 and rs2397084 can be considered risk factors for the development of systemic lupus erythematosus in Egyptian children.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26515887            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            GA genotype of the rs11465553 IL17F gene polymorphism may be associated with a significantly higher risk of graft function loss and return to dialysis after kidney transplantation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26447633            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No associations were found between rs8193036, rs2275913 and rs3748067 in IL-17A and rs763780 in IL-17F SNPs and myasthenia gravis in Chinese patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        26337284            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No evidence of the association was observed between rs3748067, rs3819025, rs763780, rs9382084, and rs1266828 polymorphisms and the risk of cervical cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26505366            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher expression level in chronic lymphocytic leukemia patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        26478573            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In vitro, CSE stimulation significantly increased IL-17F and IL-17R in 16HBE (2.5%) and A549 (5%) while IL-17A and IL-17F in PBMC (10%). IL-17A and CSE stimulation, rather than CSE or rhIL-17A alone, increased proliferation in 16HBE and apoptosis in A549            \u003ca rel=\"nofollow\"\u003e             PMID:                        26198032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A G\/G genotype of rs766748 in IL-17F, and a C\/C or C\/A genotype of rs1883136 in TRAF3IP2.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26558270            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915028660449,"sku":"BL-0308NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWKAb54bAACosHkk6Vo620_603934ca-2d40-4fdb-87a0-d09672c111fc.jpg?v=1685850887"},{"product_id":"recombinant-human-il17a-17f-protein-his-tag-bl-0310np","title":"Recombinant Human IL-17A\u002617F Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-17A\/Interleukin-17F Heterodimer is produced by our Mammalian expression system and the target gene encoding Gly24-Ala155\u0026amp;Arg31-Gln163 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ16552\u0026amp;AAH70124.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL‑17A\/F Heterodimer; IL-17A\u0026amp;IL-17F Heterodimer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe  IL-17 family include  IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F. The family is comprised of at least six proinflammatory cytokines that share a conserved cysteine-knot structure but diverge at the N-terminus. All members of the IL-17 family have a similar protein structure, with four highly conserved cysteine residues critical to their 3-dimensional shape, yet they have no sequence similarity to any other known cytokines.  IL-17 family members are glycoproteins secreted as dimers that induce local cytokine production and recruit granulocytes to sites of inflammation. IL-17 is induced by IL-15 and IL-23, mainly in activated CD4+ T cells distinct from Th1 or Th2 cells. IL-17F is the most homologous to IL-17, but is induced only by IL-23 in activated monocytes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15.1\u0026amp;16 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15-18 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 1mM EDTA, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915031183585,"sku":"BL-0310NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLYmAAvMwAAC2C06a1jM189_5e6f6e29-b831-4778-8451-a4e034526c4e.jpg?v=1685850958"},{"product_id":"recombinant-human-il28b-protein-his-tag-bl-0317np","title":"Recombinant Human IL-28B Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-28B is produced by our Mammalian expression system and the target gene encoding Val22-Val196 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ8IZI9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-28B; IL-28B; Cytokine Zcyto22; Interferon Lambda-3; IFN-Lambda-3; Interferon Lambda-4; IFN-Lambda-4; Interleukin-28C; IL-28C; IL28B; IFNL3; IFNL4; IL28C; ZCYTO22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-28B, also known as Cytokine Zcyto22, Interferon lambda-3, Interferon lambda-4, IFNL3, IFNL4, ZCYTO22 and IL28B, is a secreted cytokine which belongs to the IL-28\/IL-29 family. IL-28 has also been shown to play a role in the adaptive immune response. IL28B has immunomodulatory activity and up-regulates MHC class I antigen expression. IL28B displays potent antiviral activity and antitumor activity. In addition, IL28B is a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand\/receptor complex seems to signal through the Jak-STAT pathway.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e20.67 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e22 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 1mM EDTA, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK\/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLambda interferon family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            18365           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            607402           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:282617           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000409000           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30016335            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            When analyzing the frequency of occurrence of a polymorphic variant T\u0026gt;G [rs8099917] IL-28B gene in children with chronic hepatitis C and healthy children revealed no differences in the distribution of alleles.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30284423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            zinc can act as a potent and specific inhibitor of IFN-lambda3 signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28513591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL28B and MxA gene genotypes were detected among 231 chronic hepatitis C (CHC) carriers, 428 subjects with hepatitis C virus spontaneous clearance and 662 CHC patients with pegylated IFN-alpha and ribavirin (pegIFN-alpha\/RBV) treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29271328            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 (IL28B) and rs1800896, rs1800871, and rs1800872 (IL10) are related to treatment outcome, but previous studies clustered nonresponse and relapse patients.Frequency of rs12979860 and rs8099917 is different between relapsers and nonresponders, but similar between relapsers and responders            \u003ca rel=\"nofollow\"\u003e             PMID:                        29888255            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            only IL28B rs12979860-CT and TT genotypes seem to contribute to the occurrence of chronic HCV infection in the cohort of Uruguayan population studied. Considering that a trend towards a higher frequency of \"good\" response genotypes was observed in responder patients, we believe that IL28B rs12979860 genotyping could be a useful tool for predicting different therapies outcome, including in the DAA era.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29499724            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            our data show a significant association between rs12979860 polymorphism and hematologic response to IFN-alpha in PV and in the combined cohort of PV and ET. These findings imply that inborn variations in the genes involved in inflammation are related to the outcome of IFN-alpha treatment in MPNs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29369421            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The selected donor with a predictable and favourable IL-28B genotype will not confer a benefit on the recipient in the living donor liver transplantation setting.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29686997            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-28B polymorphisms may be useful predictive factors for chronic periodontitis (CP) and correlated to the susceptibility to CP infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28655358            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL28B rs12979860 polymorphism does not influence the susceptibility to HIV-1 and the AIDS development in Moroccan patients, however, this polymorphism may affect the response to HAART treatment as measured by CD4+ T cell counts            \u003ca rel=\"nofollow\"\u003e             PMID:                        29080719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This is the first report on a diagnostic test for simultaneous genotyping of IFNL3, ABCB11, and RNF7 in Chronic hepatitis C (CHC) patients. Reliable and inexpensive, the assay should provide useful information for the clinical management of CHC, like identification of patients at risk of rapid disease progression or with high chances of response to classic therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28860020            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results showed that INF-lambda serum concentration was increased in Alzheimer's disease (AD) and mild cognitive impairment (MCI) carrying the IFNL3 T allele compared to healthy controls (HC). Anti-HSV-1 Ab titers were higher in AD and MCI individuals carrying the IRF7 AA genotype compared to HC. IFNL3 rs12979860 and IRF7 rs6598008 polymorphisms may modulate immune responses against HSV-1 via their effect on the IFN-lam...            \u003ca rel=\"nofollow\"\u003e             PMID:                        28984602            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Regardless of viral genotype we found no association between IL28B genotype and the risk of vertical transmission of HCV. The IL28B genotype CC, which has been shown to be favourable in other settings, was not protective of vertical transmission of HCV.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28820758            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The authors concluded that in the Chinese population, HLA-A*02:01 and DRB1*11:01 might be associated with the host capacity to clear hepatitis C virus independent of IL28B, which suggests that the innate and adaptive immune responses both play an important role in the control of hepatitis C virus.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27511600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In a cohort of patients affected by HCV chronic hepatitis with genotypes 1 and 4, the prevalence of interleukin 28B (IL28B) genotypes, the possible association between IL28B polymorphism and severity of liver damage, the role of IL28B CC as a predictor of outcome were investigated            \u003ca rel=\"nofollow\"\u003e             PMID:                        27271956            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fine-tuned by RETN SNPs, intrahepatic, multi-cellular resistin reinforced IFNL3 in eliminating HCV via immunomodulation to counteract pro-inflammation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27477870            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Investigated the associations of IL-28B rs12979860 and TBX21 rs17250932, rs4794067 polymorphisms with the susceptibility to, and outcomes of, hepatitis C virus (HCV) infection; results showed no significant associations for rs12979860 polymorphisms with HCV clearance and sustained virological response            \u003ca rel=\"nofollow\"\u003e             PMID:                        29399747            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IFNL3 rs4803217 SNP is a strong, independent and superior predictor of sustained virological response and relapse in HCV genotype 1 infected chronic hepatitis C patients treated with pegylated interferon alpha and ribavirin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28638221            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-28B single nucleotide polymorphism rs8099917TT is the most frequent genotype in Cuban chronic hepatitis C patients and is associated with treatment outcome as well.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28058039            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Liver stiffness progression in patients with chronic hepatitis C virus correlated with the IL28B TT\/CC and IL28B GG\/TT genotypes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28579527            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL28B (rs8099917 and rs12979860) and IL10 (rs1800896) polymorphisms alone, or in combination, are good predictors of therapeutic response in hepatitis C virus-3a patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29340806            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In this study, limit of detection (LD), costs and turnaround time of these methods were compared in 350 subjects. As for IL28B rs12979860 polymorphisms, 348\/350 (99.4%) samples were consistent among the five methods, while results for 2\/350 (0.57%) samples were concordant by ZNAs and PCR-sequencing, and discordant by other methods            \u003ca rel=\"nofollow\"\u003e             PMID:                        28281380            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Of the 1084 patients with the IL-28 genotype, 59.4% had hepatitis C virus genotype 1 (HCV-1) infection; 85.6% had the TT genotype. Patients with advanced liver fibrosis had an older age, a lower platelet count, a higher [alpha]-fetoprotein level, a higher alanine aminotransferase level, a higher incidence of diabetes, and a higher frequency of rs8099917 non-TT genotype carriage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29517696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The SNP distribution of gene IL28 with fixed prognostic value in the population of patients with chronic hepatitis C is different from the general population, and shows the need to evaluate polymorphisms prior to treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29264884            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Polymorphisms of IFNL3 rs8099917 and IL12A rs568408 contribute to survival of HD patients, but not as independent factors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28525983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Both hepatitis C virus-specific T cell responses and IL28B rs12979860 single-nucleotide polymorphism genotype influence anti-hepatitis C virus treatment outcome in patients with chronic hepatitis C.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28440692            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IFNL3 SNPs are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28703131            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TLR2 and IL28B polymorphisms in combination showed a role in the control of HCV viral load and different HCV disease progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27183918            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings indicate that serum IFNL3 levels at baseline are higher in acute hepatitis C patients regardless of the rs8099917 polymorphism, and primary hepatitis C virus infection triggers the production of IFNL3.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29040985            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The association between IFNL3\/4 genotypes with elevated HCV VL observed in HCV g6-infected individuals may have implications for the progression of liver disease in Southeast Asian countries where this viral genotype predominates and therefore warrants further studies.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29022122            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In summary, the current study did not find a significant association between IL28B rs12979860 polymorphism and hepatocarcinogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27083168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interferon lambda polymorphisms influence regulatory pathways of cellular response to interferon and affect body iron balance in chronic hepatitis C virus infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27125837            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-28B rs12979860 SNP could be used as an independent predictor for treatment response among HCV patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28502145            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In hemodialysis patients, circulating IFN-lambda3 strongly correlates with anti-HBs antibody production after HBV vaccination and infection. IFNL3 rs8099917 polymorphisms seem to be associated with IFN-lambda3 plasma levels in hemodialysis subjects.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27595449            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results demonstrated genetic variations of IL-28B might impact liver function recovery after transplantation by influencing peripheral platelet counts and reducing liver inflammation, but weak association with transplant etiologies.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29095252            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results obtained suggest that both studied IL28B gene SNPs (single nucleotide polymorphisms), as well as the IL10 gene rs1800872 SNP are associated with predisposition to tick-borne encephalitis in Russian population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27068548            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-28B genotyping may be useful for directing patients towards lower cost therapies, and rationing use of costly direct antivirals for use in those individuals showing genetic risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28877177            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the IFNL3 rs 12979860 CC genotype may be negatively associated with hepatic steatosis in Asian chronic hepatitis C patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28797039            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-28B rs12979860 genotype was significantly related to severe necroinflammatory activity (NIA) grade of chronic hepatitis C patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28704535            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that the genotype distributions of IFNL3 and IFNL4 variants (rs4803217, rs368234815, rs117648444, and rs12979860) were in Hardy-Weinberg equilibrium.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28394349            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In summary, the data suggested that the protective effect attributed to the rs12979860 single nucleotide polymorphism minor T allele could be mediated, at least in part, by eliciting robust cytomegalovirus-specific T-cell responses.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27591738            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data confirm our new IFN-lambda3 binding assay can be used to quantify IFN-lambda receptor surface expression on a variety of cell types and reflects IFN-lambda3 responsiveness.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28274837            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In Taiwan, chronic hepatitis C (CHC) patients have a lower frequency of favorable IL28B TT genotype than healthy controls. Among patients with CHC, the frequency of TT genotype is higher in HCV genotype 2 patients than in HCV genotype 1 patients. In addition, CHC patients with TT genotype, particularly females, have a lower likelihood of advanced fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27751759            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IFNL3 SNPs genotyped have shown no association with ribavirin treatment in hepatitis C patients with genotype 3.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27498543            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            in influenza A\/H3N2 virus infection, IL-28 (rs8099917) genotypes GG and TG were associated with reduced risk of influenza like illness (ILI) symptoms while genotype TT was associated with increased risk of ILI symptom            \u003ca rel=\"nofollow\"\u003e             PMID:                        27155288            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            monocytes from carriers of an IL-28B T\/T genotype display a reduced ability to stimulate NK cell activity            \u003ca rel=\"nofollow\"\u003e             PMID:                        27583440            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            alterations in IL28B SNP genotype may occur after living donor liver transplantation, leading to modifications in the host genome or donor proteome by HCV.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27275739            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results show that detection of SNPs in IL28B combined with increased IP-10 levels increase predictability of sustained virological Response in patients treated with pegylated interferon 2alpha a plus ribavirin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26470765            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In patients infected with HCV-3 [hepatitis-C virus genotype-3], IFNlambda3 [interferon lambda-3] rs12979860, SNP[ single nucleotide polymorphisms ] has less impact on SVR [sustained virologic response ].            \u003ca rel=\"nofollow\"\u003e             PMID:                        27353984            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the association of amino acid substitutions in the HCV core protein and the IFNL3 and IFNL4 polymorphisms with the severity of liver disease, particularly in hepatocellular carcinoma development            \u003ca rel=\"nofollow\"\u003e             PMID:                        27035616            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915102290145,"sku":"BL-0317NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWKABETgAACkDsVO6tc923_a59c8ed4-82eb-4160-8afa-d9afa08b7405.jpg?v=1685853335"},{"product_id":"recombinant-human-il1racp-protein-his-tag-bl-0494np","title":"Recombinant Human IL-1RAcP Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-1 Receptor Accessory Protein is produced by our Mammalian expression system and the target gene encoding Ser21-Glu359 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q9NPH3\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q9NPH3\/entry\"\u003eQ9NPH3\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 Receptor Accessory Protein; IL-1 Receptor Accessory Protein; IL-1RAcP; Interleukin-1 Receptor 3; IL-1R-3; IL-1R3; IL1RAP; C3orf13; IL1R3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 Receptor Accessory Protein (IL-1RAcP) is a member of the interleukin-1 receptor family. It contains three Ig-like C2-type domains in the extracellular region and a long cytoplasmic domain implicated in signal transduction. IL-1RAcP acts as a non-ligand binding accessory component of the receptors for IL1α, IL1βand IL33. IL-1RAcP mediates interleukin-1-dependent activation of NF-kappa-B. It is part of the membrane-bound form of the IL-1 receptor. IL-1 RAcP takes part in the Signaling ways by the formation of a ternary complex containing IL1R1, TOLLIP, MYD88, and IRAK1 or IRAK2. In addition, IL-1RAcP modulates the response to interleukins by associating with soluble IL1R1 and enhancing interleukin-binding to the decoy receptor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e39.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50-80 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915050189025,"sku":"BL-0494NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLSuAXKLaAABzn6WZle0593_6c75681c-806d-499c-a9cc-ee8f0c833eb4.jpg?v=1685851591"},{"product_id":"recombinant-human-il20ra-protein-his-tag-bl-0569np","title":"Recombinant Human IL-20RA Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-20 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Val30-Lys250 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ9UHF4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-20 Receptor Subunit Alpha; IL-20 Receptor Subunit Alpha; IL-20R-Alpha; IL-20RA; Cytokine Receptor Class-II Member 8; Cytokine Receptor Family 2 Member 8; CRF2-8; IL-20R1; ZcytoR7; IL20RA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-20 Receptor Subunit α (IL20RA) is a single-pass type I membrane protein that is a member of the type II cytokine receptor family. IL20RA is synthetized a 553 amino acid glycoprotein precursor containing a 29 amino acid signal peptide, a 221 amino acid extracellular domain with two fibronectin type-III domains, a 24 amino acid transmembrane region, and a 279 amino acid intracellular domain. IL20RA is widely expressed with highest levels found in skin and testis and high levels in brain. IL20RA forms a heterodimer with IL20RB, and the complex serves as a receptor for IL19, IL20 and IL24. IL20RA also forms a heterodimer with the unique and specific receptor IL10RB and functions as the receptor for IL26.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e26.3 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e35-50 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe IL20RA\/IL20RB dimer is a receptor for IL19, IL20 and IL24. The IL20RA\/IL10RB dimer is a receptor for IL26.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType II cytokine receptor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6003           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            605620           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:53832           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000314976           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27799070            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            IL20R1 correlated with prognosis of patients with pancreatic cancer, and mediates pancreatic cancer cell growth and migration. It may be a potential biomarker for IL24 molecular-targeted therapy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26977011            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            crystallographic asymmetric unit contains one IL-20-IL-20R1-IL-20R2 complex, corresponding to a solvent content of approximately 54%            \u003ca rel=\"nofollow\"\u003e             PMID:                        22232181            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-20RA polymorphisms may have a role in psoriasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        19926456            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Complete mda-7\/IL-24 receptors (IL-22R1\/IL-20R2 and IL-20R1\/IL-20R2) are seldom expressed in liver cancer cell lines.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19666410            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            forms stable complex with interleukin-19 and interleukin-20 [IL-20R1][IL-20R2]            \u003ca rel=\"nofollow\"\u003e             PMID:                        14580208            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            sensitivity to recombinant interleukin-26(IL-26) of various cell lines strictly correlated with the expression of IL-20 1 receptor and blocking antibodies against either IL-10 receptor 2 or IL-20 receptor 1 inhibited IL-26-dependent signal transduction            \u003ca rel=\"nofollow\"\u003e             PMID:                        15178681            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The hypotheses that genetic variations of the IL-20-RI influence susceptibility to psoriasis was investigated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18480827            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915106124001,"sku":"BL-0569NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLVKAPHkHAACnHd-CQ2Y314_dce45421-e921-4df2-8cfc-c039524f5d85.jpg?v=1685853478"},{"product_id":"recombinant-human-il6ra-protein-his-tag-bl-0598np","title":"Recombinant Human IL-6RA Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-6 Receptor Subunit Alpha is produced by our Mammalian expression system and the target gene encoding Leu20-Asp358 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP08887\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-6 receptor subunit alpha; IL-6R subunit alpha; IL-6R-alpha; IL-6R 1; Membrane glycoprotein 80; gp80; CD126\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. IL6Ra is a part of the receptor for interleukin 6 cytokine. IL6Ra binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitates an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis. Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e38.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e60-75 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePart of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation leads to the regulation of the immune response, acute-phase reactions and hematopoiesis. The interaction with membrane-bound IL6R and IL6ST stimulates 'classic signaling', the restricted expression of the IL6R limits classic IL6 signaling to only a few tissues such as the liver and some cells of the immune system. Whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).; Signaling via the membrane-bound IL6R is mostly regenerative and anti-inflammatory (Probable). Drives naive CD4(+) T cells to the Th17 lineage, through 'cluster signaling' by dendritic cells.; Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity. The IL6:sIL6R complex (hyper-IL6) binds to IL6ST\/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the proinflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases. In complex with IL6, is required for induction of VEGF production. Plays a protective role during liver injury, being required for maintenance of tissue regeneration. 'Trans-signaling' in central nervous system regulates energy and glucose homeostasis.; Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity. The IL6:sIL6R complex (hyper-IL6) binds to IL6ST\/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the proinflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases. In complex with IL6, is required for induction of VEGF production. Plays a protective role during liver injury, being required for maintenance of tissue regeneration. 'Trans-signaling' in central nervous system regulates energy and glucose homeostasis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.; [Soluble interleukin-6 receptor subunit alpha]: Secreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 3 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6019           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            147880           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3570           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000357470           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27958380            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            a significant negative correlation of meprin beta expression and IL-6R levels on human granulocytes, providing evidence for in vivo function of this proteolytic interaction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28276471            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-6\/soluble IL-6R differentially regulate RANKL-induced osteoclast differentiation and activity through modulation of NF-kappaB, ERK and JNK signaling pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28128332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Gene IL6R polymorphic variant rs2228145(C\u0026gt;A) seems to be involved in genetic predisposition of the population of Karelia to nonalcoholic steatohepatitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29797122            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-6R was shown to be an independent prognostic factor for patients with cervical cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28741286            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Frequency of IL-6R TT (rs4129267) genotype was increased in Ankylosing Spondylitis patients.  Interleukin IL-6R (rs4129267) gene polymorphisms could serve as promising biomarkers for diagnosis and prognosis in Ankylosing Spondylitis patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29200018            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In a genome-wide meta-analysis of 20,550 patients with Crohn's disease (CD), 17,647 patients with ulcerative colitis (UC), and more than 40,000 individuals without IBD (controls), study found that rs2228145 (scaled to a 2-fold increase in s-IL6R) was associated with reduced risk of CD or UC.[meta-analysis]            \u003ca rel=\"nofollow\"\u003e             PMID:                        29775600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Analysis of the IL-6 (-572G\/C) polymorphism revealed a higher level of the GG genotype in the patients with Celiac Disease compared with the control group.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28928101            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-124, IL-6R and STAT3 are involved in the process of sulforaphane-improved CDDP chemotherapy efficacy by targeting cancer stem cell-like properties            \u003ca rel=\"nofollow\"\u003e             PMID:                        27824145            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High IL6-R expression is associated with cisplatin resistance in epithelial ovarian cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28388577            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            sIL-6R may be a useful biomarker to assess insulin resistance among morbidly obese subjects            \u003ca rel=\"nofollow\"\u003e             PMID:                        28346858            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study identified variants associated with the age of onset of Alzheimer's disease in APOE varepsilon4 carriers. Across five datasets, p.D358A had a meta P = 3 x10-4 and an odds ratio = 1.3, 95% confidence interval 1.12 -1.48. Study suggests that a common coding region variant of the IL-6 receptor results in neuroinflammatory changes that may influence the age of onset of Alzheimer's disease in APOE varepsilon4 carriers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28106546            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-6R protein expression on plasma membrane of ovarian cancer cells mediates enhanced cell migration\/invasiveness in response to IL6 in ascites.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27825119            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL6R protein levels were higher in bone than in lymph node and visceral metastases of castration-resistant prostate cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27344294            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-6R CC genotype was associated with a three times greater concussion risk and APOE4 with a 40% lower risk in college athletes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28918391            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the present study, the authors show that deletion of a triple serine (3S) motif (Ser-359 to Ser-361) adjacent to the cleavage site is sufficient to prevent IL-6R cleavage by ADAM17, but not ADAM10. We find that the impaired shedding is caused by the reduced distance between the cleavage site and the plasma membrane.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27151651            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL6R SNPs are associated with simultaneously high CRP, LDL and ApoB levels.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28769070            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CLL cells with higher CD126 expression are more resistant to treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26712690            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The mRNA expression of IL6R was inversely correlated with miR-449a in osteosarcoma tissues. In addition, JAK1\/STAT3 signaling pathway was regulated by circ_0009910\/miR-449a\/IL6R axis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29117539            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-6 receptor blockade has an effect on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27744141            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Enterovirus 71 antagonizes the antiviral activity of host STAT3 and IL-6R with partial dependence on virus-induced miR-124.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29120300            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we present evidence for the role of M2 phenotype TAM in IL-6 receptor-mediated signals, particularly tyrosine phosphorylation of STAT3, responsible for the prosurvival adaptation of tumor cells to hypoxia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26705936            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            3 SNPs (rs4329505 and rs4845626 in interleukin 6 receptor [IL6R] and rs1422794 in a disintegrin and metalloproteinase domain 19 [ADAM19]) were associated with a lower risk of suffering the most severe stages of the disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27078193            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of STOML2, a gene that plays a key role in mitochondrial function and T-cell activation, is associated with both IL-6 signaling and asthma risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26932604            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL6R is downregulated in the tissues from colonic biopsies taken from Ulcerative Colitis patients.Thus, expression levels of IL6R can be used as markers of disease or disease progression in Ulcerative Colitis patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28774868            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expanded CD8(+)IL-6Ralpha(low) EM T cells have roles in coronary artery disease through their pro-inflammatory and highly cytotoxic capacities            \u003ca rel=\"nofollow\"\u003e             PMID:                        27062409            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Both gingival crevicular fluid sIL-6R and calprotectin concentrations are significant biomarkers in the evaluation of periodontal inflammation            \u003ca rel=\"nofollow\"\u003e             PMID:                        27810997            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results argued that increased expression of sIL6R from myeloid cells and subsequent c-Maf induction were adverse events for counteracting tumor-specific Th1 generation. Overall, this work provides a mechanistic rationale for sIL6R targeting to improve the efficacy of T-cell-mediated cancer immunotherapy            \u003ca rel=\"nofollow\"\u003e             PMID:                        28235765            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results demonstrate a novel physiologic role for a disintegrin and metalloprotease 17 in regulating murine IL-6 signals during inflammatory processes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26561568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study show that soluble IL-6R is infiltrating from the circulation in an ADAM17-independent process and is involved in the controlled resolution of an acute inflammatory episode            \u003ca rel=\"nofollow\"\u003e             PMID:                        27698010            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the sIL-6R\/p28 fusion protein (FP) upregulated IFN-lambda1 expression by increasing the binding abilities of c-Fos and activating transcription factor 1 to the IFN-lambda1 promoter via the p38 MAPK signaling pathway; results demonstrate the important role of sIL-6R\/p28 FP in mediating virus-induced type III IFN production            \u003ca rel=\"nofollow\"\u003e             PMID:                        27527594            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Soluble IL-6R levels appeared to be significantly higher irrespective of disease activity in patients with large-vessel vasculitis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28466804            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            glycosylation is an important regulator for soluble IL-6R generation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28060820            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-6R rs2228145 genotype was associated with decreased risk of gastric cancer for the individuals with negative and positive Helicobacter pylori infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28442395            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The here presented data demonstrate that miR-451 may function as a potential suppressor of tumor growth, migration and angiogenesis in osteosarcoma via down-regulating IL 6R.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27908732            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            DNA hypomethylation of IL-6 gene measured in blood leukocytes was associated with increased risk of ischemic heart disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26981890            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            minor allele, with the difference eliminated upon addition of tocilizumab. In conclusion, there is evidence that neutrophils may be an important source of sIL-6R in the lungs, and the Asp358Ala variant may have pro-inflammatory effects in lung cells.d However, we were unable to identify evidence for aisease            \u003ca rel=\"nofollow\"\u003e             PMID:                        28334838            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            MiR-451 may function as a potential suppressor of tumor angiogenesis in HCC by targeting IL-6R-STAT3-VEGF signaling, suggesting.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27461244            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            high levels of IL-6R expression in spindle-shaped stromal cells, not associated with the vasculature, could be used to identify early breast cancer patients with poor outcomes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27460086            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No significant association between IL6R rs2228145 and dementia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26725994            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Rs4845617 of the IL-6R gene is associated with the neurologic status of Korean patients with ischemic stroke.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26955245            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest domains D1-D3, which contain cytokine binding module, determine which cytokine can activate interleukin-6 or interleukin-11 alpha-receptor subunits; stalk, transmembrane, or intracellular regions do not participate in ligand selectivity.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26551279            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Anti-IL-6R antibody prevented the early loss of intrahepatic islet grafts mediated by HMGB1-induced immune activation after islet transplantation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25058889            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While prior studies have found an association between PDE4D and IL6R polymorphisms and ischemic stroke, the results of this study suggest that this association may be different in a hypertensive population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26782593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Authors identified miR-125a as a direct regulator of IL-6R, and the genotype of rs12976445 might be a novel predictor of the development of DN in DM.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26563755            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results provide evidence that two IL6R gene polymorphisms rs2228145 C and rs12083537 G are associated with poor lung function in patients with asthma. Furthermore, the rs2228145 A-C variant is associated with levels of sIL-6R and IgE.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26997259            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR-125a-5p directly targets IL-6R and STAT3 expression in HEK-293T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26424054            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High serum IL-6R levels were associated with Chronic Spontaneous Urticaria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26699882            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings identify TRAF3 and PTPN22 as inhibitors of IL-6R signaling in B cells and reveal a previously uncharacterized role for TRAF3 in the regulation of plasma cell differentiation            \u003ca rel=\"nofollow\"\u003e             PMID:                        26329582            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin-6 is strongly affected by factors associated with obesity accounting for its lability and responsiveness to diet, life style and contemporaneous events.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26086344            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915020697825,"sku":"BL-0598NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLVaAdnDEAACsZta5cSs658_685a5cae-d3b8-4afd-bef5-da125a90f1c6.jpg?v=1685850705"},{"product_id":"recombinant-human-il17a-protein-his-tag-bl-0607np","title":"Recombinant Human IL-17A Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-17A is produced by our Mammalian expression system and the target gene encoding Gly24-Ala155 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQ16552\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17A; IL-17; IL-17A; Cytotoxic T-Lymphocyte-Associated Antigen 8; CTLA-8; IL17A; CTLA8; IL17\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15-22 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.001 ng\/µg (0.01 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEffector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. In airway epithelium, mediates neutrophil chemotaxis via induction of CXCL1 and CXCL5 chemokines. In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells. Effector cytokine of a subset of gamma-delta T cells that functions as part of an inflammatory circuit downstream IL1B, TLR2 and IL23A-IL12B to promote neutrophil recruitment for efficient bacterial clearance. Effector cytokine of innate immune cells including invariant natural killer cell (iNKT) and group 3 innate lymphoid cells that mediate initial neutrophilic inflammation. Involved in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection. Upon acute injury, has a direct role in epithelial barrier formation by regulating OCLN localization and tight junction biogenesis. As part of the mucosal immune response induced by commensal bacteria, enhances host's ability to resist pathogenic bacterial and fungal infections by promoting neutrophil recruitment and antimicrobial peptides release. In synergy with IL17F, mediates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers. Involved in antiviral host defense through various mechanisms. Enhances immunity against West Nile virus by promoting T cell cytotoxicity. May play a beneficial role in influenza A virus (H5N1) infection by enhancing B cell recruitment and immune response in the lung. Contributes to influenza A virus (H1N1) clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-17 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            5981           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            603149           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3605           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000344192           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30223275            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            The pooled estimate revealed an association between IL-17A rs2275913 polymorphism and the risk of gastric cancer (GC) under all genetic models (A vs. G, OR 1.187, 95% CI 1.086-1.297, P \u0026lt; 0.001; GA vs. GG, OR 1.108, 95% CI 1.008-1.218, P = 0.033; AA vs. GG, OR 1.484, 95% CI 1.236-1.781, P \u0026lt; 0.001), while no evidence of association was found with IL-17A rs3748067 or IL-17F rs763780 polymorphisms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29860554            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Over-expression of IL-17 and IL-27 are involved in the pathogenesis of liver damage in children with human cytomegalovrius infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30022757            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL23 and IL17 have roles in the pathogenesis of Tunisian pemphigus foliaceus            \u003ca rel=\"nofollow\"\u003e             PMID:                        30116153            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            our findings supported the association between IL-17 SNPs and the risk of asthma in Chinese Han population from central China. GA genotype of rs3748067 and the C carries (CT+CC) of rs763780 were associated with a higher risk of asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        30036556            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL17A and HPSE may promote tumor angiogenesis and cell proliferation and invasion in cervical cancer, possibly via the NF-kappaB signaling pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30066843            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results suggest that IL17A (rs2275913) polymorphism is associated with the development of rheumatic heart disease in South Indian population            \u003ca rel=\"nofollow\"\u003e             PMID:                        29985710            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study demonstrated the alteration of IL-17 levels in aseptic non-vasculitic cerebral sinovenous thrombosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        30246697            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In this Brazilian population, TNF and IL17 gene polymorphisms responsible for the expression of important inflammatory cytokines were associated with overall spondyloarthritis and, specifically, with ankylosing spondylitis and psoriatic arthritis, regardless of gender and HLA-B27            \u003ca rel=\"nofollow\"\u003e             PMID:                        29849482            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The single nucleotide polymorphism rs2275913 in the IL-17A gene is associated with susceptibility to viral myocarditis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29530464            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A197AA polymorphism is associated with the risk of colorectal cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29970680            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            our findings demonstrated that the AA genotype from the IL-17A rs2275913 SNP is positively associated with protection to active tuberculosis but related to higher disease severity in the Argentinean population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28098168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results from experiments suggest that the effects of IL-17 mediate activation of STAT3 signaling in breast cancer cells. Taken together, our study shows that myeloid-derived suppressor cells can be a new type of prognostic marker in breast cancer patients. Targeting IL-17\/Stat3 signaling may be a promising strategy for BC treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29655056            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study draws two main conclusions: 1) The presence of IL-17 polymorphism rs2275913 is closely related to a more severe form of the disease and as a result, a higher number of disease-modifying anti rheumatic drugs required to control it, 2) The presence of IL-17 polymorphism rs2275913 may confer a risk of developing rheumatoid arthritis in Mexican carriers            \u003ca rel=\"nofollow\"\u003e             PMID:                        28379210            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Polymorphisms of IL-17 are associated with host susceptibility to some bacterial pathogen. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        29345518            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            secreted IL-17A is not responsible for the second hit in acute pancreatitis            \u003ca rel=\"nofollow\"\u003e             PMID:                        29422392            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In carriage, an increased IL-17 and IFN-gamma levels were observed following stimulation with S. aureus strains.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29311230            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL17A G197A is associated with a higher susceptibility of developing OLP and these patients seem to present a considerable increase in IL17A serum levels.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28741807            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These findings highlight a regulatory pathway of Tiam1\/Rac1 in Th17 cells and suggest that it may be a therapeutic target in multiple sclerosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27725632            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin 17A (IL-17[G197G]) was associated with preterm birth (PTB), and the PTB group had lower IL-17A expression compared to the full-term group .            \u003ca rel=\"nofollow\"\u003e             PMID:                        29431293            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In studies of mouse and human pancreatic tumors and precursors, we found that immune cell-derived IL17 regulated development of tuft cells and stem cell features of pancreatic cancer cells via increased expression of DCLK1, POU2F3, ALDH1A1, and IL17RC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29604293            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of miR-135a in the cancer cells isolated from nasopharyngeal tumors was significantly lower than that in NP69 cells, and suppression of IL-17 by miR-135a mimic resulted in significant inhibition of NPC cell proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29734196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of IL-17 and IL-12 in patients with lupus miliaris disseminatus faciei is reported in patients and healthy controls.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27515793            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that the variants +2199 A\/C IL-23R and -197 G\/A IL-17A could contribute to rheumatoid arthritis development in the studied population            \u003ca rel=\"nofollow\"\u003e             PMID:                        28547498            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A rs2275913 polymorphism did not seem to influence RA susceptibility in Tunisian population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29584788            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that IL-17A stimulated keratinocytes activated PI3K\/AKT\/mTOR signaling and inhibited autophagy by simultaneously inhibiting autophagosome formation and enhancing autophagic flux.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29432814            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In the present review, we have discussed the cellular sources, modes of action and regulation of IL-17 and IL-33 in the context of hypersensitive diseases [Review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        29153708            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Findings identify interleukin-17A as a potential mediator of neuroanatomical remodeling of the gut innervation during inflammatory bowel diseases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28560787            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review discusses recent discoveries related to the pro-inflammatory cytokine IL17A, and its potential role in the pathogenesis of COPD. We propose that an intervention strategy targeting IL-17 signaling offers an exciting opportunity to mitigate inflammatory processes, and prevent the progression of tissue pathologies associated with COPD [Review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        28438639            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            rs2275913 gene polymorphism associated with a risk of Bacillus-Calmette-Guerin osteitis after vaccination            \u003ca rel=\"nofollow\"\u003e             PMID:                        28731539            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows that higher baseline levels of Interleukin 17 are selectively associated with greater symptomatic reduction in depressed patients treated with bupropion-SSRI combination.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28698115            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-23\/IL-17 axis and biochemical markers in the pathogenesis of Type 2 Diabetes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28757426            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher levels of TGF-beta mRNA were observed in biopsies taken from healthy controls, and the IL-23 mRNA levels were significantly increased in the peri-implantitis group (P \u0026lt; 0.0001). No differences in IL-17 mRNA levels were observed between the two groups (P \u0026gt; 0.05).            \u003ca rel=\"nofollow\"\u003e             PMID:                        27062688            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied interleukin-17 (IL-17) expression levels in blood and skin of atopic dermatitis (AD) patients and controls.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28279075            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            semen IL-17 and IL-18 levels in diabetes mellitus males were significantly higher than those in normal males and were positively correlated with blood glucose level and sperm DNA fragmentation index            \u003ca rel=\"nofollow\"\u003e             PMID:                        28858634            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            clinical significance of IL-17 and IL-23 in the pathogenesis of different types of gastric neoplasms in humans, is reported.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27869179            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The IL-17A (-832A\/G) polymorphism was not associated with accelerated silicosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28481151            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-17A was significantly upregulated in patients with the uncontrolled and refractory status. Therefore, IL-17A may play important roles in asthmatic exacerbation, and its high level, in combination with upregulated Th2 and other cytokines, may indicate the refractory endotype of asthma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28840844            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that IL17A participates in the immune response of the human host against M. tuberculosis through the activation of the autophagy process in correlation with the severity of the disease            \u003ca rel=\"nofollow\"\u003e             PMID:                        28581888            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            developed ultrasensitive methods for measuring IL-17A and IL-17F in human serum samples and found that serum from psoriasis patients had higher and a broader range of concentrations of both IL-17 proteins compared to healthy volunteers            \u003ca rel=\"nofollow\"\u003e             PMID:                        28534291            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            SNPs of rs3819024 in IL-17A and rs763780 in IL-17F were weakly related to a prognosis of tuberculosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27339100            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that aberrant NKG2D expression with IL-17 production of CD4+ T subsets in patients with type 2 diabetes            \u003ca rel=\"nofollow\"\u003e             PMID:                        27168217            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Luciferase assay using the 5'-UTR of the IL-17 F gene revealed transcriptional regulation. Induced IL-17 F production was further confirmed at the protein level by ELISA. Smad1\/5\/8 inhibitor pretreatment decreased IL-17 F expression levels in the cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28812969            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows increased IL-17A expression in early tendinopathy and proposes IL-17A as an inflammatory regulator in tendon remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27263531            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Several studies identified IL-17A as a pro-inflammatory player in atherosclerosis while its expression was associated with increased inflammation and plaque vulnerability in human atherosclerotic lesions. Moreover, IL-17A induced a pro-inflammatory, pro-thrombotic, plaque-destabilizing, and cell-attracting response of the inflammatory milieu of human plaque tissue samples. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        28034277            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            asymmetric cell divisions in psoriasis are IL17A-dependent.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28600817            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum IL-23 and IL-17 levels were elevated in patients with aneurysmal subarachnoid hemorrhage (aSAH) showing upregulation of IL-23\/IL-17 inflammatory axis after aSAH. Serum IL-23 and IL-17 showed differential correlations with post hemorrhagic complications and no correlation with clinical outcome.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28609751            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data showed that IL-17A levels were sustained in respiratory samples from cystic fibrosis patients infected by P. aeruginosa. IL-17 mediated-immunity plays a double-edged found during chronic airways infection: in one hand, it contributes to the control of P. aeruginosa burden, modulating host resistance, while, on the other, it alters host tolerance, propagating exacerbated pulmonary neutrophilia and tissue remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27189736            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            gamma delta T cells, rather than Th17cells, are the principal producers of IL-17 in acute gouty arthritis patients during the acute gout flares.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29476737            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            high expression of both IL17A and IL32 leads to enhancement of T cell responses in breast tumors            \u003ca rel=\"nofollow\"\u003e             PMID:                        28470472            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915015782625,"sku":"BL-0607NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLVmAS_HHAACLltGTQ08215_1a00a805-92ef-487f-91ee-a52768a110cd.jpg?v=1685850582"},{"product_id":"recombinant-human-il1racp-protein-his-fc-tag-bl-0708np","title":"Recombinant Human IL-1RAcP Protein (Q9NPH3-2, C-Fc-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-1 Receptor Accessory Protein is produced by our Mammalian expression system and the target gene encoding Ser21-Gln356 is expressed with a human IgG1 Fc, 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q9NPH3-2\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q9NPH3\/entry#Q9NPH3-2\"\u003eQ9NPH3-2\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 Receptor Accessory Protein; IL-1 Receptor Accessory Protein; IL-1RAcP; Interleukin-1 Receptor 3; IL-1R-3; IL-1R3; IL1RAP; C3orf13; IL1R3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-1 Receptor Accessory Protein (IL-1RAcP) is a member of the interleukin-1 receptor family. It contains three Ig-like C2-type domains in the extracellular region and a long cytoplasmic domain implicated in signal transduction. IL-1RAcP acts as a non-ligand binding accessory component of the receptors for IL1α, IL1βand IL33. IL-1RAcP mediates interleukin-1-dependent activation of NF-kappa-B. It is part of the membrane-bound form of the IL-1 receptor. IL-1 RAcP takes part in the Signaling ways by the formation of a ternary complex containing IL1R1, TOLLIP, MYD88, and IRAK1 or IRAK2. In addition, IL-1RAcP modulates the response to interleukins by associating with soluble IL1R1 and enhancing interleukin-binding to the decoy receptor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e66.7 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e80-100 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915105861857,"sku":"BL-0708NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWaAZgt8AACTjymqQjU308_c7bf91dd-3616-4525-8d6b-f6cf63230acf.jpg?v=1685853470"},{"product_id":"recombinant-human-il2rg-protein-his-tag-bl-0725np","title":"Recombinant Human IL-2RG Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Cytokine Receptor Common Subunit Gamma is produced by our Mammalian expression system and the target gene encoding Leu23-Ala262 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP31785\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCytokine receptor common subunit gamma; Interleukin-2 receptor subunit gamma; gammaC; P64; CD132 and IL2RG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL2RG contains one fibronectin type-III domain. IL2RG is an important signaling component of many interleukin receptors, including those of interleukin -2, -4, -7 and -21, and is thus referred to as the common gamma chain. IL2RG interacts with SHB upon interleukin stimulation and HTLV-1 accessory protein p12I. Defects in IL2RG are the cause of X-linked combined immunodeficiency (XCID) and severe combined immunodeficiency X-linked T-cell-negative \/B-cell-positive \/ NK-cell-negative (XSCID).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e29.3 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45-85 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCommon subunit for the receptors for a variety of interleukins. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein. Cell surface.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 5 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            6010           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            300400           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:3561           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000363318           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29388853            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            New insights of common gamma chain in hematological malignancies.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26748725            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that downregulation of miR-3940-5p promotes T-cell activity by targeting the cytokine receptor IL-2R gamma on human cutaneous T-cell lines            \u003ca rel=\"nofollow\"\u003e             PMID:                        27502164            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            systematic scoping review highlights the many potential uses of soluble interleukin-2 receptor measurement in the diagnosis and treatment of hemophagocytic syndromes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28497365            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype            \u003ca rel=\"nofollow\"\u003e             PMID:                        27566612            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            novel missense mutation in Japanese patient results in atypical X-linked severe combined immunodeficiency with the presence of T cells and NK cells and revertant somatic mosaicism            \u003ca rel=\"nofollow\"\u003e             PMID:                        26407811            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            reversion of mutation in common lymphoid progenitor results in mild phenotype of SCID            \u003ca rel=\"nofollow\"\u003e             PMID:                        26076747            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High IL2RG expression is associated with Sezary syndrome.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26551670            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Identification of a gammaC splice isoform revealed expression of soluble gammaC proteins (sgammaC). sgammaC directly interacted with surface IL-2Rbeta to suppress IL-2 signaling and to promote pro-inflammatory Th17 cell differentiation. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26468051            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study show the detection of IL2RG mutations in 2 families with X-SCID and identified 2 novel mutations, confirming the X-SCID pedigrees.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26125817            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interleukin 2 receptor subunit gamma mutation is associated with X-linked severe combined immunodeficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26409833            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26183780            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results demonstrate that IL2Rgamma has an onogenic role in JAK3-mutation-positive leukemias.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25109334            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that over-expression of the IL2RG gene may be implicated in altered immune response in schizophrenia and contribute to the pathomechanisms of this disorder            \u003ca rel=\"nofollow\"\u003e             PMID:                        24713359            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this is the first report on a de novo mutation in the IL2RG gene in a patient born after IVF            \u003ca rel=\"nofollow\"\u003e             PMID:                        23790094            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In a patient with a novel IL2RG mutation, gene-reverted CD8+ T cells accumulate over time.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23403317            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            in humans, signaling through the gammac pathway is not required for prethymic lymphoid commitment or for DNA rearrangement.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24771849            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we presented here a novel IL-2Rgammac mutation in a carrier and SCID patient presenting NK cells in the peripheral blood            \u003ca rel=\"nofollow\"\u003e             PMID:                        23940110            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Massively parallel sequencing reveals maternal somatic IL2RG mosaicism in an X-linked severe combined immunodeficiency family.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23683512            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Tax-specific cytotoxic T-lymphocyte cell treatment significantly decreases human soluble IL-2Rgamma serum concentrations and prolongation of survival time in a mouse model of adult T cell leukemia\/lymphoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23733874            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of multiorgan metastasis of human HER-2+ breast cancer in Rag2-\/-;Il2rg-\/- mice and treatment with PI3K inhibitor            \u003ca rel=\"nofollow\"\u003e             PMID:                        22737248            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data highlight the central role of IL-15 and gammac-receptor signaling in renal homeostasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22363690            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the amount of the gamma-chain transducing element is able to influence the transcription of genes involved in cell cycle progression, thus being directly involved in the regulatory control of cell proliferation of malignant hematopoietic cell            \u003ca rel=\"nofollow\"\u003e             PMID:                        22223761            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data imply that IL-21-mediated signaling is critical for long-lived humoral immunity and to restore antibody responses in IL2RG\/JAK3-deficient patients after hematopoietic cell transplantation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22039266            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We report a novel X-CID family with a unique mutation in the extracellular part of CD132 with almost normal T-cell counts but defective memory induction            \u003ca rel=\"nofollow\"\u003e             PMID:                        21831415            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21715655            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            IL-2Rgamma(c) reconstituted T cells may persist more efficiently than natural killer (NK) cells due to compensation for suboptimal IL-2Rgamma(c) signaling by T cell receptors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20592278            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival and is regulated by theaflavins            \u003ca rel=\"nofollow\"\u003e             PMID:                        19812686            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma sIL-7Ralpha and sgamma(c) are present as heterocomplexes and sgamma(c) was found to be mainly associated with sIL-7Ralpha            \u003ca rel=\"nofollow\"\u003e             PMID:                        19494261            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            presence of membrane-associated as well as soluble gamma c in cell lysates and cell free supernatants from peripheral blood lymphocyte cultures; panel of human serum samples was examined and compared with sIL-2R            \u003ca rel=\"nofollow\"\u003e             PMID:                        12036606            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In normal lung fibroblasts IL-4 \u0026amp; IL-13 induce gamma c chain \u0026amp; its association with JAK3. In myofibroblasts, constitutive gamma c chain together with JAK3 controls TYK2 phosphorylation \u0026amp; the balance between functional \u0026amp; decoy high-affinity receptors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12207328            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Human IL-21 and IL-4 bind to partially overlapping epitopes of common gamma-chain.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12504082            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The development of breast tumour is associated with an increased expression of IL-2 receptor gamma and this expression also seems to be associated with the malignancy of the tumour.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14680494            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A mutation in this locus resulting in severe combined immunodeficiency, initially diagnosed as HIV infection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15702055            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The common cytokine receptor gamma-chain is a required signaling subunit of the growth hormone receptor (GHR) complex in B cell lines. Genetic alteration of the IL2RG gene results in growth failure in X-linked severe combined immunodeficiency (X-SCID).            \u003ca rel=\"nofollow\"\u003e             PMID:                        17082603            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results confirm that signal transduction via the IL-15R, and hence NK ontogeny, is preferentially retained relative to the IL-7R as gammac expression becomes limiting.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17363735            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Review describes current state of knowledge of how the gamma c cytokine network is affected during HIV infection, with a focus on how this impairs CD4+ and CD8+ T cell function while also benefiting the virus itself.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18417356            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Report the selective expansion of genetically modified T cells using an antibody\/IL2RG receptor chimera.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18589435            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This suggests a role for gamma(C) cytokines in the pathogenesis of diseases in which CD127 expression is altered on CD8+ T cells such as in progressive viral infections and cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19011158            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Self-sufficient growth of B lymphoblastoid cells in X-linked combined immunodeficiency disease (SCID) cell lines is strongly dependent on common gamma-chain expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19234229            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the loss of NEDD4 association on IL-2Rgamma(c) is accompanied by a dramatic increase of the half-life of the receptor subunit.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19615332            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Transgenic Jak3-dependent common gamma c cytokine signals are not required for naive primary CD4-positive T cell proliferation and cell cycle regulation in vitro.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19734221            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Meta-analysis and HuGE review of genotype prevalence, gene-disease association, genetic testing, and healthcare-related. (HuGE Navigator)            \u003ca rel=\"nofollow\"\u003e             PMID:                        14726805            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The immature form of the gamma(c) chain is a 54-58 kDa intracellular component localized in the endoplasmic reticulum of resting, unstimulated CD4 T cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        11418669            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915024924897,"sku":"BL-0725NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWqAMn1yAACmma2wZmk106_bd4554a6-549e-4e67-8e4f-9d8f332bd63e.jpg?v=1685850814"},{"product_id":"recombinant-human-il18racp-protein-his-tag-bl-0728np","title":"Recombinant Human IL-18RAcP Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-18 Receptor Accessory Protein is produced by our Mammalian expression system and the target gene encoding Phe20-Arg356 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"O95256\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/O95256\/entry\"\u003eO95256\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-18 receptor accessory protein (IL18RAP); Accessory protein-like; CD218 antigen-like family member B; CDw218b; IL-1R accessory protein-like; Interleukin-1 receptor 7; Interleukin-18 receptor accessory protein-like; Interleukin-18 receptor beta£¨CD218b and IL1R7.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL-18RAP is a single-pass type I membrane protein and contains two Ig-like C2-type domains and one TIR domain, IL18RAP can be induced by IFN-alpha and IL12 in nature killer cells and T-cells. The coexpression of IL18R1 and IL18RAP is required for the activation of NF-kappa B and JNK in response to IL-18.Defects in IL18RAP are associated with Coeliac disease.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e39.4 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e56 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915071095009,"sku":"BL-0728NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWqAU3RJAACYU64d8no968_02c6fcdb-83b1-4a08-8863-57c518a87794.jpg?v=1685852198"},{"product_id":"recombinant-human-il10rb-protein-his-tag-bl-0735np","title":"Recombinant Human IL-10RB Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-10 Receptor Subunit Beta is produced by our Mammalian expression system and the target gene encoding Met20-Ser220 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q08334\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q08334\/entry\"\u003eQ08334\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-10 receptor subunit beta(IL10RB);Cytokine receptor class-II member 4;Cytokine receptor family 2 member 4;Interleukin-10 receptor subunit 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIL10RB is a single- pass type I membrane protein and contains two fibronectin type-III domains. It is an accessory chain which is essential for the active interleukin 10 receptor complex. Coexpression of IL10RB and IL10RA proteins has been shown to be required for IL10-induced signal transduction. Defects in IL10RB are the cause of inflammatory bowel disease type 25 (IBD25) which is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e24.5 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e48 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915104977121,"sku":"BL-0735NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWyAMsKmAACQzu3gy8Q202_26767d73-cde7-46d5-9aaa-fcfbdd912f9d.jpg?v=1685853436"},{"product_id":"recombinant-mouse-il17f-protein-his-tag-bl-0736np","title":"Recombinant Mouse IL-17F Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Interleukin-17F is produced by our Mammalian expression system and the target gene encoding Arg29-Ala161 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q7TNI7\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q7TNI7\/entry\"\u003eQ7TNI7\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17F; IL-17F; Cytokine ML-1; IL17F\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-17F (IL-17F) exists in a disulfide-linked heterodimer that belongs to the IL-17 family. IL-17F is expressed in activated, but not resting, CD4+ T-cells and activated monocytes. Mouse and human IL-17F share 55% sequence identity.IL-17F has been shown to stimulate the production of several other cytokines, including IL-6, IL-8, and granulocyte colony-stimulating factor. IL-17F can regulate cartilage matrix turnover and stimulates PBMC and T-cell proliferation. IL-17F is also found to inhibit the angiogenesis of endothelial cells and induce endothelial cells to produce IL2, TGFB1\/TGFB, and monocyte chemoattractant protein-1. Defects in IL-17F are the cause of familial candidiasis type 6 (CANDF6).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e15.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e17-23 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915043766497,"sku":"BL-0736NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLWyAO3B0AACmpLZnm3o912_1c2bb2f1-4e2d-475a-b823-9e19143b1ab2.jpg?v=1685851341"},{"product_id":"recombinant-human-il21r-protein-his-tag-bl-0766np","title":"Recombinant Human IL-21R Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Interleukin-21 Receptor is produced by our Mammalian expression system and the target gene encoding Cys20-Pro236 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q9HBE5\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q9HBE5\/entry\"\u003eQ9HBE5\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-21 receptor; IL-21 receptor; IL-21R; CD360\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eInterleukin-21 receptor is also known as IL-21 receptor, IL-21R, CD360. In humans, it is encoded by the IL21R gene. It belongs to the type I cytokine receptor family. Type 4 subfamily contains 2 fibronectin type-III domains. Interleukin-21 receptor is selectively expressed in lymphoid tissues and highly expressed in thymus and spleen. IL-21 is produced by CD4+ T cells in response to antigenic stimulation. Its action enhances antigen-specific responses of immune cells. The biological effects of IL-21 include induction of differentiation of T-cells-stimulated B-cells into plasma cells and memory B-cells. It also promotes the anti-tumor activity of CD8+ T-cells and NK cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e26 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e40-55 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915035672801,"sku":"BL-0766NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLXCAOJ27AACVNJwv588278_40ec4a08-c3fd-4b47-a118-b1cf1ba69665.jpg?v=1685851097"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/collections\/240_F_205135987_yHQEPIYCOeuLZixmvtGGiJltBQejn64c.jpg?v=1688685495","url":"https:\/\/www.betalifesci.com\/collections\/interleukins-and-receptors.oembed?page=15","provider":"Beta LifeScience","version":"1.0","type":"link"}